



FAMILIAL MEDITERRANEAN FEVER

A 3-in-1 Medical Reference

A Bibliography and Dictionary
for Physicians, Patients,
and Genome Researchers

TO INTERNET REFERENCES

 **ICON** Group
International, Inc.

FAMILIAL MEDITERRANEAN FEVER

A BIBLIOGRAPHY AND
DICTIONARY
FOR PHYSICIANS, PATIENTS,
AND GENOME RESEARCHERS



JAMES N. PARKER, M.D.
AND PHILIP M. PARKER, PH.D., EDITORS

ICON Health Publications
ICON Group International, Inc.
7404 Trade Street
San Diego, CA 92121 USA

Copyright ©2007 by ICON Group International, Inc.

Copyright ©2007 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Printed in the United States of America.

Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1

Publisher, Health Care: Philip Parker, Ph.D.
Editor(s): James Parker, M.D., Philip Parker, Ph.D.

Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments.

Cataloging-in-Publication Data

Parker, James N., 1961-
Parker, Philip M., 1960-

Familial Mediterranean Fever: A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers/
James N. Parker and Philip M. Parker, editors

p. cm.

Includes bibliographical references, glossary, and index.

ISBN: 0-497-11212-4

1. Familial Mediterranean Fever-Popular works. I. Title.

Disclaimer

This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services.

References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.

Copyright Notice

If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail: iconedit@san.rr.com). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. **The disclaimer above must accompany all reproductions, in whole or in part, of this book.**

Acknowledgements

The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on familial Mediterranean fever. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.

About the Editors

James N. Parker, M.D.

Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications.

Philip M. Parker, Ph.D.

Philip M. Parker is the Chaired Professor of Management Science at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.

About ICON Health Publications

To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts:

ICON Group International, Inc.
7404 Trade Street
San Diego, CA 92121 USA
Fax: 858-635-9414
Web site: www.icongrouponline.com/health

Table of Contents

FORWARD	1
CHAPTER 1. STUDIES ON FAMILIAL MEDITERRANEAN FEVER.....	3
<i>Overview</i>	3
<i>Genetics Home Reference</i>	3
<i>What Is Familial Mediterranean Fever?</i>	3
<i>How Common Is Familial Mediterranean Fever?</i>	4
<i>What Genes Are Related to Familial Mediterranean Fever?</i>	4
<i>How Do People Inherit Familial Mediterranean Fever?</i>	4
<i>Where Can I Find Additional Information about Familial Mediterranean Fever?</i>	4
<i>References</i>	6
<i>What Is the Official Name of the MEFV Gene?</i>	6
<i>What Is the Normal Function of the MEFV Gene?</i>	6
<i>What Conditions Are Related to the MEFV Gene?</i>	7
<i>Where Is the MEFV Gene Located?</i>	7
<i>References</i>	8
<i>What Is the Official Name of the SAA1 Gene?</i>	8
<i>What Is the Normal Function of the SAA1 Gene?</i>	8
<i>What Conditions Are Related to the SAA1 Gene?</i>	9
<i>Where Is the SAA1 Gene Located?</i>	9
<i>References</i>	10
<i>Federally Funded Research on Familial Mediterranean Fever</i>	11
<i>The National Library of Medicine: PubMed</i>	14
CHAPTER 2. ALTERNATIVE MEDICINE AND FAMILIAL MEDITERRANEAN FEVER.....	59
<i>Overview</i>	59
<i>National Center for Complementary and Alternative Medicine</i>	59
<i>Additional Web Resources</i>	61
<i>General References</i>	61
CHAPTER 3. BOOKS ON FAMILIAL MEDITERRANEAN FEVER.....	62
<i>Overview</i>	62
<i>The National Library of Medicine Book Index</i>	62
APPENDIX A. HELP ME UNDERSTAND GENETICS.....	64
<i>Overview</i>	64
<i>The Basics: Genes and How They Work</i>	64
<i>Genetic Mutations and Health</i>	75
<i>Inheriting Genetic Conditions</i>	81
<i>Genetic Consultation</i>	89
<i>Genetic Testing</i>	91
<i>Gene Therapy</i>	97
<i>The Human Genome Project and Genomic Research</i>	100
APPENDIX B. PHYSICIAN RESOURCES.....	103
<i>Overview</i>	103
<i>NIH Guidelines</i>	103
<i>NIH Databases</i>	104
<i>Other Commercial Databases</i>	107
APPENDIX C. PATIENT RESOURCES.....	108
<i>Overview</i>	108
<i>Patient Guideline Sources</i>	108
<i>Finding Associations</i>	110
<i>Resources for Patients and Families</i>	111
ONLINE GLOSSARIES.....	113

viii Contents

<i>Online Dictionary Directories</i>	115
FAMILIAL MEDITERRANEAN FEVER DICTIONARY	116
INDEX	155

FORWARD

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."¹ Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with familial Mediterranean fever is indexed in search engines, such as **www.google.com** or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about familial Mediterranean fever, using the most advanced research tools available and spending the least amount of time doing so.

In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to familial Mediterranean fever, from the essentials to the most advanced areas of research. Special attention has been paid to present the genetic basis and pattern of inheritance of familial Mediterranean fever. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on familial Mediterranean fever. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. **While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to familial Mediterranean fever, these are noted in the text.**

E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. **NOTE:** At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet.

For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. We hope these resources will prove useful to the widest possible audience seeking information on familial Mediterranean fever.

The Editors

¹ From the NIH, National Cancer Institute (NCI): <http://www.cancer.gov/>.

CHAPTER 1. STUDIES ON FAMILIAL MEDITERRANEAN FEVER

Overview

In this chapter, we will show you how to locate peer-reviewed references and studies on familial Mediterranean fever. For those interested in basic information about familial Mediterranean fever, we begin with a condition summary published by the National Library of Medicine.

Genetics Home Reference

Genetics Home Reference (GHR) is the National Library of Medicine's Web site for consumer information about genetic conditions and the genes or chromosomes responsible for those conditions. Here you can find a condition summary on familial Mediterranean fever that describes the major features of the condition, provides information about the condition's genetic basis, and explains its pattern of inheritance. In addition, a summary of the gene or chromosome related to familial Mediterranean fever is provided.²

The Genetics Home Reference has recently published the following summary for familial Mediterranean fever:

What Is Familial Mediterranean Fever?³

Familial Mediterranean fever is an inherited condition characterized by recurrent episodes of painful inflammation in the abdomen, chest, or joints. These episodes are often accompanied by fever and sometimes a rash. The first episode usually occurs by the age of 20, but in some cases, the initial attack occurs much later in life. Typically, episodes last 12 to 72 hours and can vary in severity and length of time between attacks. A buildup of protein

² This section has been adapted from the National Library of Medicine: <http://ghr.nlm.nih.gov/>.

³ Adapted from the Genetics Home Reference of the National Library of Medicine: <http://ghr.nlm.nih.gov/condition=familialmediterraneanfever>.

deposits (amyloidosis) occurs in some cases of familial Mediterranean fever and can lead to kidney failure if left untreated.

How Common Is Familial Mediterranean Fever?

Familial Mediterranean fever primarily affects populations originating in the Mediterranean region, particularly people of Armenian, Arabic, Turkish, and Jewish ancestry. The frequency of affected individuals in these populations ranges from 1 in 250 people to 1 in 1,000 people. This disorder is less common in other populations.

What Genes Are Related to Familial Mediterranean Fever?

Mutations in the **MEFV** (<http://ghr.nlm.nih.gov/gene=mefv>) gene cause familial Mediterranean fever.

Normal variations in the **SAA1** (<http://ghr.nlm.nih.gov/gene=saa1>) gene modify the course of familial Mediterranean fever.

The MEFV gene provides instructions for making a protein called pyrin (also known as marenosttrin), which is found in white blood cells. This protein probably helps to limit or stop the inflammation process. Mutations in the MEFV gene can lead to reduced activity of the pyrin protein, which disrupts control of the inflammation process. With impaired control, an inappropriate or prolonged inflammatory response can occur, usually accompanied by fever and pain in the abdomen, chest, or joints.

Some evidence suggests that a particular version of the SAA1 gene (called the alpha variant) may increase the risk of amyloidosis among people with familial Mediterranean fever.

How Do People Inherit Familial Mediterranean Fever?

This condition is inherited in an autosomal recessive pattern, which means two copies of the MEFV gene in each cell must be altered for a person to be affected by the disorder. Most often, the parents of an individual with an autosomal recessive disorder are carriers of one copy of the altered gene but do not show signs and symptoms of the disorder.

In rare cases, familial Mediterranean fever appears to be inherited in an autosomal dominant pattern, which means one copy of an altered MEFV gene is sufficient to cause the disorder. In these cases, an affected person has one parent with the condition.

Where Can I Find Additional Information about Familial Mediterranean Fever?

You may find the following resources about familial Mediterranean fever helpful. These materials are written for the general public.

NIH Publications - National Institutes of Health

- National Center for Biotechnology Information: Genes and Disease:
<http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=gnd.section.203>
- National Human Genome Research Institute:
<http://www.genome.gov/12510679>

MedlinePlus - Health Information

- Encyclopedia: Familial Mediterranean fever:
<http://www.nlm.nih.gov/medlineplus/ency/article/000363.htm>
- Health Topic: Fever:
<http://www.nlm.nih.gov/medlineplus/fever.html>

Educational Resources - Information Pages

- Madisons Foundation:
<http://www.madisonsfoundation.org/content/3/1/display.asp?did=130>
- Orphanet:
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=342
- The Merck Manual:
<http://www.merck.com/mmhe/sec25/ch305/ch305a.html>

Patient Support - for Patients and Families

- Chicago Center for Jewish Genetic Disorders:
<http://www.jewishgeneticscenter.org/what/sephardi/familial.asp>
- National Organization for Rare Disorders (NORD):
http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Mediterranean+Fever,+Familial

Professional Resources

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

- Gene Reviews - Clinical summary:
<http://www.genetests.org/query?dz=fmf>
- Gene Tests - DNA tests ordered by healthcare professionals:
<http://www.genetests.org/query?testid=9755>
- ClinicalTrials.gov - Linking patients to medical research:
<http://clinicaltrials.gov/search/condition=%22familial+mediterranean+fever%22?recruiting=false>
- PubMed - Recent literature:
<http://ghr.nlm.nih.gov/condition=familialmediterraneanfever/show/PubMed;jsessionid=7D7CFB66805ED27EA826F91C04BE26ED>

- OMIM - Genetic disorder catalog:
<http://www.ncbi.nlm.nih.gov/entrez/dispmim.cgi?id=249100>

References

These sources were used to develop the Genetics Home Reference condition summary on familial Mediterranean fever.

- Bakkaloglu A. Familial Mediterranean fever. *Pediatr Nephrol*. 2003 Sep;18(9):853-9. Epub 2003 Jun 27. PubMed citation
- Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, Soy Turk M, Akar S, Pepys MB, Tunca M, Hawkins PN. The genetic basis of autosomal dominant familial Mediterranean fever. *QJM*. 2000 Apr;93(4):217-21. PubMed citation
- Ozen S. Familial mediterranean fever: revisiting an ancient disease. *Eur J Pediatr*. 2003 Jul;162(7-8):449-54. Epub 2003 May 16. Review. PubMed citation
- Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. *Curr Opin Rheumatol*. 2005 Sep;17(5):586-99. PubMed citation
- Telatar M, Grody WW. Molecular genetic testing for familial Mediterranean fever. *Mol Genet Metab*. 2000 Sep-Oct;71(1-2):256-60. Review. No abstract available. PubMed citation

A summary of the genes related to familial Mediterranean fever is provided below:

What Is the Official Name of the MEFV Gene?⁴

The official name of this gene is “Mediterranean fever.”

MEFV is the gene's official symbol. The MEFV gene is also known by other names, listed below.

What Is the Normal Function of the MEFV Gene?

The MEFV gene provides instructions for making a protein called pyrin (also known as marenostriin). Pyrin is produced in certain white blood cells (neutrophils, eosinophils, and monocytes) that play a role in inflammation and in fighting infection. Inside these white blood cells, pyrin is found with the cytoskeleton, the structural framework that helps to define the shape, size, and movement of a cell. Pyrin's protein structure also allows it to interact with other molecules involved in fighting infection and in the inflammatory response.

Although pyrin's function is not fully understood, it likely assists in keeping the inflammation process under control. Research indicates that pyrin helps regulate

⁴ Adapted from the Genetics Home Reference of the National Library of Medicine:
<http://ghr.nlm.nih.gov/gene=mefv;jsessionid=7D7CFB66805ED27EA826F91C04BE26ED>.

inflammation by interacting with the cytoskeleton. Pyrin may direct the migration of white blood cells to sites of inflammation and stop or slow the inflammatory response when it is no longer needed.

What Conditions Are Related to the MEFV Gene?


Familial Mediterranean Fever - Caused by Mutations in the MEFV Gene

More than 80 MEFV mutations that cause familial Mediterranean fever have been identified. A few mutations delete small amounts of DNA from the MEFV gene, which can lead to an abnormally small protein. Most MEFV mutations, however, change one of the protein building blocks (amino acids) used to make pyrin. The most common mutation replaces the amino acid methionine with the amino acid valine at protein position 694 (written as Met694Val or M694V). Among people with familial Mediterranean fever, this particular mutation is also associated with an increased risk of developing amyloidosis, a complication in which abnormal protein deposits can lead to kidney failure. Some evidence suggests that another gene, called SAA1, can further modify the risk of developing amyloidosis among people with the M694V mutation.

Where Is the MEFV Gene Located?

Cytogenetic Location: 16p13.3

Molecular Location on chromosome 16: base pairs 3,232,028 to 3,246,627



The MEFV gene is located on the short (p) arm of chromosome 16 at position 13.3.

More precisely, the MEFV gene is located from base pair 3,232,028 to base pair 3,246,627 on chromosome 16.

References

These sources were used to develop the Genetics Home Reference gene summary on the MEFV gene.

- Bakkaloglu A. Familial Mediterranean fever. *Pediatr Nephrol*. 2003 Sep;18(9):853-9. Epub 2003 Jun 27. PubMed citation
- Delibas A, Oner A, Balci B, Demircin G, Bulbul M, Bek K, Erdogan O, Baysun S, Yilmaz E. Genetic Risk Factors of Amyloidogenesis in Familial Mediterranean Fever. *Am J Nephrol*. 2005 Aug 23;25(5):434-440 [Epub ahead of print]. PubMed citation
- Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. *Arthritis Rheum*. 2003 Apr;48(4):1149-55. PubMed citation
- Mansfield E, Chae JJ, Komarow HD, Brotz TM, Frucht DM, Aksentijevich I, Kastner DL. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. *Blood*. 2001 Aug 1;98(3):851-9. PubMed citation
- Medlej-Hashim M, Delague V, Chouery E, Salem N, Rawashdeh M, Lefranc G, Loiselet J, Megarbane A. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. *BMC Med Genet*. 2004 Feb 10;5(1):4. PubMed citation
- Notarnicola C, Didelot MN, Kone-Paut I, Seguret F, Demaille J, Touitou I. Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever. *Arthritis Rheum*. 2002 Oct;46(10):2785-93. PubMed citation
- OMIM
- Telatar M, Grody WW. Molecular genetic testing for familial Mediterranean fever. *Mol Genet Metab*. 2000 Sep-Oct;71(1-2):256-60. Review. No abstract available. PubMed citation

What Is the Official Name of the SAA1 Gene?⁵

The official name of this gene is “serum amyloid A1.”

SAA1 is the gene's official symbol. The SAA1 gene is also known by other names, listed below.

What Is the Normal Function of the SAA1 Gene?

The SAA1 gene provides instructions for making a protein called serum amyloid A1. This protein is made primarily in the liver and circulates in low levels in the blood. Although its function is not fully understood, serum amyloid A1 appears to play a role in the body's defense mechanisms. Levels of this protein in the blood and other tissues increase when the

⁵ Adapted from the Genetics Home Reference of the National Library of Medicine: <http://ghr.nlm.nih.gov/gene=saa1>.

body is challenged by injury or infection. Serum amyloid A1 may help repair damaged tissues, act as an antibacterial agent, and signal the migration of germ-fighting cells to sites of infection.

There are three versions of the serum amyloid A1 protein, known as alpha, beta, and gamma, which differ by one or two amino acids (the building blocks of proteins). The frequency of these variants differs across populations. In Caucasian populations, the alpha version predominates and gamma is rare. In the Japanese population, however, the three versions appear almost equally.

What Conditions Are Related to the SAA1 Gene?

Familial Mediterranean Fever - Course of Condition Modified by Normal Variations in the SAA1 Gene

Several studies of people with familial Mediterranean fever indicate that the alpha version of the serum amyloid A1 protein modifies the risk of a serious complication called amyloidosis. Amyloidosis involves the buildup of protein deposits that can lead to kidney failure if left untreated. Studies indicate that individuals with familial Mediterranean fever who also have the alpha version of the protein are two to seven times more likely to develop amyloidosis than are people with the beta or gamma version. It remains unclear how the alpha version of serum amyloid A1 increases the susceptibility to amyloidosis (or alternatively, how the beta and gamma versions may protect against this complication) in people with familial Mediterranean fever.


Other Disorders - Course of Condition Modified by Normal Variations in the SAA1 Gene

Several studies of people with familial Mediterranean fever indicate that the alpha version of the serum amyloid A1 protein modifies the risk of a serious complication called amyloidosis. Amyloidosis involves the buildup of protein deposits that can lead to kidney failure if left untreated. Studies indicate that individuals with familial Mediterranean fever who also have the alpha version of the protein are two to seven times more likely to develop amyloidosis than are people with the beta or gamma version. It remains unclear how the alpha version of serum amyloid A1 increases the susceptibility to amyloidosis (or alternatively, how the beta and gamma versions may protect against this complication) in people with familial Mediterranean fever.

Where Is the SAA1 Gene Located?

Cytogenetic Location: 11p15.1

Molecular Location on chromosome 11: base pairs 18,244,345 to 18,248,089



The SAA1 gene is located on the short (p) arm of chromosome 11 at position 15.1.

More precisely, the SAA1 gene is located from base pair 18,244,345 to base pair 18,248,089 on chromosome 11.

References

These sources were used to develop the Genetics Home Reference gene summary on the SAA1 gene.

- Bakkaloglu A, Duzova A, Ozen S, Balci B, Besbas N, Topaloglu R, Ozaltin F, Yilmaz E. Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. *J Rheumatol*. 2004 Jun;31(6):1139-42. PubMed citation
- Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis--phenotype-genotype correlation, treatment and prognosis. *J Nephrol*. 2003 May-Jun;16(3):431-4. Review. PubMed citation
- Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. *Amyloid*. 1998 Dec;5(4):262-5. PubMed citation
- Cazeneuve C, Ajrapietyan H, Papin S, Roudot-Thoraval F, Genevieve D, Mndjoyan E, Papazian M, Sarkisian A, Babloyan A, Boissier B, Duquesnoy P, Kouyoumdjian JC, Girodon-Boulandet E, Grateau G, Sarkisian T, Amselem S. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. *Am J Hum Genet*. 2000 Nov;67(5):1136-43. Epub 2000 Oct 03. PubMed citation
- Delibas A, Oner A, Balci B, Demircin G, Bulbul M, Bek K, Erdogan O, Baysun S, Yilmaz E. Genetic Risk Factors of Amyloidogenesis in Familial Mediterranean Fever. *Am J Nephrol*. 2005 Aug 23;25(5):434-440 [Epub ahead of print]. PubMed citation
- Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. *Arthritis Rheum*. 2003 Apr;48(4):1149-55. PubMed citation
- Medlej-Hashim M, Delague V, Chouery E, Salem N, Rawashdeh M, Lefranc G, Loiselet J, Megarbane A. Amyloidosis in familial Mediterranean fever patients: correlation with

MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet. 2004 Feb 10;5(1):4. PubMed citation

- Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, Nishinarita M, Uchida S, Nakajima A, Kim SY, Chen CL, Kamatani N. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999 Oct;105(4):360-6. PubMed citation
- OMIM
- Thorn CF, Lu ZY, Whitehead AS. Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in hepatic and epithelial cells. Eur J Immunol. 2003 Sep;33(9):2630-9. PubMed citation
- Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999 Apr;37(4):381-8. Review. PubMed citation

Federally Funded Research on Familial Mediterranean Fever

The U.S. Government supports a variety of research studies relating to familial Mediterranean fever. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.⁶

CRISP (Computerized Retrieval of Information on Scientific Projects)

CRISP is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to familial Mediterranean fever.

For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore familial Mediterranean fever. The following is typical of the type of information found when searching the CRISP database for familial Mediterranean fever:

- **Project Title: CHARACTERIZATION OF A NEURONAL UBIQUITINATION MACHINERY**

Principal Investigator & Institution: Li, Lian; Associate Professor; Pharmacology; Emory University 1784 North Decatur Road, Suite 510 Atlanta, Ga 30322

Timing: Fiscal Year 2005; Project Start 01-DEC-2003; Project End 30-NOV-2008

Summary: (provided by applicant): Protein ubiquitination has emerged as a crucial mechanism for controlling development and function of neuronal circuits, and its defective regulation has been implicated in the pathogenesis of a variety of

⁶ Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).

neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis. However, very little is presently known about the molecular machinery that controls protein ubiquitination in neurons. In the ubiquitin-proteasome pathway, substrate proteins are marked for degradation in the proteasome by covalent linkage to ubiquitin, a 76-amino acid polypeptide. The ubiquitination process involves a highly specific enzyme cascade in which ubiquitin is first activated by an E1 ubiquitin-activating enzyme, then transferred to an E2 ubiquitin-conjugating enzyme, and finally ligated to the substrate by an E3 ubiquitin-protein ligase. Of these enzymes, E3 ligase is the most important player because it determines the specificity of ubiquitin-mediated protein degradation. The importance of E3 ligases in neurodegenerative disorders is highlighted by recent findings that mutations in the E3 ligase parkin are responsible for a familial form of Parkinson's disease. In a search for neuronal proteins that regulate the neurotransmitter release machinery component SNAP-25, the applicant has discovered a novel protein, called Spring. Spring is a neuron-specific member of the RING-B-box-coiled-coil (RBCC) protein family. The importance of the RBCC family is underscored by the identification of the mutations in several RBCC proteins as the causes for a number of human diseases, including Opitz syndrome, Mulibrey nanism, and **familial Mediterranean fever**. In this project, the applicant will use a combination of biochemical, proteomic, molecular biological, and cell biological approaches to test the hypothesis that Spring functions as a novel E3 ubiquitin-protein ligase to regulate the turnover of the neurotransmitter release machinery. In addition, this project will characterize neuronal distribution and synaptic localization of Spring, and explore the possible involvement of this novel protein in Alzheimer's disease and Parkinson's disease. Successful completion of proposed studies will yield novel insights into the molecular mechanisms that control neuronal protein ubiquitination and neurotransmitter release, and provide fundamental information towards our ultimate goal of understanding and treating numerous neurological diseases and psychiatric disorders.

- **Project Title: METABOLISM OF SERUM AMYLOID A (SAA:HDL)**

Principal Investigator & Institution: Kluge-Beckerman, Barbara; Assistant Professor; Pathology and Laboratory Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167

Timing: Fiscal Year 2005; Project Start 01-JUN-1995; Project End 30-NOV-2007

Summary: (provided by applicant): The overall goal of this project is to elucidate pathogenic mechanisms of reactive (AA) amyloidosis. This type of amyloidosis develops as a complication of chronic and recurrent inflammatory conditions such as rheumatoid arthritis and **familial Mediterranean fever**, and is characterized by extracellular fibrillar deposits of amyloid A (AA) protein, a peptide proteolytically derived from the acute phase reactant serum amyloid A (SAA). While overproduction of SAA has long been recognized as a prerequisite for amyloid formation, factors governing why and how SAA starts forming fibrils, as well as the mechanism by which nascent fibrils grow into clinically significant extracellular masses, remain largely unknown. A cell culture model employing macrophages cultured in the presence of recombinant mouse SAA1.1 will be used to ascertain critical events in amyloid fibril initiation and propagation. Amyloid formation and SAA processing will be followed intracellularly and on cell surfaces via fluorescent-labeled SAA and confocal microscopy, ¹²⁵I-SAA combined with SDS-PAGE and phosphorimaging, immunocytochemistry, and Congo red staining. Focusing on the intracellular formation of an amyloid nucleus, Aim 1 will test the hypothesis that an unrelenting influx of SAA during chronic inflammation results in compromised intracellular proteolysis, which, in turn, permits fibrillization. Macrophages will be also

be subjected to two regimens of SAA treatment mimicking patterns of either chronic or recurrent inflammation to gain clues about how the duration and degree of SAA elevation influence the likelihood of fibril formation. Aim 2 will determine if the initiation of amyloid fibrillogenesis requires processing of SAA to AA. Cleavage sites in the C-terminal region of SAA will be determined by mass spectroscopy analysis of macrophage-produced amyloid. Mutant SAAI.1 proteins, designed to be protease-resistant at one of the identified sites, will be produced and tested for amyloid-forming capability. Extracellular mechanisms of fibril propagation will be investigated in Aim 3. Direct incorporation of SAA onto preformed cell surface amyloid or protofibrils (AEF) followed by in situ processing will be examined as a potential step in propagation. The ability of macrophage-generated AEF to seed, and thereby spread amyloid deposition throughout tissues, will be studied in a fibroblast model. By clarifying pathogenic mechanisms at the cellular level, these studies will help identify potential targets for drugs aimed at inhibiting amyloid formation or arresting its progression.

- **Project Title: MOLECULAR ETIOLOGY OF FAMILIAL MEDITERRANEAN FEVER**

Principal Investigator & Institution: Gumucio, Deborah L.; Associate Professor; Cell and Developmental Biology; University of Michigan at Ann Arbor 3003 South State Street, Room 1040 Ann Arbor, Mi 481091274

Timing: Fiscal Year 2005; Project Start 01-JUL-2003; Project End 31-DEC-2007

Summary: This abstract is not available.

- **Project Title: MONOCYTE PYRIN EXPRESSION IN HUMAN SEPSIS**

Principal Investigator & Institution: Hall, Mark W.; Children's Research Institute 700 Children's Dr Columbus, Oh 432052664

Timing: Fiscal Year 2006; Project Start 24-JUL-2006; Project End 30-JUN-2009

Summary: (provided by applicant): This submission describes a comprehensive 3 year training program in molecular biology and molecular genetics designed to provide Dr. Mark W. Hall with the tools to become an outstanding, independent physician-scientist. This training, combined with his K12 support to date, will give him the necessary skills to investigate the regulation of inflammation in pediatric sepsis. Dr. Hall completed his medical training in Pediatrics and Pediatric Critical Care Medicine at Children's Hospital of Pittsburgh and is now Assistant Professor at The Ohio State University / Columbus Children's Hospital. Dr. Mark D. Wewers, a leader in the field of innate immunobiology, will serve as Dr. Hall's sponsor and mentor. Dr. Hall has generated, with the help of Dr. Wewers and his laboratory staff, preliminary data from a cohort of 28 children with sepsis-induced organ failure. These data show that monocytes in survivors demonstrate a marked downregulation of mRNA for the protein pyrin compared to nonsurvivors. Pyrin is an important regulatory protein which is associated with inflammation in the disease **familial Mediterranean fever**. Pyrin and its gene MEFV have not been described in this context before. In the course of the award period we expect to: 1) understand the associations between monocyte MEFV mRNA expression, monocyte pyrin protein expression, and mortality in the setting of pediatric severe sepsis/septic shock, 2) understand the role of mRNA production versus mRNA degradation in determining MEFV mRNA levels in survivors versus nonsurvivors of pediatric severe sepsis/septic shock, and 3) test the hypothesis that reduction in monocyte MEFV mRNA expression in the setting of pediatric severe sepsis/septic shock is associated with the presence of a cis-acting polymorphism in the MEFV gene. In order to accomplish this final goal, and to provide Dr. Hall with a robust foundation in molecular genetics, he will spend time in training and experimentation in the laboratory

of Dr. Wolfgang Sadee, a world expert in the area of regulatory genetic polymorphisms. The combined facilities of Columbus Children's Research Institute, the Davis Heart and Lung Research Institute, and The Ohio State University offer an unparalleled array of scientific resources and provide an ideal setting for Dr. Hall's academic and scientific development. (End of Abstract)

The National Library of Medicine: PubMed

One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.⁷ The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals.

To generate your own bibliography of studies dealing with familial Mediterranean fever, simply go to the PubMed Web site at <http://www.ncbi.nlm.nih.gov/pubmed>. Type **familial Mediterranean fever** (or synonyms) into the search box, and click **Go**. The following is the type of output you can expect from PubMed for familial Mediterranean fever (hyperlinks lead to article summaries):

- **A case of recurrent pancreatitis due to hyperlipidemia misdiagnosed as familial Mediterranean fever.**
Author(s): Birlik M, Demir T, Zeybel M, Akar S, Onen F, Comlekci A, Tunca M, Akkoc N.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15801080&query_hl=30&itool=pubmed_docsum
- **A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis.**
Author(s): Cefle A, Kamali S, Sayarlioglu M, Inanc M, Ocal L, Aral O, Konice M, Gul A.
Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15290087&query_hl=30&itool=pubmed_docsum
- **A Japanese case of familial Mediterranean fever with homozygosity for the pyrin E148Q mutation.**
Author(s): Suzuki T, Nakamura A, Yazaki M, Ikeda S.
Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16093605&query_hl=30&itool=pubmed_docsum

⁷ PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.

- **A Japanese case of familial Mediterranean fever with onset in the fifties.**
 Author(s): Yamane T, Uchiyama K, Hata D, Nakamura M, Ishii T, Koido S, Fujise K, Tajiri H.
 Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16702743&query_hl=30&itool=pubmed_docsum
- **A Japanese patient with familial Mediterranean fever associated with compound heterozygosity for pyrin variant E148Q/M694I.**
 Author(s): Nakamura A, Yazaki M, Tokuda T, Hattori T, Ikeda S.
 Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15805719&query_hl=30&itool=pubmed_docsum
- **A note on the mutation analysis in familial Mediterranean fever.**
 Author(s): Akar N, Akar E, Ozel D, Tekin M, Ekim M, Yalcinkaya F.
 Source: Pediatric Nephrology (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12632594&query_hl=30&itool=pubmed_docsum
- **A very rare consequence of steroid therapy: ileal perforation in a patient with familial Mediterranean fever.**
 Author(s): Sakallioğlu AE, Arda IS, Sevmis S, Baskin E, Bilezikci B, Hicsonmez A.
 Source: Journal of Pediatric Surgery.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15547842&query_hl=30&itool=pubmed_docsum
- **Acute phase response in familial Mediterranean fever.**
 Author(s): Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11779767&query_hl=30&itool=pubmed_docsum
- **Adrenal axis functions in patients with familial Mediterranean fever.**
 Author(s): Sav T, Ozbakir O, Kelestimur F, GURSOY S, Baskol M, Kula M, Dundar M.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16267600&query_hl=30&itool=pubmed_docsum
- **Adrenomedullin and total nitrite levels in children with familial Mediterranean fever.**
 Author(s): Balat A, Islek I, Cekmen M, Yurekli M, Tekin D, Muslu A, Sahinoz S.
 Source: Journal of Paediatrics and Child Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16712551&query_hl=30&itool=pubmed_docsum

- **Amyloid goitre in familial Mediterranean fever: report on three patients and review of the literature.**
Author(s): Altiparmak MR, Pamuk ON, Pamuk GE, Apaydin S, Ataman R, Serdengeçti K.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12447634&query_hl=30&itool=pubmed_docsum
- **Amyloidosis in Behçet's disease and familial Mediterranean fever.**
Author(s): Akpolat T, Yilmaz E, Akpolat I, Dilek M, Karagoz F, Balci B, Ozen S.
Source: Rheumatology (Oxford, England).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12011390&query_hl=30&itool=pubmed_docsum
- **An unusual presentation of familial Mediterranean fever with prolonged hip pain and amyloidosis.**
Author(s): Ozkaya O, Canturk F, Alayli G, Akpolat I, Belet U, Diren B.
Source: Scandinavian Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15163115&query_hl=30&itool=pubmed_docsum
- **Antistreptococcal response is exaggerated in children with familial Mediterranean fever.**
Author(s): Yalcinkaya F, Ince E, Ucar T, Ozkaya N, Tekin M, Elhan AH, Tutar E, Guriz DH, Aysev D, Gokdemir R, Dogru U, Tumer N.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12223985&query_hl=30&itool=pubmed_docsum
- **Application of refractory fragment amplification system for detection of Egyptian variant of Familial Mediterranean Fever.**
Author(s): Zekri AR, el-Bassuoni MA, Hammad OM, Sakr MA, Ibrahim AA.
Source: Egypt J Immunol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15724392&query_hl=30&itool=pubmed_docsum
- **Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF.**
Author(s): Akdogan A, Calguneri M, Yavuz B, Arslan EB, Kalyoncu U, Sahiner L, Karadag O, Ertenli I, Kiraz S, Aytemir K, Akata D, Tokgozoglu L, Oto A.
Source: Journal of the American College of Cardiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17161270&query_hl=30&itool=pubmed_docsum

- **Arthritis as the sole episodic manifestation of familial Mediterranean fever.**
 Author(s): Lidar M, Kedem R, Mor A, Levartovsky D, Langevitz P, Livneh A.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15868622&query_hl=30&itool=pubmed_docsum
- **Arthritis in children with familial Mediterranean fever.**
 Author(s): Ince E, Cakar N, Tekin M, Kendirli T, Ozkaya N, Akar N, Yalcinkaya F.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12036206&query_hl=30&itool=pubmed_docsum
- **Avascular necrosis of the femoral head foreshadowing familial Mediterranean fever: apropos of three cases.**
 Author(s): Onat AM, Ozcakar L, Ureten K, Kiraz S, Ertenli I, Calguneri M.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15351872&query_hl=30&itool=pubmed_docsum
- **Behcet's disease and familial Mediterranean fever.**
 Author(s): Takeno M, Ishigatsubo Y.
 Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16880703&query_hl=30&itool=pubmed_docsum
- **Behcet's disease in Familial Mediterranean fever: characterization of the association between the two diseases.**
 Author(s): Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livneh A.
 Source: Seminars in Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10805353&query_hl=30&itool=pubmed_docsum
- **Benign cystic mesothelioma: a rare cause of ascites in a case with familial Mediterranean fever.**
 Author(s): Curgunlu A, Karter Y, Tufekci IB, Tunckale A, Karahasanoglu T.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14727459&query_hl=30&itool=pubmed_docsum
- **Beta-2-microglobulin levels of dialysis patients with renal amyloidosis secondary to familial Mediterranean fever.**
 Author(s): Sungur C, Ozen S, Ozkuyumcu C, Akpolat T, Yasavul U, Turgan C, Caglar S.
 Source: Nephron.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7991035&query_hl=30&itool=pubmed_docsum

- **Bilateral carpal tunnel syndrome associated to familial Mediterranean fever.**
Author(s): Bademci G, Erdemoglu AK, Evliyaoglu C, Atasoy P, Keskil S.
Source: Clinical Neurology and Neurosurgery.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16311153&query_hl=30&itool=pubmed_docsum
- **Bilateral uveitis in a 7-year-old patient with familial Mediterranean fever. An extremely rare complication.**
Author(s): Ozaltin F, Bakkaloglu A, Orhon M, Duzova A, Irkec M.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11760412&query_hl=30&itool=pubmed_docsum
- **Biologic and clinical advances in familial Mediterranean fever.**
Author(s): Matzner Y.
Source: Critical Reviews in Oncology/Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7695832&query_hl=30&itool=pubmed_docsum
- **Bone mineral density in children with familial Mediterranean fever.**
Author(s): Duzova A, Ozaltin F, Ozon A, Besbas N, Topaloglu R, Ozen S, Bakkaloglu A.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15168151&query_hl=30&itool=pubmed_docsum
- **Breast-feeding during colchicine therapy for familial Mediterranean fever.**
Author(s): Milunsky JM.
Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2066854&query_hl=30&itool=pubmed_docsum
- **Bullous skin lesion in familial Mediterranean fever.**
Author(s): Ronnen M, Suster SM, Schewach-Millet M.
Source: Cutis; Cutaneous Medicine for the Practitioner.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3519101&query_hl=30&itool=pubmed_docsum
- **C reactive protein: protecting from lupus in familial Mediterranean fever.**
Author(s): Ozen S, Bakkaloglu A.
Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15834062&query_hl=30&itool=pubmed_docsum

- **Cardiovascular autonomic dysfunction in familial Mediterranean fever.**
 Author(s): Rozenbaum M, Naschitz JE, Yudashkin M, Rosner I, Sabo E, Shaviv N, Gaitini L, Zuckerman E, Yeshurun D.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12022362&query_hl=30&itool=pubmed_docsum
- **Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases.**
 Author(s): Sayarlioglu M, Cefle A, Inanc M, Kamali S, Dalkilic E, Gul A, Ocal L, Aral O, Konice M.
 Source: Int J Clin Pract.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15854197&query_hl=30&itool=pubmed_docsum
- **Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever.**
 Author(s): Berkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barkai G.
 Source: American Journal of Obstetrics and Gynecology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16202748&query_hl=30&itool=pubmed_docsum
- **Chronic ascites related to encapsulating peritonitis in familial Mediterranean fever.**
 Author(s): Lelievre JD, Ranque-Francois B, Aslangul-Castier E, Adle-Biassette H, Papo T.
 Source: The American Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12106628&query_hl=30&itool=pubmed_docsum
- **Classical pathway complement activity in Familial Mediterranean fever.**
 Author(s): Mkrtychyan GM, Boyajyan AS, Ayvazyan AA, Beglaryan AA.
 Source: Clinical Biochemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16631629&query_hl=30&itool=pubmed_docsum
- **Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever.**
 Author(s): Padeh S, Shinar Y, Pras E, Zemer D, Langevitz P, Pras M, Livneh A.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12508410&query_hl=30&itool=pubmed_docsum
- **Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.**
 Author(s): Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyuturk M, Akar S, Tunca M, Hawkins PN.
 Source: Rheumatology (Oxford, England).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16403826&query_hl=30&itool=pubmed_docsum

- **Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever.**
Author(s): Yuksel S, Yalcinkaya F, Acar B, Ozcakar ZB, Ozturk B, Ekim M.
Source: Rheumatology (Oxford, England).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16880190&query_hl=30&itool=pubmed_docsum
- **Coexistence of familial Mediterranean fever and Behcet's disease in a Japanese patient.**
Author(s): Matsuda M, Nakamura A, Tsuchiya S, Yoshida T, Horie S, Ikeda S.
Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16847372&query_hl=30&itool=pubmed_docsum
- **Co-existence of Helicobacter pylori infection in patients with Familial Mediterranean Fever (FMF) and the effect of Helicobacter pylori on the frequency and severity of FMF attacks.**
Author(s): Demirturk L, Ozel AM, Cekem K, Yazgan Y, Gultepe M.
Source: Dig Liver Dis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15888278&query_hl=30&itool=pubmed_docsum
- **Colchicine in tear fluid of treated patients with familial Mediterranean fever.**
Author(s): Leibovitch I, Alster Y, Scherrmann JM, Azmon B, Barequet IS, Livneh A, O'Brien TP, Lazar M, Loewenstein A.
Source: Cornea.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12658080&query_hl=30&itool=pubmed_docsum
- **Colchicine therapy and the cognitive status of elderly patients with familial Mediterranean fever.**
Author(s): Leibovitz A, Lidar M, Baumoehl Y, Livneh A, Segal R.
Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16889161&query_hl=30&itool=pubmed_docsum
- **Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients.**
Author(s): Shinar Y, Livneh A, Villa Y, Pinhasov A, Zeitoun I, Kogan A, Achiron A.
Source: Genes and Immunity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12700594&query_hl=30&itool=pubmed_docsum

- **Comparison of amplification refractory mutation system and polymerase chain reaction-restriction fragment length polymorphism techniques used for the investigation of MEFV gene exon 10 point mutations in familial Mediterranean fever patients living in Cukurova region (Turkey).**
 Author(s): Gunesacar R, Kasap H, Erken E, Ozer HT.
 Source: Genetic Testing.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16225401&query_hl=30&itool=pubmed_docsum
- **Comparison of synovial MMP-1 and TIMP-1 levels in patients with various inflammatory arthritides: is there any difference between rheumatoid arthritis, Behcet's disease and familial Mediterranean fever?**
 Author(s): Pay S, Erdem H, Serdar M, Dinc A, Simsek I, Turan M.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12447637&query_hl=30&itool=pubmed_docsum
- **Composition of urinary glycosaminoglycans in a patient with pseudoxanthoma elasticum and familial Mediterranean fever.**
 Author(s): Volpi N, Maccari F.
 Source: Clinica Chimica Acta; International Journal of Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15913588&query_hl=30&itool=pubmed_docsum
- **Cranial nerve lesions and abnormal visually evoked potentials associated with the M694V mutation in familial Mediterranean fever.**
 Author(s): Finsterer J, Stollberger C, Shinar Y.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12189462&query_hl=30&itool=pubmed_docsum
- **Crohn disease in patients with familial Mediterranean fever.**
 Author(s): Fidler HH, Chowers Y, Lidar M, Sternberg M, Langevitz P, Livneh A.
 Source: Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12441897&query_hl=30&itool=pubmed_docsum
- **CT findings in patients with familial Mediterranean fever during an acute abdominal attack.**
 Author(s): Zissin R, Rathaus V, Gayer G, Shapiro-Feinberg M, Hertz M.
 Source: The British Journal of Radiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12595321&query_hl=30&itool=pubmed_docsum

- **Decreased incidence of asthma in patients with familial Mediterranean fever.**
Author(s): Danon YL, Laor A, Shlezinger M, Zemer D.
Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2401614&query_hl=30&itool=pubmed_docsum
- **Decreased interleukin 1 activity released from circulating monocytes of patients with familial Mediterranean fever during in vitro stimulation by lipopolysaccharide.**
Author(s): Rozenbaum M, Katz R, Rozner I, Pollack S.
Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1578456&query_hl=30&itool=pubmed_docsum
- **Decreased prevalence of atopy in paediatric patients with familial Mediterranean fever.**
Author(s): Sackesen C, Bakkaloglu A, Sekerel BE, Ozaltin F, Besbas N, Yilmaz E, Adalioglu G, Ozen S.
Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14722209&query_hl=30&itool=pubmed_docsum
- **Determination by ELISA of anti-DNA antibodies in patients with familial Mediterranean fever.**
Author(s): Flatau E, Shneyour A, Hadad N, Shimoni Z.
Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2807853&query_hl=30&itool=pubmed_docsum
- **Determination of autoantibodies in patients with familial Mediterranean fever and their first degree relatives.**
Author(s): Swissa M, Schul V, Korish S, Livneh A, Pras M, Shoenfeld Y.
Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2066952&query_hl=30&itool=pubmed_docsum
- **Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.**
Author(s): Shabtai M, Ben-Haim M, Zemer D, Malinge-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12455184&query_hl=30&itool=pubmed_docsum

- **Diagnosis delay in familial Mediterranean fever (FMF): social and gender gaps disclosed.**
 Author(s): Lidar M, Tokov I, Chetrit A, Zaks N, Langevitz P, Livneh A.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15971424&query_hl=30&itool=pubmed_docsum
- **Diagnosis of familial Mediterranean fever by a molecular genetics method.**
 Author(s): Eisenberg S, Aksentijevich I, Deng Z, Kastner DL, Matzner Y.
 Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9758573&query_hl=30&itool=pubmed_docsum
- **Diagnostic and treatment concerns in familial Mediterranean fever.**
 Author(s): Livneh A, Langevitz P.
 Source: Bailliere's Best Practice & Research. Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10985982&query_hl=30&itool=pubmed_docsum
- **Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever.**
 Author(s): Sungur C, Sungur A, Ruacan S, Arik N, Yasavul U, Turgan C, Caglar S.
 Source: Kidney International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7505040&query_hl=30&itool=pubmed_docsum
- **Diagnostic value of MEFV gene analysis in familial Mediterranean fever must still be assessed in non-classically affected populations: comment on the article by Cazeneuve et al.**
 Author(s): Touitou I.
 Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15077326&query_hl=30&itool=pubmed_docsum
- **Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behcet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis.**
 Author(s): Erdem H, Pay S, Serdar M, Simsek I, Dinc A, Musabak U, Pekel A, Turan M.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15672235&query_hl=30&itool=pubmed_docsum
- **Diffuse pulmonary amyloidosis that mimics interstitial lung disease in a patient with familial Mediterranean fever.**
 Author(s): Erdem H, Simsek I, Pay S, Dinc A, Deniz O, Ozcan A.
 Source: J Clin Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16484879&query_hl=30&itool=pubmed_docsum

- **Direct detection of common mutations in the familial Mediterranean fever gene (MEFV) using naturally occurring and primer mediated restriction fragment analysis. Mutation in brief no. 257. Online.**
Author(s): Gershoni-Baruch R, Kepten I, Shinawi M, Brik R.
Source: Human Mutation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10447272&query_hl=30&itool=pubmed_docsum
- **Does colchicine have an antifibrotic effect on development of interstitial fibrosis in renal allografts of recipients with familial Mediterranean fever?**
Author(s): Ozdemir BH, Ozdemir FN, Sezer S, Sar A, Haberal M.
Source: Transplantation Proceedings.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16549151&query_hl=30&itool=pubmed_docsum
- **Does immune activation continue during an attack-free period in familial Mediterranean fever?**
Author(s): Musabak U, Sengul A, Oktenli C, Pay S, Yesilova Z, Kenar L, Sanisoglu SY, Inal A, Tuzun A, Erdil A, Bagci S.
Source: Clinical and Experimental Immunology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15544632&query_hl=30&itool=pubmed_docsum
- **Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases?**
Author(s): Ben-Chetrit E, Levy M.
Source: Medical Hypotheses.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9848464&query_hl=30&itool=pubmed_docsum
- **Dominant inheritance in two families with familial Mediterranean fever (FMF).**
Author(s): Yuval Y, Hemo-Zisser M, Zemer D, Sohar E, Pras M.
Source: American Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7677151&query_hl=30&itool=pubmed_docsum
- **Dopamine-beta-hydroxylase activity in familial Mediterranean fever.**
Author(s): Ben-Chetrit E, Gutman A, Levy M.
Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1967473&query_hl=30&itool=pubmed_docsum
- **E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever.**
Author(s): Topaloglu R, Ozaltin F, Yilmaz E, Ozen S, Balci B, Besbas N, Bakkaloglu A.
Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15458961&query_hl=30&itool=pubmed_docsum

- **E148Q of the MEFV gene causes amyloidosis in familial Mediterranean fever patients.**
 Author(s): Akar N, Akar E, Yalcinkaya F.
 Source: Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11452963&query_hl=30&itool=pubmed_docsum
- **E148Q/M694I mutation in 3 Japanese patients with familial Mediterranean fever.**
 Author(s): Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K, Goto M, Hayashino Y, Miki M, Takayama H, Sasada M, Uchiyama T.
 Source: International Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15168590&query_hl=30&itool=pubmed_docsum
- **Early and severe amyloidosis in a patient with concurrent familial Mediterranean fever and pseudoxanthoma elasticum.**
 Author(s): Cattani D, Bouali B, Chassaing N, Martinez F, Dupont JM, Dode C, Martin L.
 Source: The British Journal of Dermatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16704654&query_hl=30&itool=pubmed_docsum
- **Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.**
 Author(s): Kiraz S, Ertenli I, Arici M, Calguneri M, Haznedaroglu I, Celik I, Pay S, Kirazli S.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9844766&query_hl=30&itool=pubmed_docsum
- **Efficacy of colchicine in familial Mediterranean fever is well established.**
 Author(s): Drenth JP.
 Source: Bmj (Clinical Research Ed.).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8696225&query_hl=30&itool=pubmed_docsum
- **Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever.**
 Author(s): Oner A, Erdogan O, Demircin G, Bulbul M, Memis L.
 Source: Pediatric Nephrology (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12698329&query_hl=30&itool=pubmed_docsum
- **Encapsulating peritonitis and familial Mediterranean fever.**
 Author(s): Dabak R, Uygur-Bayramicli O, Aydin DK, Dolapcioglu C, Gemici C, Erginel T, Turan C, Karadayi N.
 Source: World Journal of Gastroenterology : Wjg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15884137&query_hl=30&itool=pubmed_docsum

- **Endocrine function and dysfunction in familial Mediterranean fever.**
Author(s): Konstantopoulos K.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16496077&query_hl=30&itool=pubmed_docsum
- **End-stage renal disease associated with familial Mediterranean fever.**
Author(s): Tomiyama N, Oshiro S, Higashiuesato Y, Yamazato M, Sakima A, Tana T, Tozawa M, Muratani H, Iseki K, Takishita S.
Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11929185&query_hl=30&itool=pubmed_docsum
- **Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever.**
Author(s): Notarnicola C, Didelot MN, Seguret F, Demaille J, Touitou I.
Source: Genes and Immunity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11857061&query_hl=30&itool=pubmed_docsum
- **Enigmas in familial Mediterranean fever (FMF).**
Author(s): Ben-Chetrit E, Levy M.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11760391&query_hl=30&itool=pubmed_docsum
- **Epithelial cell-derived neutrophil activator-78 levels in children with familial Mediterranean fever.**
Author(s): Baskin E, Saatci U, Ozen S.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12747300&query_hl=30&itool=pubmed_docsum
- **Erysipelas-like erythema of familial Mediterranean fever: clinicopathologic correlation.**
Author(s): Barzilai A, Langevitz P, Goldberg I, Kopolovic J, Livneh A, Pras M, Trau H.
Source: Journal of the American Academy of Dermatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10775856&query_hl=30&itool=pubmed_docsum
- **Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever.**
Author(s): Sakallioglu O, Duzova A, Ozen S.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16956436&query_hl=30&itool=pubmed_docsum

- **Evaluation of disease severity in familial Mediterranean fever.**
 Author(s): Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A.
 Source: Seminars in Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16084225&query_hl=30&itool=pubmed_docsum
- **Evaluation of joints using Tc 99m-MDP bone scintigraphy in patients with familial Mediterranean fever: should bone scans be used for diagnosis and follow-up?**
 Author(s): Yildiz M, Tunc SE, Sahin M, Okudan B, Aydin O, Suslu H, Ozbek M.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15690143&query_hl=30&itool=pubmed_docsum
- **Evaluation of the hypercoagulable state by measuring protein C and antithrombin III levels in nephrotic syndrome and in familial Mediterranean fever-related amyloidosis.**
 Author(s): Topaloglu R, Saatci U, Bakkaloglu A, Besbas N, Bassoy Y.
 Source: Turk J Pediatr.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1509525&query_hl=30&itool=pubmed_docsum
- **Exclusion of the familial Mediterranean fever locus as a susceptibility region for autosomal dominant familial Hibernian fever.**
 Author(s): McDermott MF, McDermott EM, Quane KA, Jones LC, Ogunkolade BW, Curtis D, Waldron-Lynch F, Phelan M, Hitman GA, Molloy MG, Powell RJ.
 Source: Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9610811&query_hl=30&itool=pubmed_docsum
- **Expression of the familial Mediterranean fever gene and activity of the C5a inhibitor in human primary fibroblast cultures.**
 Author(s): Matzner Y, Abedat S, Shapiro E, Eisenberg S, Bar-Gil-Shitrit A, Stepensky P, Calco S, Azar Y, Urieli-Shoval S.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10887141&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005.**
 Author(s): Ozen S, Hoffman HM, Frenkel J, Kastner D.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16606647&query_hl=30&itool=pubmed_docsum

- **Familial Mediterranean fever (FMF) in Lebanon and Jordan: a population genetics study and report of three novel mutations.**
Author(s): Medlej-Hashim M, Serre JL, Corbani S, Saab O, Jalkh N, Delague V, Chouery E, Salem N, Loiselet J, Lefranc G, Megarbane A.
Source: Eur J Med Genet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16378925&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus.**
Author(s): Deltas CC, Mean R, Rossou E, Costi C, Koupepidou P, Hadjiyanni I, Hadjirossos V, Petrou P, Pierides A, Lamnisou K, Koptides M.
Source: Genetic Testing.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12180071&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever and acute anterior myocardial infarction in a young patient.**
Author(s): Uyarel H, Karabulut A, Okmen E, Cam N.
Source: Anadolu Kardiyoloji Dergisi : Akd = the Anatolian Journal of Cardiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16943116&query_hl=30&itool=pubmed_docsum
- **Familial mediterranean fever and Behcet's disease--are they associated?**
Author(s): Ben-Chetrit E, Cohen R, Chajek-Shaul T.
Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11908568&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment.**
Author(s): Zung A, Barash G, Zadik Z, Barash J.
Source: J Pediatr Endocrinol Metab.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16562589&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever and peritoneal malignant mesothelioma: a possible association?**
Author(s): Hershcovici T, Chajek-Shaul T, Hasin T, Amar S, Hiller N, Prus D, Peleg H.
Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16889173&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever associated pyrin mutations in Greece.**
Author(s): Konstantopoulos K, Kanta A, Deltas C, Atamian V, Mavrogianni D, Tzioufas AG, Kollainis I, Ritis K, Moutsopoulos HM.
Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12695165&query_hl=30&itool=pubmed_docsum

- **Familial Mediterranean fever gene (MEFV) mutations in patients with rheumatic heart disease.**
 Author(s): Tutar E, Akar N, Atalay S, Yilmaz E, Akar E, Yalcinkaya F.
 Source: Heart (British Cardiac Society).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12010946&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever in 2 Japanese families.**
 Author(s): Shinozaki K, Agematsu K, Yasui K, Nagumo H, Naitoh H, Naganuma K, Komiyama A.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12064853&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever in a childhood population in eastern Turkey.**
 Author(s): Ertekin V, Selimoglu MA, Pirim I.
 Source: Pediatrics International : Official Journal of the Japan Pediatric Society.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16354216&query_hl=30&itool=pubmed_docsum
- **Familial mediterranean fever in Arabs.**
 Author(s): El-Shanti H, Majeed HA, El-Khateeb M.
 Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16564365&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever is no longer a rare disease in Italy.**
 Author(s): La Regina M, Nucera G, Diaco M, Procopio A, Gasbarrini G, Notarnicola C, Kone-Paut I, Touitou I, Manna R.
 Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12529705&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever mimicking Fitz-Hugh-Curtis syndrome.**
 Author(s): Romero-Gomez M, Corpas R, Sanchez-Munoz D, Grande L, Caballero V.
 Source: The American Journal of Gastroenterology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12650817&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever.**
 Author(s): Odabas AR, Cetinkaya R, Selcuk Y, Bilen H.
 Source: Southern Medical Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12597306&query_hl=30&itool=pubmed_docsum

- **Familial Mediterranean Fever: association of elevated IgD plasma levels with specific MEFV mutations.**
 Author(s): Medlej-Hashim M, Petit I, Adib S, Chouery E, Salem N, Delague V, Rawashdeh M, Mansour I, Lefranc G, Naman R, Loiselet J, Lecron JC, Serre JL, Megarbane A.
 Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11781702&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever: attacks during isotretinoin treatment.**
 Author(s): Alli N, Toy GG.
 Source: Journal of the American Academy of Dermatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12451392&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever: the potential for misdiagnosis of E148V using the E148Q usual RFLP detection method.**
 Author(s): Medlej-Hashim M, Salem N, Chouery E, Rawashdeh M, Delague V, Haffar M, Mansour I, Naman R, Lefranc G, Loiselet J, Megarbane A.
 Source: Clinical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11903360&query_hl=30&itool=pubmed_docsum
- **Familial Mediterranean fever: the segregation of four different mutations in 13 individuals from one inbred family: genotype-phenotype correlation and intrafamilial variability.**
 Author(s): Gershoni-Baruch R, Shinawi M, Shamaly H, Katsinets L, Brik R.
 Source: American Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11977178&query_hl=30&itool=pubmed_docsum
- **Febrile myalgia syndrome in familial Mediterranean fever.**
 Author(s): Soylyu A, Kasap B, Turkmen M, Saylam GS, Kavukcu S.
 Source: J Clin Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16601545&query_hl=30&itool=pubmed_docsum
- **Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever).**
 Author(s): Ehrenfeld M, Levy M, Sharon P, Rachmilewitz D, Eliakim M.
 Source: Digestive Diseases and Sciences.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6284460&query_hl=30&itool=pubmed_docsum
- **Genetic counselling in familial Mediterranean fever: has the time come?**
 Author(s): Ben-Chetrit E, Sagi M.
 Source: Rheumatology (Oxford, England).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11426015&query_hl=30&itool=pubmed_docsum

- **Genetic heterogeneity in familial Mediterranean fever: comment on the article by Cazeneuve et al.**
 Author(s): Gul A.
 Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15077328&query_hl=30&itool=pubmed_docsum
- **Genetic linkage study of familial Mediterranean fever (FMF) to 16p13.3 and evidence for genetic heterogeneity in the Turkish population.**
 Author(s): Akarsu AN, Saatci U, Ozen S, Bakkaloglu A, Besbas N, Sarfarazi M.
 Source: Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9222966&query_hl=30&itool=pubmed_docsum
- **Genetic marker family studies in familial Mediterranean fever (FMF) in Armenians.**
 Author(s): Shohat T, Shohat M, Petersen GM, Sparkes RS, Langfield D, Bickal J, Korenberg JR, Schwabe AD, Rotter JI.
 Source: Clinical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2282713&query_hl=30&itool=pubmed_docsum
- **Genetic predisposition of familial Mediterranean fever.**
 Author(s): Greenfield WR.
 Source: American Family Physician.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16848379&query_hl=30&itool=pubmed_docsum
- **Genetic risk factors of amyloidogenesis in familial Mediterranean fever.**
 Author(s): Delibas A, Oner A, Balci B, Demircin G, Bulbul M, Bek K, Erdogan O, Baysun S, Yilmaz E.
 Source: American Journal of Nephrology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16118480&query_hl=30&itool=pubmed_docsum
- **Genetic screening of familial Mediterranean fever mutations in the Palestinian population.**
 Author(s): Ayeshe SK, Nassar SM, Al-Sharef WA, Abu-Libdeh BY, Darwish HM.
 Source: Saudi Med J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15951859&query_hl=30&itool=pubmed_docsum
- **Genetic screening of fourteen mutations in Jordanian familial Mediterranean fever patients.**
 Author(s): Medlej-Hashim M, Rawashdeh M, Chouery E, Mansour I, Delague V, Lefranc G, Naman R, Loiselet J, Megarbane A.
 Source: Human Mutation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10737992&query_hl=30&itool=pubmed_docsum

- **Genetic testing for familial Mediterranean fever in Austria by means of reverse-hybridization teststrips.**
 Author(s): Oberkanins C, Weinhausel A, Kriegshauser G, Moritz A, Kury F, Haas OA.
 Source: Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14578333&query_hl=30&itool=pubmed_docsum
- **Genetics of familial Mediterranean fever and its implications.**
 Author(s): Ehrlich GE.
 Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9758581&query_hl=30&itool=pubmed_docsum
- **Genetics of familial Mediterranean fever.**
 Author(s): Roda PI.
 Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10357703&query_hl=30&itool=pubmed_docsum
- **Genetics of familial Mediterranean fever.**
 Author(s): Levin M.
 Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10357702&query_hl=30&itool=pubmed_docsum
- **Genotype/phenotype correlations in Arab patients with familial Mediterranean fever.**
 Author(s): Majeed HA, El-Shanti H, Al-Khateeb MS, Rabaiha ZA.
 Source: Seminars in Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12077709&query_hl=30&itool=pubmed_docsum
- **Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever.**
 Author(s): Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I, Koziol DE, Kastner DL, Pras M, Pras E.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10914855&query_hl=30&itool=pubmed_docsum
- **Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis.**
 Author(s): Yalcinkaya F, Cakar N, Misirlioglu M, Tumer N, Akar N, Tekin M, Tastan H, Kocak H, Ozkaya N, Elhan AH.
 Source: Rheumatology (Oxford, England).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10662876&query_hl=30&itool=pubmed_docsum

- **Genotype-phenotype relation and correlation in familial Mediterranean fever.**
 Author(s): Ben-Chetrit E.
 Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11729581&query_hl=30&itool=pubmed_docsum
- **Genotypic diagnosis of familial Mediterranean fever (FMF) using new microsatellite markers: example of two extensive non-Ashkenazi Jewish pedigrees.**
 Author(s): Dupont M, Dross C, Smaoui N, Nedelec B, Grateau G, Clepet C, Gourdier I, Kone-Paut I, Delpuch M, Demaille J, Touitou I.
 Source: Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9152834&query_hl=30&itool=pubmed_docsum
- **Glomerular lesions other than amyloidosis in patients with familial Mediterranean fever.**
 Author(s): Yalcinkaya F, Tumer N.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10052466&query_hl=30&itool=pubmed_docsum
- **Growth and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment.**
 Author(s): Savgan-Gurol E, Kasapcopur O, Hatemi S, Ercan O, Caliskan S, Sever L, Ozdogan H, Arisoy N.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11760406&query_hl=30&itool=pubmed_docsum
- **Helicobacter pylori infection in Turkish children with familial Mediterranean fever: is it a cause of persistent inflammation?**
 Author(s): Ozaltin F, Bakaloglu A, Saltik IN, Demir H, Duzova A, Bulun A, Besbas N, Topaloglu R, Ozen S.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15045642&query_hl=30&itool=pubmed_docsum
- **Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin.**
 Author(s): Tidow N, Chen X, Muller C, Kawano S, Gombart AF, Fischel-Ghodsian N, Koefler HP.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10666224&query_hl=30&itool=pubmed_docsum

- **Henoch-Schonlein purpura and familial Mediterranean fever.**
Author(s): Schlesinger M, Rubinow A, Vardy PA.
Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3871752&query_hl=30&itool=pubmed_docsum
- **Heredofamilial amyloidosis: incidence in familial Mediterranean fever: A report of two families.**
Author(s): Lender M.
Source: The American Journal of the Medical Sciences.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4458445&query_hl=30&itool=pubmed_docsum
- **High factor VIII levels during attacks of familial Mediterranean fever.**
Author(s): Akar N, Ekim M, Gurman C.
Source: Pediatric Nephrology (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15127284&query_hl=30&itool=pubmed_docsum
- **High urinary neopterin levels in Familial Mediterranean Fever.**
Author(s): Simsek H, Kadayifci A, Altindag ZZ, Sahin G.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8737737&query_hl=30&itool=pubmed_docsum
- **Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups.**
Author(s): Stoffman N, Magal N, Shohat T, Lotan R, Koman S, Oron A, Danon Y, Halpern GJ, Lifshitz Y, Shohat M.
Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10854115&query_hl=30&itool=pubmed_docsum
- **Hip involvement in patients with familial Mediterranean fever. A review of ten cases.**
Author(s): Younes M, Kahn MF, Meyer O.
Source: Joint, Bone, Spine : Revue Du Rhumatisme.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12537263&query_hl=30&itool=pubmed_docsum
- **Histologic signs of inflammatory myopathy in familial Mediterranean fever.**
Author(s): Gdynia HJ, Sperfeld AD, Haerter G.
Source: J Clin Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17023819&query_hl=30&itool=pubmed_docsum

- **HLA antigen in familial Mediterranean fever.**
 Author(s): Gazit E, Orgad S, Pras M.
 Source: Tissue Antigens.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=70085&query_hl=30&itool=pubmed_docsum
- **HLA-B27-negative sacroiliitis: a manifestation of familial Mediterranean fever in childhood.**
 Author(s): Lehman TJ, Hanson V, Kornreich H, Peters RS, Schwabe AD.
 Source: Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=643416&query_hl=30&itool=pubmed_docsum
- **Human foamy virus and familial Mediterranean fever in Japan.**
 Author(s): Tamura N, Kira S.
 Source: Jama : the Journal of the American Medical Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7474216&query_hl=30&itool=pubmed_docsum
- **Hyperactive polymorphonuclear leucocytes migration in patients with Familial Mediterranean Fever.**
 Author(s): Disdier P, Fossat C, Veit V, David M, Swiader L, Harle JR, Juhan-Vague I, Weiller PJ.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8894373&query_hl=30&itool=pubmed_docsum
- **Hyperimmunoglobulinaemia D and periodic fever mimicking familial Mediterranean fever in the Mediterranean.**
 Author(s): Topaloglu R, Saatci U.
 Source: Postgraduate Medical Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1852679&query_hl=30&itool=pubmed_docsum
- **Hypermobility and fibromyalgia frequency in childhood familial Mediterranean fever.**
 Author(s): Kasapcopur O, Tengirsek M, Ercan G, Yologlu N, Caliskan S, Sever L, Arisoy N.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515793&query_hl=30&itool=pubmed_docsum
- **Hypothesis: familial Mediterranean fever--a genetic disorder of the lipocortin family?**
 Author(s): Shohat M, Korenberg JR, Schwabe AD, Rotter JI.
 Source: American Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2530899&query_hl=30&itool=pubmed_docsum

- **Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients.**
 Author(s): Brucato A, Shinar Y, Brambilla G, Robbiolo L, Ferrioli G, Patrosso MC, Zanni D, Penco S, Boiani E, Ghirardello A, Caforio AL, Bergantin A, Tombini V, Moreo A, Ashtamkar L, Doria A, Shoenfeld Y, Livneh A.
 Source: *Lupus*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16218464&query_hl=30&itool=pubmed_docsum
- **IgA nephropathy in an Italian child with familial Mediterranean fever.**
 Author(s): Rigante D, Federico G, Ferrara P, Maggiano N, Avallone L, Pugliese AL, Stabile A.
 Source: *Pediatric Nephrology* (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16133043&query_hl=30&itool=pubmed_docsum
- **Imaging findings of familial Mediterranean fever.**
 Author(s): Ishak GE, Khoury NJ, Birjawi GA, El-Zein YR, Naffaa LN, Haddad MC.
 Source: *Clinical Imaging*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16632148&query_hl=30&itool=pubmed_docsum
- **Immunosuppressive treatment of AA amyloidosis of familial Mediterranean fever.**
 Author(s): Korkmaz C.
 Source: *Clin Exp Rheumatol*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16273776&query_hl=30&itool=pubmed_docsum
- **Impaired endotoxin tolerance induction in patients with familial Mediterranean fever.**
 Author(s): Davtyan TK, Hakopyan GS, Avetisyan SA, Mkrtchyan NR.
 Source: *Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16785765&query_hl=30&itool=pubmed_docsum
- **Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey.**
 Author(s): Onen F, Sumer H, Turkay S, Akyurek O, Tunca M, Ozdogan H.
 Source: *Clin Exp Rheumatol*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515780&query_hl=30&itool=pubmed_docsum
- **Increased frequency of mutations in the gene responsible for familial Mediterranean fever (MEFV) in a cohort of patients with ulcerative colitis: evidence for a potential disease-modifying effect?**
 Author(s): Giaglis S, Mimidis K, Papadopoulos V, Thomopoulos K, Sidiropoulos P, Rafail S, Nikolopoulou V, Fragouli E, Kartalis G, Tzioufas A, Boumpas D, Ritis K.
 Source: *Digestive Diseases and Sciences*.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16614989&query_hl=30&itool=pubmed_docsum

- **Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis.**
 Author(s): Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Calguneri M, Atalar E, Ozbalkan Z, Kirazli S, Celik I.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12563687&query_hl=30&itool=pubmed_docsum
- **Infantile familial Mediterranean fever.**
 Author(s): Brik R, Shinawi M, Gershoni-Baruch R.
 Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14719476&query_hl=30&itool=pubmed_docsum
- **Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis.**
 Author(s): Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA.
 Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15696552&query_hl=30&itool=pubmed_docsum
- **Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population.**
 Author(s): Bakkaloglu A, Duzova A, Ozen S, Balci B, Besbas N, Topaloglu R, Ozaltin F, Yilmaz E.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15170927&query_hl=30&itool=pubmed_docsum
- **Interferon alfa in protracted arthritis of familial Mediterranean fever: a robust alternative for synovectomy.**
 Author(s): Ureten K, Calguneri M, Onat AM, Ozcakar L, Ertenli I, Kiraz S.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15479914&query_hl=30&itool=pubmed_docsum
- **Interferon-gamma levels in familial Mediterranean fever.**
 Author(s): Koklu S, Ozturk MA, Balci M, Yuksel O, Ertenli I, Kiraz S.
 Source: Joint, Bone, Spine : Revue Du Rhumatisme.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15681246&query_hl=30&itool=pubmed_docsum
- **Interleukin-6 (IL-6) -174 G/C polymorphism in familial Mediterranean fever patients with and without amyloidosis.**
 Author(s): Karahan ZC, Ozturk A, Akar E, Akar N.
 Source: Journal of Nephrology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16299685&query_hl=30&itool=pubmed_docsum

- **Intrafamilial segregation analysis of the p.E148Q MEFV allele in familial Mediterranean fever.**
Author(s): Tchernitchko DO, Gerard-Blanluet M, Legendre M, Cazeneuve C, Grateau G, Amselem S.
Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16439437&query_hl=30&itool=pubmed_docsum
- **Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine.**
Author(s): Lidar M, Kedem R, Langevitz P, Pras M, Livneh A.
Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14719203&query_hl=30&itool=pubmed_docsum
- **Is hyperbilirubinemia a component or just a coincidence of familial Mediterranean fever: a case report and review of the literature.**
Author(s): Yazgan Y, Demirturk L, Ozel M, Ercan M.
Source: Turk J Gastroenterol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14593543&query_hl=30&itool=pubmed_docsum
- **Is MEFV P706 polymorphism important in familial Mediterranean fever patients?**
Author(s): Akar N, Ozturk A, Ozel D, Akar E, Ekim M.
Source: Journal of Nephrology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16523438&query_hl=30&itool=pubmed_docsum
- **Is there a heterozygote advantage for familial Mediterranean fever carriers against tuberculosis infections: speculations remain?**
Author(s): Ozen S, Balci B, Ozkara S, Ozcan A, Yilmaz E, Besbas N, Ozguc M, Kastner DL, Bakkaloglu A.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12371639&query_hl=30&itool=pubmed_docsum
- **Is there a hypothalamic-pituitary-adrenal axis dysfunction in patients with familial Mediterranean fever?**
Author(s): Korkmaz C.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16365686&query_hl=30&itool=pubmed_docsum

- **Lack of association between familial Mediterranean fever and angiotensin converting enzyme gene polymorphism.**
 Author(s): Calguneri M, Ozturk MA, Kiraz S, Ertenli I, Onat AM, Ureten K, Ozbalkan Z, Haznedaroglu IC.
 Source: Joint, Bone, Spine : Revue Du Rhumatisme.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16488647&query_hl=30&itool=pubmed_docsum
- **Late histological recurrence of familial Mediterranean fever amyloidosis after renal transplantation.**
 Author(s): Thervet E, Noel LH, Legendre C, Page B, Kreis H.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8190345&query_hl=30&itool=pubmed_docsum
- **Late occurrence of chronic renal failure in familial Mediterranean fever after 20 years of colchicine treatment.**
 Author(s): Vigneau C, Petrover D, Sraer JD.
 Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11747405&query_hl=30&itool=pubmed_docsum
- **Late-onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics.**
 Author(s): Tamir N, Langevitz P, Zemer D, Pras E, Shinar Y, Padeh S, Zaks N, Pras M, Livneh A.
 Source: American Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10528243&query_hl=30&itool=pubmed_docsum
- **Letter: Colchicine for familial Mediterranean fever: possible adverse effects.**
 Author(s): Poffenbarger PL, Brinkley BR.
 Source: The New England Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4855545&query_hl=30&itool=pubmed_docsum
- **Letter: Colchicine-aspirin for recurrent polyserositis (familial Mediterranean fever).**
 Author(s): Eliakim M, Light A.
 Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4127683&query_hl=30&itool=pubmed_docsum
- **Leukocyte chemotaxis in recurrent polyserositis (familial Mediterranean fever).**
 Author(s): Bar-Eli M, Ehrenfeld M, Levy M, Gallily R, Eliakim M.
 Source: The American Journal of the Medical Sciences.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7468635&query_hl=30&itool=pubmed_docsum

- **Levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in familial Mediterranean fever (FMF) patients and their first degree relatives.**
Author(s): Oktem S, Yavuzsen TU, Sengul B, Akhunlar H, Akar S, Tunca M.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515781&query_hl=30&itool=pubmed_docsum
- **Light chain deposition disease complicating familial Mediterranean fever.**
Author(s): Vella JP, Doyle GD, Campbell E, Walshe JJ.
Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9186082&query_hl=30&itool=pubmed_docsum
- **Linkage disequilibrium mapping places the gene causing familial Mediterranean fever close to D16S246.**
Author(s): Levy EN, Shen Y, Kupelian A, Kruglyak L, Aksentijevich I, Pras E, Balow JE Jr, Linzer B, Chen X, Shelton DA, Gumucio D, Pras M, Shohat M, Rotter JI, Fischel-Ghodsian N, Richards RI, Kastner DL.
Source: American Journal of Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8644712&query_hl=30&itool=pubmed_docsum
- **Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever.**
Author(s): Diaz A, Hu C, Kastner DL, Schaner P, Reginato AM, Richards N, Gumucio DL.
Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15529356&query_hl=30&itool=pubmed_docsum
- **Lithium prophylaxis in familial Mediterranean fever.**
Author(s): Christodoulou GN, Madianos MG, Stefanis CN, Loukopoulos DL.
Source: The American Journal of Psychiatry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=464138&query_hl=30&itool=pubmed_docsum
- **Liver sinusoidal dilatation in familial Mediterranean fever.**
Author(s): Clotet B, Navas J, Grifol M, Rubies-Prat J, Foz M.
Source: Archives of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3718121&query_hl=30&itool=pubmed_docsum

- **Living with a child with familial Mediterranean fever: does it affect the quality of life of the parents?**
 Author(s): Press J, Neumann L, Abu-Shakra M, Bolotin A, Buskila D.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10728454&query_hl=30&itool=pubmed_docsum
- **Location of the gene causing hyperimmunoglobulinemia D and periodic fever syndrome differs from that for familial Mediterranean fever. International Hyper-IgD Study Group.**
 Author(s): Drenth JP, Mariman EC, Van der Velde-Visser SD, Ropers HH, Van der Meer JW.
 Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7989036&query_hl=30&itool=pubmed_docsum
- **Long-term colchicine prophylaxis in children with familial Mediterranean fever (recurrent hereditary polyserositis).**
 Author(s): Majeed HA, Carroll JE, Khuffash FA, Hijazi Z.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2112191&query_hl=30&itool=pubmed_docsum
- **Long-term colchicine therapy for renal amyloidosis in familial Mediterranean fever.**
 Author(s): Walker F, Bear RA.
 Source: Can Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7139463&query_hl=30&itool=pubmed_docsum
- **Long-term colchicine treatment in children with familial Mediterranean fever.**
 Author(s): Zemer D, Livneh A, Danon YL, Pras M, Sohar E.
 Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1859491&query_hl=30&itool=pubmed_docsum
- **Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience.**
 Author(s): Keven K, Sengul S, Kutlay S, Ekmekci Y, Anadol E, Nergizoglu G, Ates K, Erturk S, Erbay B.
 Source: Transplantation Proceedings.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15621109&query_hl=30&itool=pubmed_docsum

- **Low serum apolipoprotein AI levels in amyloidosis related to familial Mediterranean fever.**
 Author(s): Islek I, Simsek T, Baskin E, Simsek B, Kucukoduk S, Bedir A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Saatci U.
 Source: Pediatric Nephrology (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12883976&query_hl=30&itool=pubmed_docsum
- **Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation.**
 Author(s): Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12563686&query_hl=30&itool=pubmed_docsum
- **Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16.**
 Author(s): Pras E, Aksentijevich I, Gruberg L, Balow JE Jr, Prosen L, Dean M, Steinberg AD, Pras M, Kastner DL.
 Source: The New England Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1579134&query_hl=30&itool=pubmed_docsum
- **Mapping of the familial Mediterranean fever gene to chromosome 16.**
 Author(s): Gruberg L, Aksentijevich I, Pras E, Kastner DL, Pras M.
 Source: American Journal of Reproductive Immunology (New York, N.Y. : 1989).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1285890&query_hl=30&itool=pubmed_docsum
- **Massive renal and adrenal calcifications in a young dialysis patient with familial Mediterranean fever.**
 Author(s): Delanaye P, Krzesinski JM.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15632359&query_hl=30&itool=pubmed_docsum
- **MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study.**
 Author(s): Balci B, Tinaztepe K, Yilmaz E, Gucer S, Ozen S, Topaloglu R, Besbas N, Ozguc M, Bakkaloglu A.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12401847&query_hl=30&itool=pubmed_docsum

- **MEFV mutation carriers and diseases other than familial Mediterranean fever: proved and non-proved associations; putative biological advantage.**
 Author(s): Cattani D.
 Source: Current Drug Targets. Inflammation and Allergy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15720243&query_hl=30&itool=pubmed_docsum
- **MEFV mutations and phenotype-genotype correlations in North African Jews and Armenians with familial Mediterranean fever.**
 Author(s): Cattani D, Dervichian M, Thomas M, Dode C, Touitou I.
 Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11729572&query_hl=30&itool=pubmed_docsum
- **MEFV mutations in familial Mediterranean fever: association of M694V homozygosity with arthritis.**
 Author(s): Olgun A, Akman S, Kurt I, Tuzun A, Kutluay T.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14727057&query_hl=30&itool=pubmed_docsum
- **MEFV mutations in multiplex families with familial Mediterranean fever: is a particular genotype necessary for amyloidosis?**
 Author(s): Tekin M, Yalcinkaya F, Cakar N, Akar N, Misirlioglu M, Tastan H, Tumer N.
 Source: Clinical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10905662&query_hl=30&itool=pubmed_docsum
- **MEFV mutations in Turkish patients suffering from Familial Mediterranean Fever.**
 Author(s): Akar N, Misiroglu M, Yalcinkaya F, Akar E, Cakar N, Tumer N, Akcakus M, Tastan H, Matzner Y.
 Source: Human Mutation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10612841&query_hl=30&itool=pubmed_docsum
- **Meningismus after metamorphin administration in a patient with Familial Mediterranean fever.**
 Author(s): Kapur S, Mutagi H, Raphael J.
 Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16987863&query_hl=30&itool=pubmed_docsum
- **Meningitis associated with familial Mediterranean fever.**
 Author(s): Karachaliou I, Karachalios G, Charalabopoulos A, Charalabopoulos K.
 Source: Int J Clin Pract Suppl.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15875625&query_hl=30&itool=pubmed_docsum

- **Microalbuminuria in the course of familial Mediterranean fever.**
 Author(s): Baskin E, Saatci U.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15388834&query_hl=30&itool=pubmed_docsum

- **Molecular diagnosis of familial Mediterranean fever.**
 Author(s): Nir-Paz R, Ben-Chetrit E.
 Source: The New England Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10627216&query_hl=30&itool=pubmed_docsum

- **Molecular genetic testing for familial Mediterranean fever.**
 Author(s): Telatar M, Grody WW.
 Source: Molecular Genetics and Metabolism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11001819&query_hl=30&itool=pubmed_docsum

- **Multiplex molecular diagnosis of MEFV mutations in patients with familial Mediterranean fever by LightCycler real-time PCR.**
 Author(s): Rossou E, Kouvatzi A, Aslanidis C, Deltas C.
 Source: Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16120953&query_hl=30&itool=pubmed_docsum

- **Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population.**
 Author(s): Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N, Saatci U, Bakkaloglu A, Ozguc M.
 Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11464248&query_hl=30&itool=pubmed_docsum

- **Mutational analysis of the PRYSPRY domain of pyrin and implications for familial Mediterranean fever (FMF).**
 Author(s): Goulielmos GN, Fragouli E, Aksentijevich I, Sidiropoulos P, Boumpas DT, Eliopoulos E.
 Source: Biochemical and Biophysical Research Communications.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16730661&query_hl=30&itool=pubmed_docsum

- **Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation?**
 Author(s): Ozen S, Bakkaloglu A, Yilmaz E, Duzova A, Balci B, Topaloglu R, Besbas N.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12966608&query_hl=30&itool=pubmed_docsum

- **Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever.**
 Author(s): Dode C, Pecheux C, Cazeneuve C, Cattan D, Dervichian M, Goossens M, Delpech M, Amselem S, Grateau G.
 Source: American Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10842288&query_hl=30&itool=pubmed_docsum
- **Nailfold capillary abnormalities in patients with familial Mediterranean fever.**
 Author(s): Dinc A, Melikoglu M, Korkmaz C, Fresko I, Ozdogan H, Yazici H.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11760397&query_hl=30&itool=pubmed_docsum
- **Necrotizing crescentic glomerulonephritis with granulomatous vasculitis in a patient with familial Mediterranean fever and renal amyloidosis.**
 Author(s): Cefle A, Kilicaslan I, Gul A, Kamali S, Inanc M, Konice M.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515794&query_hl=30&itool=pubmed_docsum
- **Necrotizing vasculitis associated with familial Mediterranean fever.**
 Author(s): Hatemi G, Masatlioglu S, Gogus F, Ozdogan H.
 Source: The American Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15464709&query_hl=30&itool=pubmed_docsum
- **Neurologic manifestations in familial Mediterranean fever.**
 Author(s): Gedalia A, Zamir S.
 Source: Pediatric Neurology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8216544&query_hl=30&itool=pubmed_docsum
- **Neutrophil adhesion molecule expression in familial Mediterranean fever: discordance between the intravascular regulation of beta2 integrin and L-selectin expression in acute attack.**
 Author(s): Molad Y, Fridenberg A, Bloch K, Langevitz P, Mukamel M, Sulkes J, Pras M, Livneh A.
 Source: Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14989371&query_hl=30&itool=pubmed_docsum
- **New interest in an old disease: familial Mediterranean fever.**
 Author(s): Ozen S.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10609078&query_hl=30&itool=pubmed_docsum

- **Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF).**
 Author(s): Bernot A, da Silva C, Petit JL, Cruaud C, Caloustian C, Castet V, Ahmed-Arab M, Dross C, Dupont M, Cattani D, Smaoui N, Dode C, Pecheux C, Nedelec B, Medaxian J, Rozenbaum M, Rosner I, Delpech M, Grateau G, Demaille J, Weissenbach J, Touitou I.
 Source: Human Molecular Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9668175&query_hl=30&itool=pubmed_docsum
- **Non-isotopic RNase cleavage assay for mutation detection in MEFV, the gene responsible for familial Mediterranean fever, in a cohort of Greek patients.**
 Author(s): Ritis K, Giaglis S, Spathari N, Micheli A, Zonios D, Tzoanopoulos D, Deltas CC, Rafail S, Mean R, Papadopoulos V, Tzioufas AG, Moutsopoulos HM, Kartalis G.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15020340&query_hl=30&itool=pubmed_docsum
- **Non-period leg pain in patients with familial Mediterranean fever.**
 Author(s): Dinc A.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10836960&query_hl=30&itool=pubmed_docsum
- **Ocular involvement in siblings with familial Mediterranean fever.**
 Author(s): Akman A, Varan B, Akova YA, Aydin P.
 Source: Journal of Pediatric Ophthalmology and Strabismus.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11310705&query_hl=30&itool=pubmed_docsum
- **Once-daily use of colchicine in children with familial Mediterranean fever.**
 Author(s): Kosan C, Ozkan B.
 Source: Clinical Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15378145&query_hl=30&itool=pubmed_docsum
- **Optic neuritis associated with familial Mediterranean fever.**
 Author(s): Lossos A, Eliashiv S, Ben-Chetrit E, Reches A.
 Source: J Clin Neuroophthalmol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8340482&query_hl=30&itool=pubmed_docsum

- **Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects.**
 Author(s): Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8164212&query_hl=30&itool=pubmed_docsum
- **Oxidative stress status in familial Mediterranean fever with or without proteinuria.**
 Author(s): Gurbuz M, Yamanel L, Bulucu F, Inal V, Aydin A.
 Source: Free Radical Biology & Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15607910&query_hl=30&itool=pubmed_docsum
- **Oxyradical-mediated chromosome damage in patients with familial Mediterranean fever.**
 Author(s): Emerit I, Arutyunyan R, Sarkisian T, Mejlumian H, Torosian E, Panossian AG.
 Source: Free Radical Biology & Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8406126&query_hl=30&itool=pubmed_docsum
- **Periodic fever compatible with familial Mediterranean fever.**
 Author(s): Takahashi M, Ebe T, Kohara T, Inagaki M, Isonuma H, Hibiya I, Mori T, Watanabe K, Ikemoto H.
 Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1450498&query_hl=30&itool=pubmed_docsum
- **Periodic fever in infants: familial Mediterranean fever only?**
 Author(s): Ben-Chetrit E.
 Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14719474&query_hl=30&itool=pubmed_docsum
- **Peritoneal amyloidosis caused by Familial Mediterranean Fever.**
 Author(s): Poturoglu S, Mungan Z, Boztas G, Kaymakoglu S, Ozdil S, Akyuz F, Aksoy N, Kamali S, Pinarbasi B, Cevikbas U, Okten A.
 Source: Journal of Gastroenterology and Hepatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15683444&query_hl=30&itool=pubmed_docsum
- **PFAPA syndrome mimicking familial Mediterranean fever: report of a Turkish child.**
 Author(s): Atas B, Caksen H, Arslan S, Tuncer O, Kirimi E, Odabas D.
 Source: The Journal of Emergency Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14654177&query_hl=30&itool=pubmed_docsum

- **Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update.**
 Author(s): Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R.
 Source: Current Drug Targets. Inflammation and Allergy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15720245&query_hl=30&itool=pubmed_docsum
- **Plasma dopamine beta-hydroxylase activity in familial Mediterranean fever.**
 Author(s): Courillon-Mallet A, Cauet N, Dervichian M, Launay JM, Cattan D.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1506166&query_hl=30&itool=pubmed_docsum
- **Plasma interleukin-10 and interleukin-12 levels in patients with familial Mediterranean fever.**
 Author(s): Erken E, Ozer HT, Gunesacar R.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16397779&query_hl=30&itool=pubmed_docsum
- **Polyarteritis nodosa in a case of familial Mediterranean fever.**
 Author(s): Bakkaloglu SA, Muzac S, Akpek S, Soylemezoglu O, Buyan N, Hasanoglu E.
 Source: Pediatric Nephrology (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14963762&query_hl=30&itool=pubmed_docsum
- **Polyglandular endocrine failure in a patient with amyloidosis secondary to familial Mediterranean fever.**
 Author(s): Keven K, Oztas E, Aksoy H, Duman N, Erbay B, Erturk S.
 Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11728999&query_hl=30&itool=pubmed_docsum
- **Possible effect of subclinical inflammation on daily life in familial Mediterranean fever.**
 Author(s): Ozcakar ZB, Yalcinkaya F, Yuksel S, Acar B, Gokmen D, Ekim M.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16172947&query_hl=30&itool=pubmed_docsum
- **Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever.**
 Author(s): Belmahi L, Sefiani A, Fouveau C, Feingold J, Delpéch M, Grateau G, Dode C.
 Source: Comptes Rendus Biologies.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16439335&query_hl=30&itool=pubmed_docsum

- **Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura.**
 Author(s): Gershoni-Baruch R, Broza Y, Brik R.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14615741&query_hl=30&itool=pubmed_docsum
- **Prevalence and significance of mutations in the familial Mediterranean fever gene in patients with Crohn's disease.**
 Author(s): Karban A, Dagan E, Eliakim R, Herman A, Nesher S, Weiss B, Berkowitz D, Shamir R, Gershoni-Baruch R.
 Source: Genes and Immunity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15674370&query_hl=30&itool=pubmed_docsum
- **Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148.**
 Author(s): Booth DR, Lachmann HJ, Gillmore JD, Booth SE, Hawkins PN.
 Source: Qjm : Monthly Journal of the Association of Physicians.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11588211&query_hl=30&itool=pubmed_docsum
- **Protracted febrile myalgia of familial Mediterranean fever.**
 Author(s): Kotevoglu N, Sahin F, Ozkiris SO, Bankaoglu M, Sakiz D, Kuran B.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515790&query_hl=30&itool=pubmed_docsum
- **Psychosocial correlates of incidence of attacks in children with Familial Mediterranean Fever.**
 Author(s): Gidron Y, Berkovitch M, Press J.
 Source: Journal of Behavioral Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12776380&query_hl=30&itool=pubmed_docsum
- **Pulmonary amyloidosis in familial Mediterranean fever.**
 Author(s): Sahan C, Cengiz K.
 Source: Acta Clin Belg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16881565&query_hl=30&itool=pubmed_docsum
- **Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway.**
 Author(s): Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, Kastner DL.
 Source: Proceedings of the National Academy of Sciences of the United States of America.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14595024&query_hl=30&itool=pubmed_docsum

- **Pyrin Q148 mutation and familial Mediterranean fever.**
 Author(s): Ozen S, Besbas N, Bakkaloglu A, Yilmaz E.
 Source: Qjm : Monthly Journal of the Association of Physicians.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11978906&query_hl=30&itool=pubmed_docsum
- **Quality of life of patients with familial Mediterranean fever.**
 Author(s): Buskila D, Zaks N, Neumann L, Livneh A, Greenberg S, Pras M, Langevitz P.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9272294&query_hl=30&itool=pubmed_docsum
- **Reactive amyloidosis and familial Mediterranean fever (FMF).**
 Author(s): Takahashi N, Suzuki E, Gejyo F.
 Source: Intern Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12058876&query_hl=30&itool=pubmed_docsum
- **Recurrent episodic fever. A presenting feature of familial Mediterranean fever.**
 Author(s): Majeed HA, Rawashdeh M, Qubain H.
 Source: J Med Liban.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9795516&query_hl=30&itool=pubmed_docsum
- **Recurrent hyperbilirubinaemia, a feature of familial Mediterranean fever: report of a child and review of the literature.**
 Author(s): Majeed HA, Halabi I, al-Taleb O.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9691995&query_hl=30&itool=pubmed_docsum
- **Recurrent pericarditis as a manifestation of familial Mediterranean fever.**
 Author(s): Ercan Tutar H, Imamoglu A, Atalay S.
 Source: Circulation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10662763&query_hl=30&itool=pubmed_docsum
- **Recurrent pericarditis in familial Mediterranean fever.**
 Author(s): Tutar HE, Imamoglu A, Atalay S.
 Source: Acta Paediatrica (Oslo, Norway : 1992).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10519355&query_hl=30&itool=pubmed_docsum
- **Recurrent urticaria as a rare manifestation of familial Mediterranean fever.**
 Author(s): Alonso R, Cistero-Bahima A, Enrique E, San Miguel-Moncin MM.
 Source: J Invest Allergol Clin Immunol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12109534&query_hl=30&itool=pubmed_docsum

- **Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever.**
 Author(s): Notarnicola C, Didelot MN, Kone-Paut I, Seguret F, Demaille J, Touitou I.
 Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12384939&query_hl=30&itool=pubmed_docsum
- **Reflex sympathetic dystrophy arising in a patient with familial Mediterranean fever.**
 Author(s): Bodur H, Gunduz OH, Yucel M.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10651087&query_hl=30&itool=pubmed_docsum
- **Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment.**
 Author(s): Simsek B, Islek I, Simsek T, Kucukoduk S, Cengiz K.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10648685&query_hl=30&itool=pubmed_docsum
- **Regression of nephrotic syndrome in amyloidosis of familial Mediterranean fever following colchicine treatment.**
 Author(s): Livneh A, Shtrasburg S, Langevitz P.
 Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11007856&query_hl=30&itool=pubmed_docsum
- **Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product.**
 Author(s): Dowds TA, Masumoto J, Chen FF, Ogura Y, Inohara N, Nunez G.
 Source: Biochemical and Biophysical Research Communications.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12615073&query_hl=30&itool=pubmed_docsum
- **Remission of nephrotic syndrome in amyloidosis of familial Mediterranean fever following colchicine treatment.**
 Author(s): Odabas H.
 Source: Ann Saudi Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16761461&query_hl=30&itool=pubmed_docsum
- **Renal amyloidosis as a first manifestation of Familial Mediterranean Fever.**
 Author(s): Konstantopoulos K, Michael S, Kanta A, Pecheux C, Grateau J, Helioti H, Stathakis C.
 Source: Scandinavian Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10777128&query_hl=30&itool=pubmed_docsum

- **Renal amyloidosis in familial Mediterranean fever.**
 Author(s): Ozen S.
 Source: Kidney International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14871446&query_hl=30&itool=pubmed_docsum
- **Renal transplantation in amyloidosis secondary to familial Mediterranean fever.**
 Author(s): Sever MS, Turkmen A, Sahin S, Yildiz A, Ecder T, Kayacan MS, Nane I, Aydin AE, Eldegez U.
 Source: Transplantation Proceedings.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11750451&query_hl=30&itool=pubmed_docsum
- **Reproductive system in familial Mediterranean fever: an overview.**
 Author(s): Ben-Chetrit E, Levy M.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12972465&query_hl=30&itool=pubmed_docsum
- **Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever.**
 Author(s): Zemer D, Livneh A, Langevitz P.
 Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1736782&query_hl=30&itool=pubmed_docsum
- **Reverse hybridization vs. DNA sequencing in the molecular diagnosis of Familial Mediterranean fever.**
 Author(s): Delague V, Kriegshauser G, Oberkanins C, Megarbane A.
 Source: Genetic Testing.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15140375&query_hl=30&itool=pubmed_docsum
- **Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.**
 Author(s): Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Basoy Y, Yilmaz E.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12942707&query_hl=30&itool=pubmed_docsum
- **Rubinstein-Taybi syndrome and familial Mediterranean fever in a single patient: two distinct genetic diseases located on chromosome 16p13.3.**
 Author(s): Kalyoncu U, Tufan A, Karadag O, Kisacik B, Akdogan A, Calguneri M.
 Source: Journal of the National Medical Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17052063&query_hl=30&itool=pubmed_docsum

- **Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis.**
 Author(s): Balaban B, Yasar E, Ozgul A, Dincer K, Kalyon TA.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15711787&query_hl=30&itool=pubmed_docsum
- **Seronegative spondyloarthropathy of familial Mediterranean fever.**
 Author(s): Incel NA, Saracoglu M, Erdem HR.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12611376&query_hl=30&itool=pubmed_docsum
- **Serum amyloid A1 -13 T/C alleles in Turkish familial Mediterranean fever patients with and without amyloidosis.**
 Author(s): Akar N, Hasipek M, Ozturk A, Akar E, Tekin M.
 Source: Journal of Nephrology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16874691&query_hl=30&itool=pubmed_docsum
- **Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever.**
 Author(s): Haznedaroglu S, Ozturk MA, Sancak B, Goker B, Onat AM, Bukan N, Ertenli I, Kiraz S, Calguneri M.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16273770&query_hl=30&itool=pubmed_docsum
- **Serum leptin is not a diagnostic marker for familial Mediterranean fever attacks.**
 Author(s): Toy B, Tarcin O, Bagci S, Ustundag Y, Inal A, Tiftikci A.
 Source: Mediators of Inflammation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16883064&query_hl=30&itool=pubmed_docsum
- **Severe outcome of juvenile idiopathic arthritis (JIA) associated with familial Mediterranean fever (FMF).**
 Author(s): Rozenbaum M, Rosner I.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515792&query_hl=30&itool=pubmed_docsum
- **Small bowel obstruction by a carcinoid tumor in a patient with familial Mediterranean fever.**
 Author(s): Gabizon I, Giladi H, Ovnat A, Dukhno O, Flusser D, Sukenik S.
 Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16805241&query_hl=30&itool=pubmed_docsum

- **Sonographic evaluation of the tendons in familial Mediterranean fever and Behcet's disease.**
 Author(s): Ozcakar L, Onat AM, Ureten K, Cetin A, Kiraz S, Ertenli I, Calguneri M, Akinci A.
 Source: Joint, Bone, Spine : Revue Du Rhumatisme.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16650792&query_hl=30&itool=pubmed_docsum
- **Spinal cord stimulation for relief of abdominal pain in two patients with familial Mediterranean fever.**
 Author(s): Kapur S, Mutagi H, Raphael J.
 Source: British Journal of Anaesthesia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17062615&query_hl=30&itool=pubmed_docsum
- **Spontaneous renal laceration as the presenting feature of polyarteritis nodosa in a patient with familial Mediterranean fever after hepatitis A infection.**
 Author(s): Candan F, Ayan S, Tas F, Gokce G, Elagoz S.
 Source: Rheumatology International.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15765217&query_hl=30&itool=pubmed_docsum
- **Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient.**
 Author(s): Seyahi E, Ozdogan H, Masatlioglu S, Yazici H.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12371635&query_hl=30&itool=pubmed_docsum
- **Sustained, progressive, nonresolving abdominal pain: a previously undescribed clinical presentation of familial Mediterranean fever.**
 Author(s): Radisic M, Santamarina J, Froment R.
 Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16328089&query_hl=30&itool=pubmed_docsum
- **The carotid-femoral (aortic) pulse wave velocity as a marker of arterial stiffness in familial Mediterranean fever.**
 Author(s): Yildiz M, Masatlioglu S, Seymen P, Aytac E, Sahin B, Seymen HO.
 Source: The Canadian Journal of Cardiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17102830&query_hl=30&itool=pubmed_docsum
- **The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever.**
 Author(s): Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A.
 Source: Arthritis and Rheumatism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12687559&query_hl=30&itool=pubmed_docsum

- **The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever.**
 Author(s): Gershoni-Baruch R, Brik R, Shinawi M, Livneh A.
 Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11938447&query_hl=30&itool=pubmed_docsum
- **The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever.**
 Author(s): Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A.
 Source: Eur Rev Med Pharmacol Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16910346&query_hl=30&itool=pubmed_docsum
- **The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever.**
 Author(s): Tunca M, Akar S, Hawkins PN, Booth SE, Sengul B, Yavuzsen TU, Oktem S, Soyuturk M, Akkoc N, Booth DR.
 Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12461684&query_hl=30&itool=pubmed_docsum
- **Third International Conference on Familial Mediterranean Fever and Other Hereditary Inflammatory Disorders.**
 Author(s): Langevitz P, Livneh A.
 Source: Isr Med Assoc J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12674673&query_hl=30&itool=pubmed_docsum
- **Thoracic and lung involvement in familial Mediterranean fever (FMF).**
 Author(s): Lidar M, Pras M, Langevitz P, Livneh A.
 Source: Clinics in Chest Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12092043&query_hl=30&itool=pubmed_docsum
- **Thoughts on the proposed links between Behcet's disease and familial Mediterranean fever.**
 Author(s): Ben-Chetrit E, Yazici H.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12371627&query_hl=30&itool=pubmed_docsum
- **Tuberculous ileitis in a renal transplant recipient with familial Mediterranean fever: Gray-scale and power Doppler sonographic findings.**
 Author(s): Yilmaz E, Balci A, Sal S, Cakmakci H.
 Source: Journal of Clinical Ultrasound : Jcu.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12478654&query_hl=30&itool=pubmed_docsum

- **Tubular functions in familial Mediterranean fever.**
 Author(s): Akkus S, Caliskan S, Kasapcopur O.
 Source: Turk J Pediatr.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12458807&query_hl=30&itool=pubmed_docsum

- **Unmasking of isolated hypoaldosteronism after renal allotransplantation in familial Mediterranean fever.**
 Author(s): Silver J, Rosler A, Friedlander M, Popovtzer MM.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7045036&query_hl=30&itool=pubmed_docsum

- **Unusual immunologic findings in familial Mediterranean fever.**
 Author(s): Savi M, Asinari G, Gaudiano V, Olivetti G, Neri TM.
 Source: Archives of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=637649&query_hl=30&itool=pubmed_docsum

- **Unusual presentation of familial Mediterranean fever: role of genetic diagnosis.**
 Author(s): Nir-Paz R, Ben-Chetrit E, Pikarsky E, Hassin D, Hasin Y, Chajek-Shaul T.
 Source: Annals of the Rheumatic Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11005788&query_hl=30&itool=pubmed_docsum

- **Urinary albumin excretion in patients with familial Mediterranean fever: a pilot study.**
 Author(s): Oren S, Viskoper JR, Ilan S, Schlesinger M.
 Source: The American Journal of the Medical Sciences.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2039023&query_hl=30&itool=pubmed_docsum

- **Urinary glycosaminoglycans in the course of familial Mediterranean fever.**
 Author(s): Baskin E, Saatci U, Ciliv G, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S.
 Source: European Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12692710&query_hl=30&itool=pubmed_docsum

- **Urinary neopterin level in familial Mediterranean fever.**
 Author(s): Arat-Altindag Z, Sahin G, Ozyilkan E, Isimer A, Telatar H.
 Source: Presse Medicale (Paris, France : 1983).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8072985&query_hl=30&itool=pubmed_docsum

- **Urine leukotriene B4 in familial Mediterranean fever and other forms of right lower abdominal pain.**
 Author(s): Bentancur AG, Naveh N, Lancri J, Selah BA, Shtrasburg S, Livneh A.
 Source: Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15995103&query_hl=30&itool=pubmed_docsum
- **Urine leukotriene B4 in familial Mediterranean fever.**
 Author(s): Bentancur AG, Naveh N, Lancri J, Selah BA, Livneh A.
 Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15515787&query_hl=30&itool=pubmed_docsum
- **Use of metamamol in patients with Familial Mediterranean Fever.**
 Author(s): Kapur S, Mutagi H, Raphael J.
 Source: Anaesthesia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16867110&query_hl=30&itool=pubmed_docsum
- **Variable expression of vasculitis in siblings with familial Mediterranean fever.**
 Author(s): Lange-Sperandio B, Mohring K, Gutzler F, Mehls O.
 Source: Pediatric Nephrology (Berlin, Germany).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15015067&query_hl=30&itool=pubmed_docsum
- **Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups.**
 Author(s): Pras M, Bronshpigel N, Zemer D, Gafni J.
 Source: Johns Hopkins Med J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7054581&query_hl=30&itool=pubmed_docsum
- **Vasculitis in familial Mediterranean fever.**
 Author(s): Ozdogan H, Arisoy N, Kasapcapur O, Sever L, Caliskan S, Tuzuner N, Mat C, Yazici H.
 Source: The Journal of Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9034991&query_hl=30&itool=pubmed_docsum
- **Vasculopathy, Behcet's syndrome, and familial Mediterranean fever.**
 Author(s): Ozen S.
 Source: Current Opinion in Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10503660&query_hl=30&itool=pubmed_docsum

- **Watermelon stomach and familial Mediterranean fever.**
Author(s): Michopoulos S, Tsibouris P, Sotiropoulou M, Petraki K, Vassilopoulos D, Kralios N.
Source: The American Journal of Gastroenterology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11513209&query_hl=30&itool=pubmed_docsum
- **Whipple's disease, familial Mediterranean fever, adult-onset Still's disease, and enteropathic arthritis.**
Author(s): McMenemy A.
Source: Current Opinion in Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1380277&query_hl=30&itool=pubmed_docsum
- **Whipple's disease, familial Mediterranean fever, and adult-onset Still's disease.**
Author(s): McMenemy A.
Source: Current Opinion in Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1716941&query_hl=30&itool=pubmed_docsum
- **Y688X, the first nonsense mutation in familial Mediterranean fever (FMF).**
Author(s): Notarnicola C, Manna R, Rey JM, Touitou I.
Source: Human Mutation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11139259&query_hl=30&itool=pubmed_docsum

CHAPTER 2. ALTERNATIVE MEDICINE AND FAMILIAL MEDITERRANEAN FEVER

Overview

In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to familial Mediterranean fever. At the conclusion of this chapter, we will provide additional sources.

National Center for Complementary and Alternative Medicine

The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (<http://nccam.nih.gov/>) has created a link to the National Library of Medicine's databases to facilitate research for articles that specifically relate to familial Mediterranean fever and complementary medicine. To search the database, go to the following Web site: <http://www.nlm.nih.gov/nccam/camonpubmed.html>. Select **CAM on PubMed**. Enter **familial Mediterranean fever** (or synonyms) into the search box. Click **Go**. The following references provide information on particular aspects of complementary and alternative medicine that are related to familial Mediterranean fever:

- **Allogeneic bone marrow transplantation: cure for familial Mediterranean fever.**
 Author(s): Milledge J, Shaw PJ, Mansour A, Williamson S, Bennetts B, Roscioli T, Curtin J, Christodoulou J.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12130485&query_hl=1&itool=pubmed_docsum
- **Colchicine derivatives inhibit neopterin production in human peripheral blood mononuclear cells (PBMC).**
 Author(s): Altindag ZZ, Werner-Felmayer G, Sahin G, Wachter H, Fuchs D.
 Source: Clinical and Experimental Immunology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9067535&query_hl=1&itool=pubmed_docsum

- **Degradation of amyloid by a serum component and inhibition of degradation.**
Author(s): Kedar I, Sohar E, Ravid M.
Source: The Journal of Laboratory and Clinical Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6802914&query_hl=1&itool=pubmed_docsum
- **Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard-- a standardized fixed combination of *Andrographis paniculata* Nees, with *Eleutherococcus senticosus* Maxim, *Schizandra chinensis* Bail. and *Glycyrrhiza glabra* L. extracts in patients with Familial Mediterranean Fever.**
Author(s): Amaryan G, Astvatsatryan V, Gabrielyan E, Panossian A, Panosyan V, Wikman G.
Source: Phytomedicine : International Journal of Phytotherapy and Phytopharmacology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12809357&query_hl=1&itool=pubmed_docsum
- **Familial mediterranean fever medicated with an herbal medicine in Japan.**
Author(s): Komatsu M, Takahashi T, Uemura N, Takada G.
Source: Pediatrics International : Official Journal of the Japan Pediatric Society.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15043671&query_hl=1&itool=pubmed_docsum
- **Letter: Periodic fever suppressed by reserpine.**
Author(s): Hayashi A, Suzuki T, Shimizu A, Yamamura Y.
Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=55872&query_hl=1&itool=pubmed_docsum
- **Multiple sclerosis: the rational basis for treatment with colchicine and evening primrose oil.**
Author(s): Horrobin DF.
Source: Medical Hypotheses.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=313499&query_hl=1&itool=pubmed_docsum
- **Near fatal acute colchicine intoxication in a child. A case report.**
Author(s): Goldbart A, Press J, Sofer S, Kapelushnik J.
Source: European Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11131346&query_hl=1&itool=pubmed_docsum
- **Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno-Guard.**
Author(s): Panossian A, Hambartsumyan M, Panosyan L, Abrahamyan H, Mamikonyan G, Gabrielyan E, Amaryan G, Astvatsatryan V, Wikman G.

Source: Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14623176&query_hl=1&itool=pubmed_docsum

- **Tumor necrosis factor-alpha gene promoter polymorphism in patients with familial Mediterranean fever.**
Author(s): Celebi Kobak A, Kobak S, Kabasakal Y, Akarca US.
Source: Clinical Rheumatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17057944&query_hl=1&itool=pubmed_docsum

Additional Web Resources

A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample:

- Alternative Medicine Foundation, Inc.: <http://www.herbmed.org/>
- AOL: <http://health.aol.com/healthyliving/althealth>
- Chinese Medicine: <http://www.newcenturynutrition.com/>
- drkoop.com®: <http://www.drkoop.com/naturalmedicine.html>
- Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
- Google: <http://directory.google.com/Top/Health/Alternative/>
- Healthnotes: <http://www.healthnotes.com/>
- Open Directory Project: <http://dmoz.org/Health/Alternative/>
- Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/

The following is a specific Web list relating to familial Mediterranean fever; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation:

- **General Overview**

Amyloidosis

Source: Integrative Medicine Communications; www.drkoop.com

General References

A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at <http://www.nlm.nih.gov/medlineplus/alternativemedicine.html>. This Web site provides a general overview of various topics and can lead to a number of general sources.

CHAPTER 3. BOOKS ON FAMILIAL MEDITERRANEAN FEVER

Overview

This chapter provides bibliographic book references relating to familial Mediterranean fever. In addition to online booksellers such as www.amazon.com and www.bn.com, the National Library of Medicine is an excellent source for book titles on familial Mediterranean fever. Your local medical library also may have these titles available for loan.

The National Library of Medicine Book Index

The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, <http://locatorplus.gov/>, and then select **LocatorPlus**. Once you are in the search area, simply type **familial Mediterranean fever** (or synonyms) into the search box, and select the Quick Limit Option for Keyword, Title, or Journal Title Search: **Books**. From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine⁸:

- **Recurrent polyserositis, familial Mediterranean fever, periodic disease** Author: Eliakim, Marcel.; Year: 1981; Elsevier; New York; ISBN: 9780444803
<http://www.amazon.com/exec/obidos/ASIN/9780444803/icongroupinterna>

⁸ In addition to LocatorPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a **Books** button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. See <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books>.

APPENDICES

APPENDIX A. HELP ME UNDERSTAND GENETICS

Overview

This appendix presents basic information about genetics in clear language and provides links to online resources.⁹

The Basics: Genes and How They Work

This section gives you information on the basics of cells, DNA, genes, chromosomes, and proteins.

What Is a Cell?

Cells are the basic building blocks of all living things. The human body is composed of trillions of cells. They provide structure for the body, take in nutrients from food, convert those nutrients into energy, and carry out specialized functions. Cells also contain the body's hereditary material and can make copies of themselves.

Cells have many parts, each with a different function. Some of these parts, called organelles, are specialized structures that perform certain tasks within the cell. Human cells contain the following major parts, listed in alphabetical order:

- **Cytoplasm:** The cytoplasm is fluid inside the cell that surrounds the organelles.
- **Endoplasmic reticulum (ER):** This organelle helps process molecules created by the cell and transport them to their specific destinations either inside or outside the cell.
- **Golgi apparatus:** The golgi apparatus packages molecules processed by the endoplasmic reticulum to be transported out of the cell.
- **Lysosomes and peroxisomes:** These organelles are the recycling center of the cell. They digest foreign bacteria that invade the cell, rid the cell of toxic substances, and recycle worn-out cell components.

⁹ This appendix is an excerpt from the National Library of Medicine's handbook, *Help Me Understand Genetics*. For the full text of the *Help Me Understand Genetics* handbook, see <http://ghr.nlm.nih.gov/handbook>.

- **Mitochondria:** Mitochondria are complex organelles that convert energy from food into a form that the cell can use. They have their own genetic material, separate from the DNA in the nucleus, and can make copies of themselves.
- **Nucleus:** The nucleus serves as the cell's command center, sending directions to the cell to grow, mature, divide, or die. It also houses DNA (deoxyribonucleic acid), the cell's hereditary material. The nucleus is surrounded by a membrane called the nuclear envelope, which protects the DNA and separates the nucleus from the rest of the cell.
- **Plasma membrane:** The plasma membrane is the outer lining of the cell. It separates the cell from its environment and allows materials to enter and leave the cell.
- **Ribosomes:** Ribosomes are organelles that process the cell's genetic instructions to create proteins. These organelles can float freely in the cytoplasm or be connected to the endoplasmic reticulum.


What Is DNA?

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person's body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

The information in DNA is stored as a code made up of four chemical bases: adenine (A), guanine (G), cytosine (C), and thymine (T). Human DNA consists of about 3 billion bases, and more than 99 percent of those bases are the same in all people. The order, or sequence, of these bases determines the information available for building and maintaining an organism, similar to the way in which letters of the alphabet appear in a certain order to form words and sentences.

DNA bases pair up with each other, A with T and C with G, to form units called base pairs. Each base is also attached to a sugar molecule and a phosphate molecule. Together, a base, sugar, and phosphate are called a nucleotide. Nucleotides are arranged in two long strands that form a spiral called a double helix. The structure of the double helix is somewhat like a ladder, with the base pairs forming the ladder's rungs and the sugar and phosphate molecules forming the vertical sidepieces of the ladder.

An important property of DNA is that it can replicate, or make copies of itself. Each strand of DNA in the double helix can serve as a pattern for duplicating the sequence of bases. This is critical when cells divide because each new cell needs to have an exact copy of the DNA present in the old cell.



U.S. National Library of Medicine

DNA is a double helix formed by base pairs attached to a sugar-phosphate backbone.

What Is Mitochondrial DNA?

Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA. This genetic material is known as mitochondrial DNA or mtDNA.

Mitochondria are structures within cells that convert the energy from food into a form that cells can use. Each cell contains hundreds to thousands of mitochondria, which are located in the fluid that surrounds the nucleus (the cytoplasm).

Mitochondria produce energy through a process called oxidative phosphorylation. This process uses oxygen and simple sugars to create adenosine triphosphate (ATP), the cell's main energy source. A set of enzyme complexes, designated as complexes I-V, carry out oxidative phosphorylation within mitochondria.

In addition to energy production, mitochondria play a role in several other cellular activities. For example, mitochondria help regulate the self-destruction of cells (apoptosis). They are also necessary for the production of substances such as cholesterol and heme (a component of hemoglobin, the molecule that carries oxygen in the blood).


Mitochondrial DNA contains 37 genes, all of which are essential for normal mitochondrial function. Thirteen of these genes provide instructions for making enzymes involved in oxidative phosphorylation. The remaining genes provide instructions for making molecules called transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), which are chemical cousins of

DNA. These types of RNA help assemble protein building blocks (amino acids) into functioning proteins.

What Is a Gene?

A gene is the basic physical and functional unit of heredity. Genes, which are made up of DNA, act as instructions to make molecules called proteins. In humans, genes vary in size from a few hundred DNA bases to more than 2 million bases. The Human Genome Project has estimated that humans have between 20,000 and 25,000 genes.

Every person has two copies of each gene, one inherited from each parent. Most genes are the same in all people, but a small number of genes (less than 1 percent of the total) are slightly different between people. Alleles are forms of the same gene with small differences in their sequence of DNA bases. These small differences contribute to each person's unique physical features.




Genes are made up of DNA. Each chromosome contains many genes.

What Is a Chromosome?

In the nucleus of each cell, the DNA molecule is packaged into thread-like structures called chromosomes. Each chromosome is made up of DNA tightly coiled many times around proteins called histones that support its structure.

Chromosomes are not visible in the cell's nucleus—not even under a microscope—when the cell is not dividing. However, the DNA that makes up chromosomes becomes more tightly packed during cell division and is then visible under a microscope. Most of what researchers know about chromosomes was learned by observing chromosomes during cell division.


Each chromosome has a constriction point called the centromere, which divides the chromosome into two sections, or "arms." The short arm of the chromosome is labeled the "p arm." The long arm of the chromosome is labeled the "q arm." The location of the centromere on each chromosome gives the chromosome its characteristic shape, and can be used to help describe the location of specific genes.



DNA and histone proteins are packaged into structures called chromosomes.

How Many Chromosomes Do People Have?

In humans, each cell normally contains 23 pairs of chromosomes, for a total of 46. Twenty-two of these pairs, called autosomes, look the same in both males and females. The 23rd pair, the sex chromosomes, differ between males and females. Females have two copies of the X chromosome, while males have one X and one Y chromosome.



U.S. National Library of Medicine

The 22 autosomes are numbered by size.

The other two chromosomes, X and Y, are the sex chromosomes.

This picture of the human chromosomes lined up in pairs is called a karyotype.

How Do Geneticists Indicate the Location of a Gene?

Geneticists use maps to describe the location of a particular gene on a chromosome. One type of map uses the cytogenetic location to describe a gene’s position. The cytogenetic location is based on a distinctive pattern of bands created when chromosomes are stained with certain chemicals. Another type of map uses the molecular location, a precise description of a gene’s position on a chromosome. The molecular location is based on the sequence of DNA building blocks (base pairs) that make up the chromosome.

Cytogenetic Location

Geneticists use a standardized way of describing a gene’s cytogenetic location. In most cases, the location describes the position of a particular band on a stained chromosome:

17q12

It can also be written as a range of bands, if less is known about the exact location:


17q12-q21

The combination of numbers and letters provide a gene’s “address” on a chromosome. This address is made up of several parts:

- The chromosome on which the gene can be found. The first number or letter used to describe a gene’s location represents the chromosome. Chromosomes 1 through 22 (the autosomes) are designated by their chromosome number. The sex chromosomes are designated by X or Y.

- The arm of the chromosome. Each chromosome is divided into two sections (arms) based on the location of a narrowing (constriction) called the centromere. By convention, the shorter arm is called p, and the longer arm is called q. The chromosome arm is the second part of the gene's address. For example, 5q is the long arm of chromosome 5, and Xp is the short arm of the X chromosome.
- The position of the gene on the p or q arm. The position of a gene is based on a distinctive pattern of light and dark bands that appear when the chromosome is stained in a certain way. The position is usually designated by two digits (representing a region and a band), which are sometimes followed by a decimal point and one or more additional digits (representing sub-bands within a light or dark area). The number indicating the gene position increases with distance from the centromere. For example: 14q21 represents position 21 on the long arm of chromosome 14. 14q21 is closer to the centromere than 14q22.

Sometimes, the abbreviations "cen" or "ter" are also used to describe a gene's cytogenetic location. "Cen" indicates that the gene is very close to the centromere. For example, 16pcen refers to the short arm of chromosome 16 near the centromere. "Ter" stands for terminus, which indicates that the gene is very close to the end of the p or q arm. For example, 14qter refers to the tip of the long arm of chromosome 14. ("Tel" is also sometimes used to describe a gene's location. "Tel" stands for telomeres, which are at the ends of each chromosome. The abbreviations "tel" and "ter" refer to the same location.)



The CFTR gene is located on the long arm of chromosome 7 at position 7q31.2.

Molecular Location

The Human Genome Project, an international research effort completed in 2003, determined the sequence of base pairs for each human chromosome. This sequence information allows researchers to provide a more specific address than the cytogenetic location for many genes. A gene's molecular address pinpoints the location of that gene in terms of base pairs. For example, the molecular location of the APOE gene on chromosome 19 begins with base pair 50,100,901 and ends with base pair 50,104,488. This range describes the gene's precise position on chromosome 19 and indicates the size of the gene (3,588 base pairs). Knowing a gene's molecular location also allows researchers to determine exactly how far the gene is from other genes on the same chromosome.

Different groups of researchers often present slightly different values for a gene's molecular location. Researchers interpret the sequence of the human genome using a variety of methods, which can result in small differences in a gene's molecular address. For example, the National Center for Biotechnology Information (NCBI) identifies the molecular location of the APOE gene as base pair 50,100,901 to base pair 50,104,488 on chromosome 19. The Ensembl database identifies the location of this gene as base pair 50,100,879 to base pair 50,104,489 on chromosome 19. Neither of these addresses is incorrect; they represent different interpretations of the same data. For consistency, Genetics Home Reference presents data from NCBI for the molecular location of genes.

What Are Proteins and What Do They Do?

Proteins are large, complex molecules that play many critical roles in the body. They do most of the work in cells and are required for the structure, function, and regulation of the body's tissues and organs.

Proteins are made up of hundreds or thousands of smaller units called amino acids, which are attached to one another in long chains. There are 20 different types of amino acids that can be combined to make a protein. The sequence of amino acids determines each protein's unique 3-dimensional structure and its specific function.

Examples of Protein Functions

Proteins can be described according to their large range of functions in the body, listed in alphabetical order:

Function	Description	Example
Antibody	Antibodies bind to specific foreign particles, such as viruses and bacteria, to help protect the body.	Immunoglobulin G (IgG)
Enzyme	Enzymes carry out almost all of the thousands of chemical reactions that take place in cells. They also assist with the formation of new molecules by reading the genetic information stored in DNA.	Phenylalanine hydroxylase
Messenger	Messenger proteins, such as some types of hormones, transmit signals to coordinate biological processes between different cells, tissues, and organs.	Growth hormone
Structural component	These proteins provide structure and support for cells. On a larger scale, they also allow the body to move.	Actin
Transport/storage	These proteins bind and carry atoms and small molecules within cells and throughout the body.	Ferritin

How Does a Gene Make a Protein?


Most genes contain the information needed to make functional molecules called proteins. (A few genes produce other molecules that help the cell assemble proteins.) The journey from gene to protein is complex and tightly controlled within each cell. It consists of two major steps: transcription and translation. Together, transcription and translation are known as gene expression.

During the process of transcription, the information stored in a gene's DNA is transferred to a similar molecule called RNA (ribonucleic acid) in the cell nucleus. Both RNA and DNA are made up of a chain of nucleotide bases, but they have slightly different chemical properties. The type of RNA that contains the information for making a protein is called messenger RNA (mRNA) because it carries the information, or message, from the DNA out of the nucleus into the cytoplasm.

Translation, the second step in getting from a gene to a protein, takes place in the cytoplasm. The mRNA interacts with a specialized complex called a ribosome, which "reads" the sequence of mRNA bases. Each sequence of three bases, called a codon, usually codes for

one particular amino acid. (Amino acids are the building blocks of proteins.) A type of RNA called transfer RNA (tRNA) assembles the protein, one amino acid at a time. Protein assembly continues until the ribosome encounters a “stop” codon (a sequence of three bases that does not code for an amino acid).

The flow of information from DNA to RNA to proteins is one of the fundamental principles of molecular biology. It is so important that it is sometimes called the “central dogma.”



Through the processes of transcription and translation, information from genes is used to make proteins.

Can Genes Be Turned On and Off in Cells?

Each cell expresses, or turns on, only a fraction of its genes. The rest of the genes are repressed, or turned off. The process of turning genes on and off is known as gene regulation. Gene regulation is an important part of normal development. Genes are turned on and off in different patterns during development to make a brain cell look and act different from a liver cell or a muscle cell, for example. Gene regulation also allows cells to react quickly to changes in their environments. Although we know that the regulation of genes is critical for life, this complex process is not yet fully understood.


Gene regulation can occur at any point during gene expression, but most commonly occurs at the level of transcription (when the information in a gene’s DNA is transferred to mRNA). Signals from the environment or from other cells activate proteins called transcription factors. These proteins bind to regulatory regions of a gene and increase or decrease the level of transcription. By controlling the level of transcription, this process can determine the amount of protein product that is made by a gene at any given time.

How Do Cells Divide?

There are two types of cell division: mitosis and meiosis. Most of the time when people refer to “cell division,” they mean mitosis, the process of making new body cells. Meiosis is the type of cell division that creates egg and sperm cells.

Mitosis is a fundamental process for life. During mitosis, a cell duplicates all of its contents, including its chromosomes, and splits to form two identical daughter cells. Because this process is so critical, the steps of mitosis are carefully controlled by a number of genes. When mitosis is not regulated correctly, health problems such as cancer can result.

The other type of cell division, meiosis, ensures that humans have the same number of chromosomes in each generation. It is a two-step process that reduces the chromosome number by half—from 46 to 23—to form sperm and egg cells. When the sperm and egg cells unite at conception, each contributes 23 chromosomes so the resulting embryo will have the usual 46. Meiosis also allows genetic variation through a process of DNA shuffling while the cells are dividing.



Mitosis and meiosis, the two types of cell division.

How Do Genes Control the Growth and Division of Cells?

A variety of genes are involved in the control of cell growth and division. The cell cycle is the cell’s way of replicating itself in an organized, step-by-step fashion. Tight regulation of this process ensures that a dividing cell’s DNA is copied properly, any errors in the DNA are repaired, and each daughter cell receives a full set of chromosomes. The cycle has checkpoints (also called restriction points), which allow certain genes to check for mistakes and halt the cycle for repairs if something goes wrong.

If a cell has an error in its DNA that cannot be repaired, it may undergo programmed cell death (apoptosis). Apoptosis is a common process throughout life that helps the body get rid of cells it doesn't need. Cells that undergo apoptosis break apart and are recycled by a type of white blood cell called a macrophage. Apoptosis protects the body by removing genetically damaged cells that could lead to cancer, and it plays an important role in the development of the embryo and the maintenance of adult tissues.

Cancer results from a disruption of the normal regulation of the cell cycle. When the cycle proceeds without control, cells can divide without order and accumulate genetic defects that can lead to a cancerous tumor.

Genetic Mutations and Health

This section presents basic information about gene mutations, chromosomal changes, and conditions that run in families.¹⁰

What Is a Gene Mutation and How Do Mutations Occur?

A gene mutation is a permanent change in the DNA sequence that makes up a gene. Mutations range in size from a single DNA building block (DNA base) to a large segment of a chromosome.

Gene mutations occur in two ways: they can be inherited from a parent or acquired during a person's lifetime. Mutations that are passed from parent to child are called hereditary mutations or germline mutations (because they are present in the egg and sperm cells, which are also called germ cells). This type of mutation is present throughout a person's life in virtually every cell in the body.

Mutations that occur only in an egg or sperm cell, or those that occur just after fertilization, are called new (de novo) mutations. De novo mutations may explain genetic disorders in which an affected child has a mutation in every cell, but has no family history of the disorder.

Acquired (or somatic) mutations occur in the DNA of individual cells at some time during a person's life. These changes can be caused by environmental factors such as ultraviolet radiation from the sun, or can occur if a mistake is made as DNA copies itself during cell division. Acquired mutations in somatic cells (cells other than sperm and egg cells) cannot be passed on to the next generation.

Mutations may also occur in a single cell within an early embryo. As all the cells divide during growth and development, the individual will have some cells with the mutation and some cells without the genetic change. This situation is called mosaicism.

Some genetic changes are very rare; others are common in the population. Genetic changes that occur in more than 1 percent of the population are called polymorphisms. They are common enough to be considered a normal variation in the DNA. Polymorphisms are

¹⁰ This section has been adapted from the National Library of Medicine's handbook, *Help Me Understand Genetics*, which presents basic information about genetics in clear language and provides links to online resources: <http://ghr.nlm.nih.gov/handbook>.

responsible for many of the normal differences between people such as eye color, hair color, and blood type. Although many polymorphisms have no negative effects on a person's health, some of these variations may influence the risk of developing certain disorders.

How Can Gene Mutations Affect Health and Development?

To function correctly, each cell depends on thousands of proteins to do their jobs in the right places at the right times. Sometimes, gene mutations prevent one or more of these proteins from working properly. By changing a gene's instructions for making a protein, a mutation can cause the protein to malfunction or to be missing entirely. When a mutation alters a protein that plays a critical role in the body, it can disrupt normal development or cause a medical condition. A condition caused by mutations in one or more genes is called a genetic disorder.

In some cases, gene mutations are so severe that they prevent an embryo from surviving until birth. These changes occur in genes that are essential for development, and often disrupt the development of an embryo in its earliest stages. Because these mutations have very serious effects, they are incompatible with life.

It is important to note that genes themselves do not cause disease—genetic disorders are caused by mutations that make a gene function improperly. For example, when people say that someone has “the cystic fibrosis gene,” they are usually referring to a mutated version of the CFTR gene, which causes the disease. All people, including those without cystic fibrosis, have a version of the CFTR gene.

Do All Gene Mutations Affect Health and Development?

No, only a small percentage of mutations cause genetic disorders—most have no impact on health or development. For example, some mutations alter a gene's DNA base sequence but do not change the function of the protein made by the gene.

Often, gene mutations that could cause a genetic disorder are repaired by certain enzymes before the gene is expressed (makes a protein). Each cell has a number of pathways through which enzymes recognize and repair mistakes in DNA. Because DNA can be damaged or mutated in many ways, DNA repair is an important process by which the body protects itself from disease.

A very small percentage of all mutations actually have a positive effect. These mutations lead to new versions of proteins that help an organism and its future generations better adapt to changes in their environment. For example, a beneficial mutation could result in a protein that protects the organism from a new strain of bacteria.

For More Information about DNA Repair and the Health Effects of Gene Mutations

- The University of Utah Genetic Science Learning Center provides information about genetic disorders that explains why some mutations cause disorders but others do not. (Refer to the questions in the far right column.)
See <http://learn.genetics.utah.edu/units/disorders/whataregd/>.

- Additional information about DNA repair is available from the NCBI Science Primer. In the chapter called “What Is A Cell?”, scroll down to the heading “DNA Repair Mechanisms.” See http://www.ncbi.nlm.nih.gov/About/primer/genetics_cell.html.

What Kinds of Gene Mutations Are Possible?

The DNA sequence of a gene can be altered in a number of ways. Gene mutations have varying effects on health, depending on where they occur and whether they alter the function of essential proteins. The types of mutations include:

- **Missense mutation:** This type of mutation is a change in one DNA base pair that results in the substitution of one amino acid for another in the protein made by a gene.
- **Nonsense mutation:** A nonsense mutation is also a change in one DNA base pair. Instead of substituting one amino acid for another, however, the altered DNA sequence prematurely signals the cell to stop building a protein. This type of mutation results in a shortened protein that may function improperly or not at all.
- **Insertion:** An insertion changes the number of DNA bases in a gene by adding a piece of DNA. As a result, the protein made by the gene may not function properly.
- **Deletion:** A deletion changes the number of DNA bases by removing a piece of DNA. Small deletions may remove one or a few base pairs within a gene, while larger deletions can remove an entire gene or several neighboring genes. The deleted DNA may alter the function of the resulting protein(s).
- **Duplication:** A duplication consists of a piece of DNA that is abnormally copied one or more times. This type of mutation may alter the function of the resulting protein.
- **Frameshift mutation:** This type of mutation occurs when the addition or loss of DNA bases changes a gene’s reading frame. A reading frame consists of groups of 3 bases that each code for one amino acid. A frameshift mutation shifts the grouping of these bases and changes the code for amino acids. The resulting protein is usually nonfunctional. Insertions, deletions, and duplications can all be frameshift mutations.
- **Repeat expansion:** Nucleotide repeats are short DNA sequences that are repeated a number of times in a row. For example, a trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is made up of 4-base-pair sequences. A repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated. This type of mutation can cause the resulting protein to function improperly.

Can Changes in Chromosomes Affect Health and Development?

Changes that affect entire chromosomes or segments of chromosomes can cause problems with growth, development, and function of the body’s systems. These changes can affect many genes along the chromosome and alter the proteins made by those genes. Conditions caused by a change in the number or structure of chromosomes are known as chromosomal disorders.

Human cells normally contain 23 pairs of chromosomes, for a total of 46 chromosomes in each cell. A change in the number of chromosomes leads to a chromosomal disorder. These

changes can occur during the formation of reproductive cells (eggs and sperm) or in early fetal development. A gain or loss of chromosomes from the normal 46 is called aneuploidy. The most common form of aneuploidy is trisomy, or the presence of an extra chromosome in each cell. “Tri-” is Greek for “three”; people with trisomy have three copies of a particular chromosome in each cell instead of the normal two copies. Down syndrome is an example of a condition caused by trisomy – people with Down syndrome typically have three copies of chromosome 21 in each cell, for a total of 47 chromosomes per cell.

Monosomy, or the loss of one chromosome from each cell, is another kind of aneuploidy. “Mono-” is Greek for “one”; people with monosomy have one copy of a particular chromosome in each cell instead of the normal two copies. Turner syndrome is a condition caused by monosomy. Women with Turner syndrome are often missing one copy of the X chromosome in every cell, for a total of 45 chromosomes per cell.

Chromosomal disorders can also be caused by changes in chromosome structure. These changes are caused by the breakage and reunion of chromosome segments when an egg or sperm cell is formed or in early fetal development. Pieces of DNA can be rearranged within one chromosome, or transferred between two or more chromosomes. The effects of structural changes depend on their size and location. Many different structural changes are possible; some cause medical problems, while others may have no effect on a person’s health.

Many cancer cells also have changes in their chromosome number or structure. These changes most often occur in somatic cells (cells other than eggs and sperm) during a person’s lifetime.

Can Changes in Mitochondrial DNA Affect Health and Development?

Mitochondria are structures within cells that convert the energy from food into a form that cells can use. Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA (known as mitochondrial DNA or mtDNA). In some cases, inherited changes in mitochondrial DNA can cause problems with growth, development, and function of the body’s systems. These mutations disrupt the mitochondria’s ability to generate energy efficiently for the cell.

Conditions caused by mutations in mitochondrial DNA often involve multiple organ systems. The effects of these conditions are most pronounced in organs and tissues that require a lot of energy (such as the heart, brain, and muscles). Although the health consequences of inherited mitochondrial DNA mutations vary widely, frequently observed features include muscle weakness and wasting, problems with movement, diabetes, kidney failure, heart disease, loss of intellectual functions (dementia), hearing loss, and abnormalities involving the eyes and vision.

Mitochondrial DNA is also prone to noninherited (somatic) mutations. Somatic mutations occur in the DNA of certain cells during a person’s lifetime, and typically are not passed to future generations. Because mitochondrial DNA has a limited ability to repair itself when it is damaged, these mutations tend to build up over time. A buildup of somatic mutations in mitochondrial DNA has been associated with some forms of cancer and an increased risk of certain age-related disorders such as heart disease, Alzheimer disease, and Parkinson disease. Additionally, research suggests that the progressive accumulation of these mutations over a person’s lifetime may play a role in the normal process of aging.

What Are Complex or Multifactorial Disorders?

Researchers are learning that nearly all conditions and diseases have a genetic component. Some disorders, such as sickle cell anemia and cystic fibrosis, are caused by mutations in a single gene. The causes of many other disorders, however, are much more complex. Common medical problems such as heart disease, diabetes, and obesity do not have a single genetic cause—they are likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. Conditions caused by many contributing factors are called complex or multifactorial disorders.

Although complex disorders often cluster in families, they do not have a clear-cut pattern of inheritance. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified. By 2010, however, researchers predict they will have found the major contributing genes for many common complex disorders.

What Information about a Genetic Condition Can Statistics Provide?

Statistical data can provide general information about how common a condition is, how many people have the condition, or how likely it is that a person will develop the condition. Statistics are not personalized, however—they offer estimates based on groups of people. By taking into account a person's family history, medical history, and other factors, a genetics professional can help interpret what statistics mean for a particular patient.

Common Statistical Terms

Some statistical terms are commonly used when describing genetic conditions and other disorders. These terms include:

Statistical Term	Description	Examples
<i>Incidence</i>	The incidence of a gene mutation or a genetic disorder is the number of people who are born with the mutation or disorder in a specified group per year. Incidence is often written in the form "1 in [a number]" or as a total number of live births.	About 1 in 200,000 people in the United States are born with syndrome A each year. An estimated 15,000 infants with syndrome B were born last year worldwide.

<i>Prevalence</i>	The prevalence of a gene mutation or a genetic disorder is the total number of people in a specified group at a given time who have the mutation or disorder. This term includes both newly diagnosed and pre-existing cases in people of any age. Prevalence is often written in the form "1 in [a number]" or as a total number of people who have a condition.	Approximately 1 in 100,000 people in the United States have syndrome A at the present time. About 100,000 children worldwide currently have syndrome B.
<i>Mortality</i>	Mortality is the number of deaths from a particular disorder occurring in a specified group per year. Mortality is usually expressed as a total number of deaths.	An estimated 12,000 people worldwide died from syndrome C in 2002.
<i>Lifetime risk</i>	Lifetime risk is the average risk of developing a particular disorder at some point during a lifetime. Lifetime risk is often written as a percentage or as "1 in [a number]." It is important to remember that the risk per year or per decade is much lower than the lifetime risk. In addition, other factors may increase or decrease a person's risk as compared with the average.	Approximately 1 percent of people in the United States develop disorder D during their lifetimes. The lifetime risk of developing disorder D is 1 in 100.

Naming Genetic Conditions

Genetic conditions are not named in one standard way (unlike genes, which are given an official name and symbol by a formal committee). Doctors who treat families with a particular disorder are often the first to propose a name for the condition. Expert working groups may later revise the name to improve its usefulness. Naming is important because it allows accurate and effective communication about particular conditions, which will ultimately help researchers find new approaches to treatment.

Disorder names are often derived from one or a combination of sources:

- The basic genetic or biochemical defect that causes the condition (for example, alpha-1 antitrypsin deficiency)
- One or more major signs or symptoms of the disorder (for example, sickle cell anemia)
- The parts of the body affected by the condition (for example, retinoblastoma)
- The name of a physician or researcher, often the first person to describe the disorder (for example, Marfan syndrome, which was named after Dr. Antoine Bernard-Jean Marfan)

- A geographic area (for example, familial Mediterranean fever, which occurs mainly in populations bordering the Mediterranean Sea)
- The name of a patient or family with the condition (for example, amyotrophic lateral sclerosis, which is also called Lou Gehrig disease after a famous baseball player who had the condition).

Disorders named after a specific person or place are called eponyms. There is debate as to whether the possessive form (e.g., Alzheimer's disease) or the nonpossessive form (Alzheimer disease) of eponyms is preferred. As a rule, medical geneticists use the nonpossessive form, and this form may become the standard for doctors in all fields of medicine. Genetics Home Reference uses the nonpossessive form of eponyms.

Genetics Home Reference consults with experts in the field of medical genetics to provide the current, most accurate name for each disorder. Alternate names are included as synonyms.

Naming genes

The HUGO Gene Nomenclature Committee (HGNC) designates an official name and symbol (an abbreviation of the name) for each known human gene. Some official gene names include additional information in parentheses, such as related genetic conditions, subtypes of a condition, or inheritance pattern. The HGNC is a non-profit organization funded by the U.K. Medical Research Council and the U.S. National Institutes of Health. The Committee has named more than 13,000 of the estimated 20,000 to 25,000 genes in the human genome.

During the research process, genes often acquire several alternate names and symbols. Different researchers investigating the same gene may each give the gene a different name, which can cause confusion. The HGNC assigns a unique name and symbol to each human gene, which allows effective organization of genes in large databanks, aiding the advancement of research. For specific information about how genes are named, refer to the HGNC's Guidelines for Human Gene Nomenclature.

Genetics Home Reference describes genes using the HGNC's official gene names and gene symbols. Genetics Home Reference frequently presents the symbol and name separated with a colon (for example, FGFR4: Fibroblast growth factor receptor 4).


Inheriting Genetic Conditions

This section gives you information on inheritance patterns and understanding risk.

What Does It Mean If a Disorder Seems to Run in My Family?

A particular disorder might be described as "running in a family" if more than one person in the family has the condition. Some disorders that affect multiple family members are caused by gene mutations, which can be inherited (passed down from parent to child). Other conditions that appear to run in families are not inherited. Instead, environmental factors such as dietary habits or a combination of genetic and environmental factors are responsible for these disorders.

It is not always easy to determine whether a condition in a family is inherited. A genetics professional can use a person's family history (a record of health information about a person's immediate and extended family) to help determine whether a disorder has a genetic component.



U.S. National Library of Medicine

Some disorders are seen in more than one generation of a family.

Why Is It Important to Know My Family Medical History?

A family medical history is a record of health information about a person and his or her close relatives. A complete record includes information from three generations of relatives, including children, brothers and sisters, parents, aunts and uncles, nieces and nephews, grandparents, and cousins.

Families have many factors in common, including their genes, environment, and lifestyle. Together, these factors can give clues to medical conditions that may run in a family. By noticing patterns of disorders among relatives, healthcare professionals can determine whether an individual, other family members, or future generations may be at an increased risk of developing a particular condition.

A family medical history can identify people with a higher-than-usual chance of having common disorders, such as heart disease, high blood pressure, stroke, certain cancers, and diabetes. These complex disorders are influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. A family history also can provide information about the risk of rarer conditions caused by mutations in a single gene, such as cystic fibrosis and sickle cell anemia.

While a family medical history provides information about the risk of specific health concerns, having relatives with a medical condition does not mean that an individual will definitely develop that condition. On the other hand, a person with no family history of a disorder may still be at risk of developing that disorder.

Knowing one's family medical history allows a person to take steps to reduce his or her risk. For people at an increased risk of certain cancers, healthcare professionals may recommend more frequent screening (such as mammography or colonoscopy) starting at an earlier age. Healthcare providers may also encourage regular checkups or testing for people with a medical condition that runs in their family. Additionally, lifestyle changes such as adopting a healthier diet, getting regular exercise, and quitting smoking help many people lower their chances of developing heart disease and other common illnesses.

The easiest way to get information about family medical history is to talk to relatives about their health. Have they had any medical problems, and when did they occur? A family gathering could be a good time to discuss these issues. Additionally, obtaining medical records and other documents (such as obituaries and death certificates) can help complete a family medical history. It is important to keep this information up-to-date and to share it with a healthcare professional regularly.

What Are the Different Ways in which a Genetic Condition Can Be Inherited?

Some genetic conditions are caused by mutations in a single gene. These conditions are usually inherited in one of several straightforward patterns, depending on the gene involved:

Inheritance Pattern	Description	Examples
Autosomal dominant	One mutated copy of the gene in each cell is sufficient for a person to be affected by an autosomal dominant disorder. Each affected person usually has one affected parent. Autosomal dominant disorders tend to occur in every generation of an affected family.	Huntington disease, neurofibromatosis type 1

Autosomal recessive	Two mutated copies of the gene are present in each cell when a person has an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Autosomal recessive disorders are typically not seen in every generation of an affected family.	cystic fibrosis, sickle cell anemia
X-linked dominant	X-linked dominant disorders are caused by mutations in genes on the X chromosome. Females are more frequently affected than males, and the chance of passing on an X-linked dominant disorder differs between men and women. Families with an X-linked dominant disorder often have both affected males and affected females in each generation. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons (no male-to-male transmission).	fragile X syndrome
X-linked recessive	X-linked recessive disorders are also caused by mutations in genes on the X chromosome. Males are more frequently affected than females, and the chance of passing on the disorder differs between men and women. Families with an X-linked recessive disorder often have affected males, but rarely affected females, in each generation. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons (no male-to-male transmission).	hemophilia, Fabry disease
Codominant	In codominant inheritance, two different versions (alleles) of a gene can be expressed, and each version makes a slightly different protein. Both alleles influence the genetic trait or determine the characteristics of the genetic condition.	ABO blood group, alpha-1 antitrypsin deficiency
Mitochondrial	This type of inheritance, also known as maternal inheritance, applies to genes in mitochondrial DNA. Mitochondria, which are structures in each cell that convert molecules into energy, each contain a small amount of DNA. Because only egg cells contribute mitochondria to the developing embryo, only females can pass on mitochondrial conditions to their children. Mitochondrial disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass mitochondrial traits to their children.	Leber hereditary optic neuropathy (LHON)

Many other disorders are caused by a combination of the effects of multiple genes or by interactions between genes and the environment. Such disorders are more difficult to analyze because their genetic causes are often unclear, and they do not follow the patterns of inheritance described above. Examples of conditions caused by multiple genes or gene/environment interactions include heart disease, diabetes, schizophrenia, and certain types of cancer. Disorders caused by changes in the number or structure of chromosomes do not follow the straightforward patterns of inheritance listed above. Other genetic factors can also influence how a disorder is inherited.

If a Genetic Disorder Runs in My Family, What Are the Chances That My Children Will Have the Condition?

When a genetic disorder is diagnosed in a family, family members often want to know the likelihood that they or their children will develop the condition. This can be difficult to predict in some cases because many factors influence a person's chances of developing a genetic condition. One important factor is how the condition is inherited. For example:

- **Autosomal dominant inheritance:** A person affected by an autosomal dominant disorder has a 50 percent chance of passing the mutated gene to each child. The chance that a child will not inherit the mutated gene is also 50 percent.
- **Autosomal recessive inheritance:** Two unaffected people who each carry one copy of the mutated gene for an autosomal recessive disorder (carriers) have a 25 percent chance with each pregnancy of having a child affected by the disorder. The chance with each pregnancy of having an unaffected child who is a carrier of the disorder is 50 percent, and the chance that a child will not have the disorder and will not be a carrier is 25 percent.
- **X-linked dominant inheritance:** The chance of passing on an X-linked dominant condition differs between men and women because men have one X chromosome and one Y chromosome, while women have two X chromosomes. A man passes on his Y chromosome to all of his sons and his X chromosome to all of his daughters. Therefore, the sons of a man with an X-linked dominant disorder will not be affected, but all of his daughters will inherit the condition. A woman passes on one or the other of her X chromosomes to each child. Therefore, a woman with an X-linked dominant disorder has a 50 percent chance of having an affected daughter or son with each pregnancy.
- **X-linked recessive inheritance:** Because of the difference in sex chromosomes, the probability of passing on an X-linked recessive disorder also differs between men and women. The sons of a man with an X-linked recessive disorder will not be affected, and his daughters will carry one copy of the mutated gene. With each pregnancy, a woman who carries an X-linked recessive disorder has a 50 percent chance of having sons who are affected and a 50 percent chance of having daughters who carry one copy of the mutated gene.
- **Codominant inheritance:** In codominant inheritance, each parent contributes a different version of a particular gene, and both versions influence the resulting genetic trait. The chance of developing a genetic condition with codominant inheritance, and the characteristic features of that condition, depend on which versions of the gene are passed from parents to their child.
- **Mitochondrial inheritance:** Mitochondria, which are the energy-producing centers inside cells, each contain a small amount of DNA. Disorders with mitochondrial inheritance result from mutations in mitochondrial DNA. Although mitochondrial

disorders can affect both males and females, only females can pass mutations in mitochondrial DNA to their children. A woman with a disorder caused by changes in mitochondrial DNA will pass the mutation to all of her daughters and sons, but the children of a man with such a disorder will not inherit the mutation.

It is important to note that the chance of passing on a genetic condition applies equally to each pregnancy. For example, if a couple has a child with an autosomal recessive disorder, the chance of having another child with the disorder is still 25 percent (or 1 in 4). Having one child with a disorder does not “protect” future children from inheriting the condition. Conversely, having a child without the condition does not mean that future children will definitely be affected.

Although the chances of inheriting a genetic condition appear straightforward, factors such as a person’s family history and the results of genetic testing can sometimes modify those chances. In addition, some people with a disease-causing mutation never develop any health problems or may experience only mild symptoms of the disorder. If a disease that runs in a family does not have a clear-cut inheritance pattern, predicting the likelihood that a person will develop the condition can be particularly difficult.

Estimating the chance of developing or passing on a genetic disorder can be complex. Genetics professionals can help people understand these chances and help them make informed decisions about their health.

Factors that Influence the Effects of Particular Genetic Changes

Reduced penetrance and variable expressivity are factors that influence the effects of particular genetic changes. These factors usually affect disorders that have an autosomal dominant pattern of inheritance, although they are occasionally seen in disorders with an autosomal recessive inheritance pattern.

Reduced Penetrance

Penetrance refers to the proportion of people with a particular genetic change (such as a mutation in a specific gene) who exhibit signs and symptoms of a genetic disorder. If some people with the mutation do not develop features of the disorder, the condition is said to have reduced (or incomplete) penetrance. Reduced penetrance often occurs with familial cancer syndromes. For example, many people with a mutation in the BRCA1 or BRCA2 gene will develop cancer during their lifetime, but some people will not. Doctors cannot predict which people with these mutations will develop cancer or when the tumors will develop.

Reduced penetrance probably results from a combination of genetic, environmental, and lifestyle factors, many of which are unknown. This phenomenon can make it challenging for genetics professionals to interpret a person’s family medical history and predict the risk of passing a genetic condition to future generations.

Variable Expressivity

Although some genetic disorders exhibit little variation, most have signs and symptoms that differ among affected individuals. Variable expressivity refers to the range of signs and

symptoms that can occur in different people with the same genetic condition. For example, the features of Marfan syndrome vary widely— some people have only mild symptoms (such as being tall and thin with long, slender fingers), while others also experience life-threatening complications involving the heart and blood vessels. Although the features are highly variable, most people with this disorder have a mutation in the same gene (FBN1).

As with reduced penetrance, variable expressivity is probably caused by a combination of genetic, environmental, and lifestyle factors, most of which have not been identified. If a genetic condition has highly variable signs and symptoms, it may be challenging to diagnose.

What Do Geneticists Mean by Anticipation?

The signs and symptoms of some genetic conditions tend to become more severe and appear at an earlier age as the disorder is passed from one generation to the next. This phenomenon is called anticipation. Anticipation is most often seen with certain genetic disorders of the nervous system, such as Huntington disease, myotonic dystrophy, and fragile X syndrome.

Anticipation typically occurs with disorders that are caused by an unusual type of mutation called a trinucleotide repeat expansion. A trinucleotide repeat is a sequence of three DNA building blocks (nucleotides) that is repeated a number of times in a row. DNA segments with an abnormal number of these repeats are unstable and prone to errors during cell division. The number of repeats can change as the gene is passed from parent to child. If the number of repeats increases, it is known as a trinucleotide repeat expansion. In some cases, the trinucleotide repeat may expand until the gene stops functioning normally. This expansion causes the features of some disorders to become more severe with each successive generation.

Most genetic disorders have signs and symptoms that differ among affected individuals, including affected people in the same family. Not all of these differences can be explained by anticipation. A combination of genetic, environmental, and lifestyle factors is probably responsible for the variability, although many of these factors have not been identified. Researchers study multiple generations of affected family members and consider the genetic cause of a disorder before determining that it shows anticipation.

What Is Genomic Imprinting?

Genomic imprinting is a factor that influences how some genetic conditions are inherited.

People inherit two copies of their genes—one from their mother and one from their father. Usually both copies of each gene are active, or “turned on,” in cells. In some cases, however, only one of the two copies is normally turned on. Which copy is active depends on the parent of origin: some genes are normally active only when they are inherited from a person’s father; others are active only when inherited from a person’s mother. This phenomenon is known as genomic imprinting.

In genes that undergo genomic imprinting, the parent of origin is often marked, or “stamped,” on the gene during the formation of egg and sperm cells. This stamping process, called methylation, is a chemical reaction that attaches small molecules called methyl groups to certain segments of DNA. These molecules identify which copy of a gene was inherited

from the mother and which was inherited from the father. The addition and removal of methyl groups can be used to control the activity of genes.

Only a small percentage of all human genes undergo genomic imprinting. Researchers are not yet certain why some genes are imprinted and others are not. They do know that imprinted genes tend to cluster together in the same regions of chromosomes. Two major clusters of imprinted genes have been identified in humans, one on the short (p) arm of chromosome 11 (at position 11p15) and another on the long (q) arm of chromosome 15 (in the region 15q11 to 15q13).

What Is Uniparental Disomy?

Uniparental disomy is a factor that influences how some genetic conditions are inherited.

Uniparental disomy (UPD) occurs when a person receives two copies of a chromosome, or part of a chromosome, from one parent and no copies from the other parent. UPD can occur as a random event during the formation of egg or sperm cells or may happen in early fetal development.

In many cases, UPD likely has no effect on health or development. Because most genes are not imprinted, it doesn't matter if a person inherits both copies from one parent instead of one copy from each parent. In some cases, however, it does make a difference whether a gene is inherited from a person's mother or father. A person with UPD may lack any active copies of essential genes that undergo genomic imprinting. This loss of gene function can lead to delayed development, mental retardation, or other medical problems.

Several genetic disorders can result from UPD or a disruption of normal genomic imprinting. The most well-known conditions include Prader-Willi syndrome, which is characterized by uncontrolled eating and obesity, and Angelman syndrome, which causes mental retardation and impaired speech. Both of these disorders can be caused by UPD or other errors in imprinting involving genes on the long arm of chromosome 15. Other conditions, such as Beckwith-Wiedemann syndrome (a disorder characterized by accelerated growth and an increased risk of cancerous tumors), are associated with abnormalities of imprinted genes on the short arm of chromosome 11.

Are Chromosomal Disorders Inherited?

Although it is possible to inherit some types of chromosomal abnormalities, most chromosomal disorders (such as Down syndrome and Turner syndrome) are not passed from one generation to the next.

Some chromosomal conditions are caused by changes in the number of chromosomes. These changes are not inherited, but occur as random events during the formation of reproductive cells (eggs and sperm). An error in cell division called nondisjunction results in reproductive cells with an abnormal number of chromosomes. For example, a reproductive cell may accidentally gain or lose one copy of a chromosome. If one of these atypical reproductive cells contributes to the genetic makeup of a child, the child will have an extra or missing chromosome in each of the body's cells.

Changes in chromosome structure can also cause chromosomal disorders. Some changes in chromosome structure can be inherited, while others occur as random accidents during the formation of reproductive cells or in early fetal development. Because the inheritance of these changes can be complex, people concerned about this type of chromosomal abnormality may want to talk with a genetics professional.

Some cancer cells also have changes in the number or structure of their chromosomes. Because these changes occur in somatic cells (cells other than eggs and sperm), they cannot be passed from one generation to the next.

Why Are Some Genetic Conditions More Common in Particular Ethnic Groups?

Some genetic disorders are more likely to occur among people who trace their ancestry to a particular geographic area. People in an ethnic group often share certain versions of their genes, which have been passed down from common ancestors. If one of these shared genes contains a disease-causing mutation, a particular genetic disorder may be more frequently seen in the group.

Examples of genetic conditions that are more common in particular ethnic groups are sickle cell anemia, which is more common in people of African, African-American, or Mediterranean heritage; and Tay-Sachs disease, which is more likely to occur among people of Ashkenazi (eastern and central European) Jewish or French Canadian ancestry. It is important to note, however, that these disorders can occur in any ethnic group.

Genetic Consultation

This section presents information on finding and visiting a genetic counselor or other genetics professional.

What Is a Genetic Consultation?

A genetic consultation is a health service that provides information and support to people who have, or may be at risk for, genetic disorders. During a consultation, a genetics professional meets with an individual or family to discuss genetic risks or to diagnose, confirm, or rule out a genetic condition.

Genetics professionals include medical geneticists (doctors who specialize in genetics) and genetic counselors (certified healthcare workers with experience in medical genetics and counseling). Other healthcare professionals such as nurses, psychologists, and social workers trained in genetics can also provide genetic consultations.

Consultations usually take place in a doctor's office, hospital, genetics center, or other type of medical center. These meetings are most often in-person visits with individuals or families, but they are occasionally conducted in a group or over the telephone.

Why Might Someone Have a Genetic Consultation?

Individuals or families who are concerned about an inherited condition may benefit from a genetic consultation. The reasons that a person might be referred to a genetic counselor, medical geneticist, or other genetics professional include:

- A personal or family history of a genetic condition, birth defect, chromosomal disorder, or hereditary cancer.
- Two or more pregnancy losses (miscarriages), a stillbirth, or a baby who died.
- A child with a known inherited disorder, a birth defect, mental retardation, or developmental delay.
- A woman who is pregnant or plans to become pregnant at or after age 35. (Some chromosomal disorders occur more frequently in children born to older women.)
- Abnormal test results that suggest a genetic or chromosomal condition.
- An increased risk of developing or passing on a particular genetic disorder on the basis of a person's ethnic background.
- People related by blood (for example, cousins) who plan to have children together. (A child whose parents are related may be at an increased risk of inheriting certain genetic disorders.)

A genetic consultation is also an important part of the decision-making process for genetic testing. A visit with a genetics professional may be helpful even if testing is not available for a specific condition, however.

What Happens during a Genetic Consultation?

A genetic consultation provides information, offers support, and addresses a patient's specific questions and concerns. To help determine whether a condition has a genetic component, a genetics professional asks about a person's medical history and takes a detailed family history (a record of health information about a person's immediate and extended family). The genetics professional may also perform a physical examination and recommend appropriate tests.

If a person is diagnosed with a genetic condition, the genetics professional provides information about the diagnosis, how the condition is inherited, the chance of passing the condition to future generations, and the options for testing and treatment.

During a consultation, a genetics professional will:

- Interpret and communicate complex medical information.
- Help each person make informed, independent decisions about their health care and reproductive options.
- Respect each person's individual beliefs, traditions, and feelings.

A genetics professional will NOT:

- Tell a person which decision to make.
- Advise a couple not to have children.

- Recommend that a woman continue or end a pregnancy.
- Tell someone whether to undergo testing for a genetic disorder.

How Can I Find a Genetics Professional in My Area?

To find a genetics professional in your community, you may wish to ask your doctor for a referral. If you have health insurance, you can also contact your insurance company to find a medical geneticist or genetic counselor in your area who participates in your plan.

Several resources for locating a genetics professional in your community are available online:

- GeneTests from the University of Washington provides a list of genetics clinics around the United States and international genetics clinics. You can also access the list by clicking on “Clinic Directory” at the top of the GeneTests home page. Clinics can be chosen by state or country, by service, and/or by specialty. State maps can help you locate a clinic in your area. See <http://www.genetests.org/>.
- The National Society of Genetic Counselors offers a searchable directory of genetic counselors in the United States. You can search by location, name, area of practice/specialization, and/or ZIP Code. See <http://www.nsgc.org/resource/link.cfm>.
- The National Cancer Institute provides a Cancer Genetics Services Directory, which lists professionals who provide services related to cancer genetics. You can search by type of cancer or syndrome, location, and/or provider name at the following Web site: http://cancer.gov/search/genetics_services/.

Genetic Testing

This section presents information on the benefits, costs, risks, and limitations of genetic testing.

What Is Genetic Testing?

Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder. Several hundred genetic tests are currently in use, and more are being developed.

Genetic testing is voluntary. Because testing has both benefits and limitations, the decision about whether to be tested is a personal and complex one. A genetic counselor can help by providing information about the pros and cons of the test and discussing the social and emotional aspects of testing.

What Are the Types of Genetic Tests?

Genetic testing can provide information about a person's genes and chromosomes. Available types of testing include:

- **Newborn screening** is used just after birth to identify genetic disorders that can be treated early in life. Millions of babies are tested each year in the United States. All states currently test infants for phenylketonuria (a genetic disorder that causes mental retardation if left untreated) and congenital hypothyroidism (a disorder of the thyroid gland). Most states also test for other genetic disorders.
- **Diagnostic testing** is used to identify or rule out a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical signs and symptoms. Diagnostic testing can be performed before birth or at any time during a person's life, but is not available for all genes or all genetic conditions. The results of a diagnostic test can influence a person's choices about health care and the management of the disorder.
- **Carrier testing** is used to identify people who carry one copy of a gene mutation that, when present in two copies, causes a genetic disorder. This type of testing is offered to individuals who have a family history of a genetic disorder and to people in certain ethnic groups with an increased risk of specific genetic conditions. If both parents are tested, the test can provide information about a couple's risk of having a child with a genetic condition.
- **Prenatal testing** is used to detect changes in a fetus's genes or chromosomes before birth. This type of testing is offered during pregnancy if there is an increased risk that the baby will have a genetic or chromosomal disorder. In some cases, prenatal testing can lessen a couple's uncertainty or help them make decisions about a pregnancy. It cannot identify all possible inherited disorders and birth defects, however.
- **Preimplantation testing**, also called preimplantation genetic diagnosis (PGD), is a specialized technique that can reduce the risk of having a child with a particular genetic or chromosomal disorder. It is used to detect genetic changes in embryos that were created using assisted reproductive techniques such as in-vitro fertilization. In-vitro fertilization involves removing egg cells from a woman's ovaries and fertilizing them with sperm cells outside the body. To perform preimplantation testing, a small number of cells are taken from these embryos and tested for certain genetic changes. Only embryos without these changes are implanted in the uterus to initiate a pregnancy.
- **Predictive and presymptomatic types of testing** are used to detect gene mutations associated with disorders that appear after birth, often later in life. These tests can be helpful to people who have a family member with a genetic disorder, but who have no features of the disorder themselves at the time of testing. Predictive testing can identify mutations that increase a person's risk of developing disorders with a genetic basis, such as certain types of cancer. Presymptomatic testing can determine whether a person will develop a genetic disorder, such as hemochromatosis (an iron overload disorder), before any signs or symptoms appear. The results of predictive and presymptomatic testing can provide information about a person's risk of developing a specific disorder and help with making decisions about medical care.
- **Forensic testing** uses DNA sequences to identify an individual for legal purposes. Unlike the tests described above, forensic testing is not used to detect gene mutations associated with disease. This type of testing can identify crime or catastrophe victims, rule out or implicate a crime suspect, or establish biological relationships between people (for example, paternity).

How Is Genetic Testing Done?

Once a person decides to proceed with genetic testing, a medical geneticist, primary care doctor, specialist, or nurse practitioner can order the test. Genetic testing is often done as part of a genetic consultation.

Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue. For example, a procedure called a buccal smear uses a small brush or cotton swab to collect a sample of cells from the inside surface of the cheek. The sample is sent to a laboratory where technicians look for specific changes in chromosomes, DNA, or proteins, depending on the suspected disorder. The laboratory reports the test results in writing to a person's doctor or genetic counselor.

Newborn screening tests are done on a small blood sample, which is taken by pricking the baby's heel. Unlike other types of genetic testing, a parent will usually only receive the result if it is positive. If the test result is positive, additional testing is needed to determine whether the baby has a genetic disorder.

Before a person has a genetic test, it is important that he or she understands the testing procedure, the benefits and limitations of the test, and the possible consequences of the test results. The process of educating a person about the test and obtaining permission is called informed consent.

What Is Direct-to-Consumer Genetic Testing?

Traditionally, genetic tests have been available only through healthcare providers such as physicians, nurse practitioners, and genetic counselors. Healthcare providers order the appropriate test from a laboratory, collect and send the samples, and interpret the test results. Direct-to-consumer genetic testing refers to genetic tests that are marketed directly to consumers via television, print advertisements, or the Internet. This form of testing, which is also known as at-home genetic testing, provides access to a person's genetic information without necessarily involving a doctor or insurance company in the process.

If a consumer chooses to purchase a genetic test directly, the test kit is mailed to the consumer instead of being ordered through a doctor's office. The test typically involves collecting a DNA sample at home, often by swabbing the inside of the cheek, and mailing the sample back to the laboratory. In some cases, the person must visit a health clinic to have blood drawn. Consumers are notified of their results by mail or over the telephone, or the results are posted online. In some cases, a genetic counselor or other healthcare provider is available to explain the results and answer questions. The price for this type of at-home genetic testing ranges from several hundred dollars to more than a thousand dollars.

The growing market for direct-to-consumer genetic testing may promote awareness of genetic diseases, allow consumers to take a more proactive role in their health care, and offer a means for people to learn about their ancestral origins. At-home genetic tests, however, have significant risks and limitations. Consumers are vulnerable to being misled by the results of unproven or invalid tests. Without guidance from a healthcare provider, they may make important decisions about treatment or prevention based on inaccurate, incomplete, or misunderstood information about their health. Consumers may also experience an invasion of genetic privacy if testing companies use their genetic information in an unauthorized way.

Genetic testing provides only one piece of information about a person's health—other genetic and environmental factors, lifestyle choices, and family medical history also affect a person's risk of developing many disorders. These factors are discussed during a consultation with a doctor or genetic counselor, but in many cases are not addressed by at-home genetic tests. More research is needed to fully understand the benefits and limitations of direct-to-consumer genetic testing.

What Do the Results of Genetic Tests Mean?

The results of genetic tests are not always straightforward, which often makes them challenging to interpret and explain. Therefore, it is important for patients and their families to ask questions about the potential meaning of genetic test results both before and after the test is performed. When interpreting test results, healthcare professionals consider a person's medical history, family history, and the type of genetic test that was done.

A positive test result means that the laboratory found a change in a particular gene, chromosome, or protein of interest. Depending on the purpose of the test, this result may confirm a diagnosis, indicate that a person is a carrier of a particular genetic mutation, identify an increased risk of developing a disease (such as cancer) in the future, or suggest a need for further testing. Because family members have some genetic material in common, a positive test result may also have implications for certain blood relatives of the person undergoing testing. It is important to note that a positive result of a predictive or presymptomatic genetic test usually cannot establish the exact risk of developing a disorder. Also, health professionals typically cannot use a positive test result to predict the course or severity of a condition.

A negative test result means that the laboratory did not find a change in the gene, chromosome, or protein under consideration. This result can indicate that a person is not affected by a particular disorder, is not a carrier of a specific genetic mutation, or does not have an increased risk of developing a certain disease. It is possible, however, that the test missed a disease-causing genetic alteration because many tests cannot detect all genetic changes that can cause a particular disorder. Further testing may be required to confirm a negative result.

In some cases, a negative result might not give any useful information. This type of result is called uninformative, indeterminate, inconclusive, or ambiguous. Uninformative test results sometimes occur because everyone has common, natural variations in their DNA, called polymorphisms, that do not affect health. If a genetic test finds a change in DNA that has not been associated with a disorder in other people, it can be difficult to tell whether it is a natural polymorphism or a disease-causing mutation. An uninformative result cannot confirm or rule out a specific diagnosis, and it cannot indicate whether a person has an increased risk of developing a disorder. In some cases, testing other affected and unaffected family members can help clarify this type of result.

What Is the Cost of Genetic Testing, and How Long Does It Take to Get the Results?

The cost of genetic testing can range from under \$100 to more than \$2,000, depending on the nature and complexity of the test. The cost increases if more than one test is necessary or if multiple family members must be tested to obtain a meaningful result. For newborn

screening, costs vary by state. Some states cover part of the total cost, but most charge a fee of \$15 to \$60 per infant.

From the date that a sample is taken, it may take a few weeks to several months to receive the test results. Results for prenatal testing are usually available more quickly because time is an important consideration in making decisions about a pregnancy. The doctor or genetic counselor who orders a particular test can provide specific information about the cost and time frame associated with that test.

Will Health Insurance Cover the Costs of Genetic Testing?

In many cases, health insurance plans will cover the costs of genetic testing when it is recommended by a person's doctor. Health insurance providers have different policies about which tests are covered, however. A person interested in submitting the costs of testing may wish to contact his or her insurance company beforehand to ask about coverage.

Some people may choose not to use their insurance to pay for testing because the results of a genetic test can affect a person's health insurance coverage. Instead, they may opt to pay out-of-pocket for the test. People considering genetic testing may want to find out more about their state's privacy protection laws before they ask their insurance company to cover the costs.

What Are the Benefits of Genetic Testing?

Genetic testing has potential benefits whether the results are positive or negative for a gene mutation. Test results can provide a sense of relief from uncertainty and help people make informed decisions about managing their health care. For example, a negative result can eliminate the need for unnecessary checkups and screening tests in some cases. A positive result can direct a person toward available prevention, monitoring, and treatment options. Some test results can also help people make decisions about having children. Newborn screening can identify genetic disorders early in life so treatment can be started as early as possible.

What Are the Risks and Limitations of Genetic Testing?

The physical risks associated with most genetic tests are very small, particularly for those tests that require only a blood sample or buccal smear (a procedure that samples cells from the inside surface of the cheek). The procedures used for prenatal testing carry a small but real risk of losing the pregnancy (miscarriage) because they require a sample of amniotic fluid or tissue from around the fetus.

Many of the risks associated with genetic testing involve the emotional, social, or financial consequences of the test results. People may feel angry, depressed, anxious, or guilty about their results. In some cases, genetic testing creates tension within a family because the results can reveal information about other family members in addition to the person who is tested. The possibility of genetic discrimination in employment or insurance is also a concern.

Genetic testing can provide only limited information about an inherited condition. The test often can't determine if a person will show symptoms of a disorder, how severe the symptoms will be, or whether the disorder will progress over time. Another major limitation is the lack of treatment strategies for many genetic disorders once they are diagnosed.

A genetics professional can explain in detail the benefits, risks, and limitations of a particular test. It is important that any person who is considering genetic testing understand and weigh these factors before making a decision.

What Is Genetic Discrimination?

Genetic discrimination occurs when people are treated differently by their employer or insurance company because they have a gene mutation that causes or increases the risk of an inherited disorder. People who undergo genetic testing may be at risk for genetic discrimination.

The results of a genetic test are normally included in a person's medical records. When a person applies for life, disability, or health insurance, the insurance company may ask to look at these records before making a decision about coverage. An employer may also have the right to look at an employee's medical records. As a result, genetic test results could affect a person's insurance coverage or employment. People making decisions about genetic testing should be aware that when test results are placed in their medical records, the results might not be kept private.

Fear of discrimination is a common concern among people considering genetic testing. Several laws at the federal and state levels help protect people against genetic discrimination; however, genetic testing is a fast-growing field and these laws don't cover every situation.

How Does Genetic Testing in a Research Setting Differ from Clinical Genetic Testing?

The main differences between clinical genetic testing and research testing are the purpose of the test and who receives the results. The goals of research testing include finding unknown genes, learning how genes work, and advancing our understanding of genetic conditions. The results of testing done as part of a research study are usually not available to patients or their healthcare providers. Clinical testing, on the other hand, is done to find out about an inherited disorder in an individual patient or family. People receive the results of a clinical test and can use them to help them make decisions about medical care or reproductive issues.

It is important for people considering genetic testing to know whether the test is available on a clinical or research basis. Clinical and research testing both involve a process of informed consent in which patients learn about the testing procedure, the risks and benefits of the test, and the potential consequences of testing.

Gene Therapy

This section presents information on experimental techniques, safety, ethics, and availability of gene therapy.

What Is Gene Therapy?

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Researchers are testing several approaches to gene therapy, including:

- Replacing a mutated gene that causes disease with a healthy copy of the gene.
- Inactivating, or "knocking out," a mutated gene that is functioning improperly.
- Introducing a new gene into the body to help fight a disease.

Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under study to make sure that it will be safe and effective. Gene therapy is currently only being tested for the treatment of diseases that have no other cures.


How Does Gene Therapy Work?

Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.

A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors because they can deliver the new gene by infecting the cell. The viruses are modified so they can't cause disease when used in people. Some types of virus, such as retroviruses, integrate their genetic material (including the new gene) into a chromosome in the human cell. Other viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is not integrated into a chromosome.

The vector can be injected or given intravenously (by IV) directly into a specific tissue in the body, where it is taken up by individual cells. Alternately, a sample of the patient's cells can be removed and exposed to the vector in a laboratory setting. The cells containing the vector are then returned to the patient. If the treatment is successful, the new gene delivered by the vector will make a functioning protein.

Researchers must overcome many technical challenges before gene therapy will be a practical approach to treating disease. For example, scientists must find better ways to deliver genes and target them to particular cells. They must also ensure that new genes are precisely controlled by the body.



A new gene is injected into an adenovirus vector, which is used to introduce the modified DNA into a human cell. If the treatment is successful, the new gene will make a functional protein.

Is Gene Therapy Safe?

Gene therapy is under study to determine whether it could be used to treat disease. Current research is evaluating the safety of gene therapy; future studies will test whether it is an effective treatment option. Several studies have already shown that this approach can have very serious health risks, such as toxicity, inflammation, and cancer. Because the techniques are relatively new, some of the risks may be unpredictable; however, medical researchers, institutions, and regulatory agencies are working to ensure that gene therapy research is as safe as possible.

Comprehensive federal laws, regulations, and guidelines help protect people who participate in research studies (called clinical trials). The U.S. Food and Drug Administration (FDA) regulates all gene therapy products in the United States and oversees research in this area. Researchers who wish to test an approach in a clinical trial must first obtain permission from the FDA. The FDA has the authority to reject or suspend clinical trials that are suspected of being unsafe for participants.

The National Institutes of Health (NIH) also plays an important role in ensuring the safety of gene therapy research. NIH provides guidelines for investigators and institutions (such as universities and hospitals) to follow when conducting clinical trials with gene therapy. These guidelines state that clinical trials at institutions receiving NIH funding for this type of research must be registered with the NIH Office of Biotechnology Activities. The protocol, or plan, for each clinical trial is then reviewed by the NIH Recombinant DNA Advisory Committee (RAC) to determine whether it raises medical, ethical, or safety issues that warrant further discussion at one of the RAC's public meetings.

An Institutional Review Board (IRB) and an Institutional Biosafety Committee (IBC) must approve each gene therapy clinical trial before it can be carried out. An IRB is a committee of scientific and medical advisors and consumers that reviews all research within an institution. An IBC is a group that reviews and approves an institution's potentially hazardous research studies. Multiple levels of evaluation and oversight ensure that safety concerns are a top priority in the planning and carrying out of gene therapy research.

What Are the Ethical Issues surrounding Gene Therapy?

Because gene therapy involves making changes to the body's set of basic instructions, it raises many unique ethical concerns. The ethical questions surrounding gene therapy include:

- How can "good" and "bad" uses of gene therapy be distinguished?
- Who decides which traits are normal and which constitute a disability or disorder?
- Will the high costs of gene therapy make it available only to the wealthy?
- Could the widespread use of gene therapy make society less accepting of people who are different?
- Should people be allowed to use gene therapy to enhance basic human traits such as height, intelligence, or athletic ability?

Current gene therapy research has focused on treating individuals by targeting the therapy to body cells such as bone marrow or blood cells. This type of gene therapy cannot be passed on to a person's children. Gene therapy could be targeted to egg and sperm cells (germ cells), however, which would allow the inserted gene to be passed on to future generations. This approach is known as germline gene therapy.

The idea of germline gene therapy is controversial. While it could spare future generations in a family from having a particular genetic disorder, it might affect the development of a fetus in unexpected ways or have long-term side effects that are not yet known. Because people who would be affected by germline gene therapy are not yet born, they can't choose whether to have the treatment. Because of these ethical concerns, the U.S. Government does not allow federal funds to be used for research on germline gene therapy in people.

Is Gene Therapy Available to Treat My Disorder?

Gene therapy is currently available only in a research setting. The U.S. Food and Drug Administration (FDA) has not yet approved any gene therapy products for sale in the United States.

Hundreds of research studies (clinical trials) are under way to test gene therapy as a treatment for genetic conditions, cancer, and HIV/AIDS. If you are interested in participating in a clinical trial, talk with your doctor or a genetics professional about how to participate.

You can also search for clinical trials online. ClinicalTrials.gov, a service of the National Institutes of Health, provides easy access to information on clinical trials. You can search for

specific trials or browse by condition or trial sponsor. You may wish to refer to a list of gene therapy trials that are accepting (or will accept) patients.

The Human Genome Project and Genomic Research

This section presents information on the goals, accomplishments, and next steps in understanding the human genome.

What Is a Genome?

A genome is an organism's complete set of DNA, including all of its genes. Each genome contains all of the information needed to build and maintain that organism. In humans, a copy of the entire genome—more than 3 billion DNA base pairs—is contained in all cells that have a nucleus.

What Was the Human Genome Project and Why Has It Been Important?

The Human Genome Project was an international research effort to determine the sequence of the human genome and identify the genes that it contains. The Project was coordinated by the National Institutes of Health and the U.S. Department of Energy. Additional contributors included universities across the United States and international partners in the United Kingdom, France, Germany, Japan, and China. The Human Genome Project formally began in 1990 and was completed in 2003, 2 years ahead of its original schedule.

The work of the Human Genome Project has allowed researchers to begin to understand the blueprint for building a person. As researchers learn more about the functions of genes and proteins, this knowledge will have a major impact in the fields of medicine, biotechnology, and the life sciences.

What Were the Goals of the Human Genome Project?

The main goals of the Human Genome Project were to provide a complete and accurate sequence of the 3 billion DNA base pairs that make up the human genome and to find all of the estimated 20,000 to 25,000 human genes. The Project also aimed to sequence the genomes of several other organisms that are important to medical research, such as the mouse and the fruit fly.

In addition to sequencing DNA, the Human Genome Project sought to develop new tools to obtain and analyze the data and to make this information widely available. Also, because advances in genetics have consequences for individuals and society, the Human Genome Project committed to exploring the consequences of genomic research through its Ethical, Legal, and Social Implications (ELSI) program.

What Did the Human Genome Project Accomplish?

In April 2003, researchers announced that the Human Genome Project had completed a high-quality sequence of essentially the entire human genome. This sequence closed the

gaps from a working draft of the genome, which was published in 2001. It also identified the locations of many human genes and provided information about their structure and organization. The Project made the sequence of the human genome and tools to analyze the data freely available via the Internet.

In addition to the human genome, the Human Genome Project sequenced the genomes of several other organisms, including brewers' yeast, the roundworm, and the fruit fly. In 2002, researchers announced that they had also completed a working draft of the mouse genome. By studying the similarities and differences between human genes and those of other organisms, researchers can discover the functions of particular genes and identify which genes are critical for life.

The Project's Ethical, Legal, and Social Implications (ELSI) program became the world's largest bioethics program and a model for other ELSI programs worldwide.

What Were Some of the Ethical, Legal, and Social Implications Addressed by the Human Genome Project?

The Ethical, Legal, and Social Implications (ELSI) program was founded in 1990 as an integral part of the Human Genome Project. The mission of the ELSI program was to identify and address issues raised by genomic research that would affect individuals, families, and society. A percentage of the Human Genome Project budget at the National Institutes of Health and the U.S. Department of Energy was devoted to ELSI research.

The ELSI program focused on the possible consequences of genomic research in four main areas:

- Privacy and fairness in the use of genetic information, including the potential for genetic discrimination in employment and insurance.
- The integration of new genetic technologies, such as genetic testing, into the practice of clinical medicine.
- Ethical issues surrounding the design and conduct of genetic research with people, including the process of informed consent.
- The education of healthcare professionals, policy makers, students, and the public about genetics and the complex issues that result from genomic research.

What Are the Next Steps in Genomic Research?

Discovering the sequence of the human genome was only the first step in understanding how the instructions coded in DNA lead to a functioning human being. The next stage of genomic research will begin to derive meaningful knowledge from the DNA sequence. Research studies that build on the work of the Human Genome Project are under way worldwide.

The objectives of continued genomic research include the following:

- Determine the function of genes and the elements that regulate genes throughout the genome.

- Find variations in the DNA sequence among people and determine their significance. These variations may one day provide information about a person's disease risk and response to certain medications.
- Discover the 3-dimensional structures of proteins and identify their functions.
- Explore how DNA and proteins interact with one another and with the environment to create complex living systems.
- Develop and apply genome-based strategies for the early detection, diagnosis, and treatment of disease.
- Sequence the genomes of other organisms, such as the rat, cow, and chimpanzee, in order to compare similar genes between species.
- Develop new technologies to study genes and DNA on a large scale and store genomic data efficiently.
- Continue to explore the ethical, legal, and social issues raised by genomic research.

What Is Pharmacogenomics?

Pharmacogenomics is the study of how genes affect a person's response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person's genetic makeup.

Many drugs that are currently available are "one size fits all," but they don't work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects (called adverse drug reactions). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body's response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions.

The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.

APPENDIX B. PHYSICIAN RESOURCES

Overview

In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.

NIH Guidelines

Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute¹¹:

- National Institutes of Health (NIH); guidelines consolidated across agencies available at <http://health.nih.gov/>
- National Institute of General Medical Sciences (NIGMS); fact sheets available at <http://www.nigms.nih.gov/Publications/FactSheets.htm>
- National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: <http://www.nlm.nih.gov/medlineplus/healthtopics.html>
- National Cancer Institute (NCI); guidelines available at <http://www.cancer.gov/cancertopics/pdq>
- National Eye Institute (NEI); guidelines available at <http://www.nei.nih.gov/health/>
- National Heart, Lung, and Blood Institute (NHLBI); guidelines available at <http://www.nhlbi.nih.gov/guidelines/index.htm>
- National Human Genome Research Institute (NHGRI); research available at <http://www.genome.gov/page.cfm?pageID=10000375>
- National Institute on Aging (NIA); guidelines available at <http://www.nia.nih.gov/HealthInformation/Publications/>
- National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at <http://www.niaaa.nih.gov/Publications/>

¹¹ These publications are typically written by one or more of the various NIH Institutes.

- National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at <http://www.niaid.nih.gov/publications/>
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at <http://www.niams.nih.gov/hi/index.htm>
- National Institute of Child Health and Human Development (NICHD); guidelines available at <http://www.nichd.nih.gov/publications/pubskey.cfm>
- National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at <http://www.nidcd.nih.gov/health/>
- National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at <http://www.nidcr.nih.gov/HealthInformation/>
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at <http://www.niddk.nih.gov/health/health.htm>
- National Institute on Drug Abuse (NIDA); guidelines available at <http://www.nida.nih.gov/DrugAbuse.html>
- National Institute of Environmental Health Sciences (NIEHS); environmental health information available at <http://www.niehs.nih.gov/external/facts.htm>
- National Institute of Mental Health (NIMH); guidelines available at <http://www.nimh.nih.gov/healthinformation/index.cfm>
- National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
- National Institute of Biomedical Imaging and Bioengineering; general information at <http://www.nibib.nih.gov/HealthEdu>
- National Center for Complementary and Alternative Medicine (NCCAM); health information available at <http://nccam.nih.gov/health/>
- National Center for Research Resources (NCRR); various information directories available at <http://www.ncrr.nih.gov/publications.asp>
- Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
- Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at <http://www.cdc.gov/publications.htm>

NIH Databases

In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.¹² Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic

¹² Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (<http://medlineplus.gov/> or <http://www.nlm.nih.gov/medlineplus/databases.html>).

citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine¹³:

- **Bioethics:** Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
- **HIV/AIDS Resources:** Describes various links and databases dedicated to HIV/AIDS research: <http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html>
- **NLM Online Exhibitions:** Describes “Exhibitions in the History of Medicine”: <http://www.nlm.nih.gov/exhibition/exhibition.html>. Additional resources for historical scholarship in medicine: <http://www.nlm.nih.gov/hmd/index.html>
- **Biotechnology Information:** Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: <http://www.ncbi.nlm.nih.gov/>
- **Population Information:** The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
- **Cancer Information:** Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
- **Profiles in Science:** Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: <http://www.profiles.nlm.nih.gov/>
- **Chemical Information:** Provides links to various chemical databases and references: <http://sis.nlm.nih.gov/Chem/ChemMain.html>
- **Clinical Alerts:** Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
- **Space Life Sciences:** Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
- **MEDLINE:** Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
- **Toxicology and Environmental Health Information (TOXNET):** Databases covering toxicology and environmental health: <http://sis.nlm.nih.gov/Tox/ToxMain.html>
- **Visible Human Interface:** Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html

¹³ See <http://www.nlm.nih.gov/databases/index.html>.

The NLM Gateway¹⁴

The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM's information resources or databases.¹⁵ To use the NLM Gateway, simply go to the search site at <http://gateway.nlm.nih.gov/gw/Cmd>. Type **familial Mediterranean fever** (or synonyms) into the search box and click **Search**. The results will be presented in a tabular form, indicating the number of references in each database category.

Results Summary

Category	Items Found
Journal Articles	2155
Books / Periodicals / Audio Visual	13
Consumer Health	72
Meeting Abstracts	0
Other Collections	0
Total	2240

HSTAT¹⁶

HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.¹⁷ These documents include clinical practice guidelines, quick-reference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ's Put Prevention Into Practice.¹⁸ Simply search by **familial Mediterranean fever** (or synonyms) at the following Web site: <http://text.nlm.nih.gov>.

Coffee Break: Tutorials for Biologists¹⁹

Coffee Break is a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. Here you will find a collection of short reports on recent biological discoveries. Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are

¹⁴ Adapted from NLM: <http://gateway.nlm.nih.gov/gw/Cmd?Overview.x>.

¹⁵ The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH).

¹⁶ Adapted from HSTAT: <http://www.nlm.nih.gov/pubs/factsheets/hstat.html>.

¹⁷ The HSTAT URL is <http://hstat.nlm.nih.gov/>.

¹⁸ Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's *Guide to Clinical Preventive Services*; the independent, nonfederal Task Force on Community Services' *Guide to Community Preventive Services*; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations.

¹⁹ Adapted from <http://www.ncbi.nlm.nih.gov/Coffeekbreak/Archive/FAQ.html>.

used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.²⁰ Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.²¹ This site has new articles every few weeks, so it can be considered an online magazine of sorts. It is intended for general background information. You can access the Coffee Break Web site at the following hyperlink: <http://www.ncbi.nlm.nih.gov/Coffeebreak/>.

Other Commercial Databases

In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are some examples that may interest you:

- **MD Consult:** Access to electronic clinical resources, see <http://www.mdconsult.com/>.
- **Medical Matrix:** Lists over 6000 medical Web sites and links to over 1.5 million documents with clinical content, see <http://www.medmatrix.org/>.
- **Medical World Search:** Searches full text from thousands of selected medical sites on the Internet; see <http://www.mwsearch.com/>.

²⁰ The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story.

²¹ After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process.

APPENDIX C. PATIENT RESOURCES

Overview

Official agencies, as well as federally funded institutions supported by national grants, frequently publish a variety of guidelines written with the patient in mind. These are typically called **Fact Sheets** or **Guidelines**. They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. Since new guidelines on familial Mediterranean fever can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.

Patient Guideline Sources

This section directs you to sources which either publish fact sheets or can help you find additional guidelines on topics related to familial Mediterranean fever. Due to space limitations, these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly.

The National Institutes of Health

The NIH gateway to patients is located at <http://health.nih.gov/>. From this site, you can search across various sources and institutes, a number of which are summarized below.

Topic Pages: MEDLINEplus

The National Library of Medicine has created a vast and patient-oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are **health topic pages** which list links to available materials relevant to familial Mediterranean fever. To access this system, log on to <http://www.nlm.nih.gov/medlineplus/healthtopics.html>. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following when searched for **familial Mediterranean fever**:

Arrhythmia

<http://www.nlm.nih.gov/medlineplus/arrhythmia.html>

Autoimmune Diseases

<http://www.nlm.nih.gov/medlineplus/autoimmunediseases.html>

Coronary Artery Disease

<http://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html>

Creutzfeldt-Jakob Disease

<http://www.nlm.nih.gov/medlineplus/creutzfeldtjakobdisease.html>

Crohn's Disease

<http://www.nlm.nih.gov/medlineplus/crohnsdisease.html>

Hemorrhagic Fevers

<http://www.nlm.nih.gov/medlineplus/hemorrhagicfevers.html>

Immune System and Disorders

<http://www.nlm.nih.gov/medlineplus/immunesystemanddisorders.html>

Kidney Failure

<http://www.nlm.nih.gov/medlineplus/kidneyfailure.html>

Lupus

<http://www.nlm.nih.gov/medlineplus/lupus.html>

Metabolic Disorders

<http://www.nlm.nih.gov/medlineplus/metabolicdisorders.html>

Newborn Screening

<http://www.nlm.nih.gov/medlineplus/newbornscreening.html>

You may also choose to use the search utility provided by MEDLINEplus at the following Web address: <http://www.nlm.nih.gov/medlineplus/>. Simply type a keyword into the search box and click **Search**. This utility is similar to the NIH search utility, with the exception that it only includes materials that are linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search.

Healthfinder™

Healthfinder™ is sponsored by the U.S. Department of Health and Human Services and offers links to hundreds of other sites that contain healthcare information. This Web site is located at <http://www.healthfinder.gov>. Again, keyword searches can be used to find guidelines. The following was recently found in this database:

- **MedlinePlus: Fever**

Summary: Specific Conditions; Familial Mediterranean Fever (Mayo Foundation for Medical Education and Research). Familial Mediterranean fever.

Source: www.nlm.nih.gov

<http://www.nlm.nih.gov/medlineplus/fever.html>

- **NORD - National Organization for Rare Disorders, Inc.**

Source: www.rarediseases.org

http://www.rarediseases.org/search/rdblist.html?query_start=701

The NIH Search Utility

The NIH search utility allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEB-SPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to familial Mediterranean fever. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: <http://health.nih.gov/index.asp>. Under **Search Health Topics**, type **familial Mediterranean fever** (or synonyms) into the search box, and click **Search**.

Additional Web Sources

A number of Web sites are available to the public that often link to government sites. These can also point you in the direction of essential information. The following is a representative sample:

- Family Village: <http://www.familyvillage.wisc.edu/specific.htm>
- Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
- Med Help International: <http://www.medhelp.org/HealthTopics/A.html>
- Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
- Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
- WebMD® Health: http://www.webmd.com/diseases_and_conditions/default.htm

Finding Associations

There are several Internet directories that provide lists of medical associations with information on or resources relating to familial Mediterranean fever. By consulting all of associations listed in this chapter, you will have nearly exhausted all sources for patient associations concerned with familial Mediterranean fever.

The National Health Information Center (NHIC)

The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about familial Mediterranean fever. For more information, see the NHIC’s Web site at <http://www.health.gov/NHIC/> or contact an information specialist by calling 1-800-336-4797.

Directory of Health Organizations

The Directory of Health Organizations, provided by the National Library of Medicine Specialized Information Services, is a comprehensive source of information on associations. The Directory of Health Organizations database can be accessed via the Internet at <http://sis.nlm.nih.gov/dirline.html>. It is composed of two parts: DIRLINE and Health Hotlines.

The DIRLINE database comprises some 10,000 records of organizations, research centers, and government institutes and associations that primarily focus on health and biomedicine. Simply type in **familial Mediterranean fever** (or a synonym), and you will receive information on all relevant organizations listed in the database.

Health Hotlines directs you to toll-free numbers to over 300 organizations. You can access this database directly at <http://healthhotlines.nlm.nih.gov/>. On this page, you are given the option to search by keyword or by browsing the subject list. When you have received your search results, click on the name of the organization for its description and contact information.

The National Organization for Rare Disorders, Inc.

The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by health topic. You can access this database at the following Web site: <http://www.rarediseases.org/search/orgsearch.html>. Type **familial Mediterranean fever** (or a synonym) into the search box, and click **Submit Query**.

Resources for Patients and Families

The following are organizations that provide support and advocacy for patient with genetic conditions and their families²²:

- Genetic Alliance: <http://geneticalliance.org>
- Genetic and Rare Diseases Information Center:
http://rarediseases.info.nih.gov/html/resources/info_cntr.html
- Madisons Foundation: <http://www.madisonsfoundation.org/>
- March of Dimes: <http://www.marchofdimes.com>
- National Organization for Rare Disorders (NORD): <http://www.rarediseases.org/>

For More Information on Genetics

The following publications offer detailed information for patients about the science of genetics:

- What Is a Genome?:
http://www.ncbi.nlm.nih.gov/About/primer/genetics_genome.html

²² Adapted from the National Library of Medicine: <http://ghr.nlm.nih.gov/ghr/resource/patients>.

- A Science Called Genetics: <http://publications.nigms.nih.gov/genetics/science.html>
- Genetic Mapping: <http://www.genome.gov/10000715>

ONLINE GLOSSARIES

The Internet provides access to a number of free-to-use medical dictionaries. The National Library of Medicine has compiled the following list of online dictionaries:

- ADAM Medical Encyclopedia (A.D.A.M., Inc.), comprehensive medical reference:
<http://www.nlm.nih.gov/medlineplus/encyclopedia.html>
- MedicineNet.com Medical Dictionary (MedicineNet, Inc.):
<http://www.medterms.com/Script/Main/hp.asp>
- Merriam-Webster Medical Dictionary (Inteli-Health, Inc.):
<http://www.intelihealth.com/IH/>
- Multilingual Glossary of Technical and Popular Medical Terms in Eight European Languages (European Commission) - Danish, Dutch, English, French, German, Italian, Portuguese, and Spanish: <http://allserv.rug.ac.be/~rvdstich/eugloss/welcome.html>
- On-line Medical Dictionary (CancerWEB): <http://cancerweb.ncl.ac.uk/omd/>
- Rare Diseases Terms (Office of Rare Diseases):
<http://ord.aspensys.com/asp/diseases/diseases.asp>
- Technology Glossary (National Library of Medicine) - Health Care Technology:
<http://www.nlm.nih.gov/archive/20040831/nichsr/ta101/ta10108.html>

Beyond these, MEDLINEplus contains a very patient-friendly encyclopedia covering every aspect of medicine (licensed from A.D.A.M., Inc.). The ADAM Medical Encyclopedia can be accessed at <http://www.nlm.nih.gov/medlineplus/encyclopedia.html>. ADAM is also available on commercial Web sites such as drkoop.com (<http://www.drkoop.com/>) and Web MD (http://my.webmd.com/adam/asset/adam_disease_articles/a_to_z/a). The NIH suggests the following Web sites in the ADAM Medical Encyclopedia when searching for information on familial Mediterranean fever:

- **Basic Guidelines for Familial Mediterranean Fever**

Familial Mediterranean fever

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/000363.htm>

- **Signs & Symptoms for Familial Mediterranean Fever**

Abdominal pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003120.htm>

Ankle pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003167.htm>

Chest pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003079.htm>

Chills

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003091.htm>

Elbow pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003172.htm>

Erythema

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003220.htm>

Fever

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003090.htm>

Foot pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003183.htm>

Hip pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003179.htm>

Joint pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003261.htm>

Knee pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003187.htm>

Shoulder pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003171.htm>

Wrist pain

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003175.htm>

- **Diagnostics and Tests for Familial Mediterranean Fever**

ANA

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003535.htm>

Ceruloplasmin

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003662.htm>

C-reactive protein

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003356.htm>

ESR

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003638.htm>

Fibrinogen

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003650.htm>

Haptoglobin

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003634.htm>

Plasma fibrinogen

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003650.htm>

White blood cell count

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003643.htm>

X-ray

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003337.htm>

- **Background Topics for Familial Mediterranean Fever**

Symptomatic

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002293.htm>

Online Dictionary Directories

The following are additional online directories compiled by the National Library of Medicine, including a number of specialized medical dictionaries:

- Medical Dictionaries: Medical & Biological (World Health Organization):
<http://www.who.int/hlt/virtuallibrary/English/diction.htm#Medical>
- Patient Education: Glossaries (DMOZ Open Directory Project):
http://dmoz.org/Health/Education/Patient_Education/Glossaries/
- Web of Online Dictionaries (Bucknell University):
<http://www.yourdictionary.com/diction5.html#medicine>

FAMILIAL MEDITERRANEAN FEVER

DICTIONARY

The definitions below are derived from official public sources, including the National Institutes of Health [NIH] and the European Union [EU].

3-dimensional: 3-D. A graphic display of depth, width, and height. Three-dimensional radiation therapy uses computers to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible. [NIH]

Abdomen: That portion of the body that lies between the thorax and the pelvis. [NIH]

Abdominal: Having to do with the abdomen, which is the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs. [NIH]

Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region. [NIH]

Acetylcholine: A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. [NIH]

Acetylgalactosamine: The N-acetyl derivative of galactosamine. [NIH]

Acetylglucosamine: The N-acetyl derivative of glucosamine. [NIH]

Acne: A disorder of the skin marked by inflammation of oil glands and hair glands. [NIH]

Acne Vulgaris: A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors. [NIH]

Actin: Essential component of the cell skeleton. [NIH]

Adaptability: Ability to develop some form of tolerance to conditions extremely different from those under which a living organism evolved. [NIH]

Adenine: A purine base and a fundamental unit of adenine nucleotides. [NIH]

Adenosine: A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [NIH]

Adenosine Triphosphate: Adenosine 5'-(tetrahydrogen triphosphate). An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [NIH]

Adenovirus: A group of viruses that cause respiratory tract and eye infections. Adenoviruses used in gene therapy are altered to carry a specific tumor-fighting gene. [NIH]

Adipocytes: Fat-storing cells found mostly in the abdominal cavity and subcutaneous tissue. Fat is usually stored in the form of triglycerides. [NIH]

Adrenal Glands: Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney. [NIH]

Adrenergic: Activated by, characteristic of, or secreting epinephrine or substances with similar activity; the term is applied to those nerve fibres that liberate norepinephrine at a synapse when a nerve impulse passes, i.e., the sympathetic fibres. [EU]

Adverse Effect: An unwanted side effect of treatment. [NIH]

Aerobic: In biochemistry, reactions that need oxygen to happen or happen when oxygen is present. [NIH]

Afferent: Concerned with the transmission of neural impulse toward the central part of the nervous system. [NIH]

Agonist: In anatomy, a prime mover. In pharmacology, a drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances. [EU]

Albumin: 1. Any protein that is soluble in water and moderately concentrated salt solutions and is coagulable by heat. 2. Serum albumin; the major plasma protein (approximately 60 per cent of the total), which is responsible for much of the plasma colloidal osmotic pressure and serves as a transport protein carrying large organic anions, such as fatty acids, bilirubin, and many drugs, and also carrying certain hormones, such as cortisol and thyroxine, when their specific binding globulins are saturated. Albumin is synthesized in the liver. Low serum levels occur in protein malnutrition, active inflammation and serious hepatic and renal disease. [EU]

Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. [NIH]

Alkaloid: A member of a large group of chemicals that are made by plants and have nitrogen in them. Some alkaloids have been shown to work against cancer. [NIH]

Alleles: Mutually exclusive forms of the same gene, occupying the same locus on homologous chromosomes, and governing the same biochemical and developmental process. [NIH]

Allograft: An organ or tissue transplant between two humans. [NIH]

Alpha-1: A protein with the property of inactivating proteolytic enzymes such as leucocyte collagenase and elastase. [NIH]

Alternative medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used instead of standard treatments. Alternative medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]

Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining protein conformation. [NIH]

Amino Acids: Organic compounds that generally contain an amino (-NH₂) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. [NIH]

Amino Acids: Organic compounds that generally contain an amino (-NH₂) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. [NIH]

Amnion: The extraembryonic membrane which contains the embryo and amniotic fluid. [NIH]

Amniotic Fluid: Amniotic cavity fluid which is produced by the amnion and fetal lungs and kidneys. [NIH]

Amplification: The production of additional copies of a chromosomal DNA sequence, found as either intrachromosomal or extrachromosomal DNA. [NIH]

Amyloid: A general term for a variety of different proteins that accumulate as extracellular fibrils of 7-10 nm and have common structural features, including a beta-pleated sheet conformation and the ability to bind such dyes as Congo red and thioflavine (Kandel, Schwartz, and Jessel, Principles of Neural Science, 3rd ed). [NIH]

Amyloidosis: A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands. [NIH]

Anaesthesia: Loss of feeling or sensation. Although the term is used for loss of tactile sensibility, or of any of the other senses, it is applied especially to loss of the sensation of pain, as it is induced to permit performance of surgery or other painful procedures. [EU]

Anaphylatoxins: The family of peptides C3a, C4a, C5a, and C5a des-arginine produced in the serum during complement activation. They produce smooth muscle contraction, mast cell histamine release, affect platelet aggregation, and act as mediators of the local inflammatory process. The order of anaphylatoxin activity from strongest to weakest is C5a, C3a, C4a, and C5a des-arginine. The latter is the so-called "classical" anaphylatoxin but shows no spasmogenic activity though it contains some chemotactic ability. [NIH]

Anatomical: Pertaining to anatomy, or to the structure of the organism. [EU]

Anemia: A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. [NIH]

Aneuploidy: The chromosomal constitution of cells which deviate from the normal by the addition or subtraction of chromosomes or chromosome pairs. In a normally diploid cell the loss of a chromosome pair is termed nullisomy (symbol: $2N-2$), the loss of a single chromosome is monosomy (symbol: $2N-1$), the addition of a chromosome pair is tetrasomy (symbol: $2N+2$), the addition of a single chromosome is trisomy (symbol: $2N+1$). [NIH]

Angioid Streaks: Small breaks in the elastin-filled tissue of the retina. [NIH]

Anions: Negatively charged atoms, radicals or groups of atoms which travel to the anode or positive pole during electrolysis. [NIH]

Annealing: The spontaneous alignment of two single DNA strands to form a double helix. [NIH]

Antibacterial: A substance that destroys bacteria or suppresses their growth or reproduction. [EU]

Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the antigen that induced their synthesis in cells of the lymphoid series (especially plasma cells), or with an antigen closely related to it. [NIH]

Antibody: A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen. [NIH]

Anticoagulant: A drug that helps prevent blood clots from forming. Also called a blood thinner. [NIH]

Antigen: Any substance which is capable, under appropriate conditions, of inducing a

specific immune response and of reacting with the products of that response, that is, with specific antibody or specifically sensitized T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (q.v.) combines with antibody or a specific receptor on a lymphocyte. Abbreviated Ag. [EU]

Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. [NIH]

Antihypertensive: An agent that reduces high blood pressure. [EU]

Anti-inflammatory: Having to do with reducing inflammation. [NIH]

Anti-Inflammatory Agents: Substances that reduce or suppress inflammation. [NIH]

Antipsychotic: Effective in the treatment of psychosis. Antipsychotic drugs (called also neuroleptic drugs and major tranquilizers) are a chemically diverse (including phenothiazines, thioxanthenes, butyrophenones, dibenzoxazepines, dibenzodiazepines, and diphenylbutylpiperidines) but pharmacologically similar class of drugs used to treat schizophrenic, paranoid, schizoaffective, and other psychotic disorders; acute delirium and dementia, and manic episodes (during induction of lithium therapy); to control the movement disorders associated with Huntington's chorea, Gilles de la Tourette's syndrome, and ballismus; and to treat intractable hiccups and severe nausea and vomiting. Antipsychotic agents bind to dopamine, histamine, muscarinic cholinergic, α -adrenergic, and serotonin receptors. Blockade of dopaminergic transmission in various areas is thought to be responsible for their major effects: antipsychotic action by blockade in the mesolimbic and mesocortical areas; extrapyramidal side effects (dystonia, akathisia, parkinsonism, and tardive dyskinesia) by blockade in the basal ganglia; and antiemetic effects by blockade in the chemoreceptor trigger zone of the medulla. Sedation and autonomic side effects (orthostatic hypotension, blurred vision, dry mouth, nasal congestion and constipation) are caused by blockade of histamine, cholinergic, and adrenergic receptors. [EU]

Anuria: Inability to form or excrete urine. [NIH]

Anus: The opening of the rectum to the outside of the body. [NIH]

Apoptosis: One of the two mechanisms by which cell death occurs (the other being the pathological process of necrosis). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA (DNA fragmentation) at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. [NIH]

Aqueous: Having to do with water. [NIH]

Arginine: An essential amino acid that is physiologically active in the L-form. [NIH]

Arterial: Pertaining to an artery or to the arteries. [EU]

Arteries: The vessels carrying blood away from the heart. [NIH]

Arterioles: The smallest divisions of the arteries located between the muscular arteries and the capillaries. [NIH]

Artery: Vessel-carrying blood from the heart to various parts of the body. [NIH]

Articular: Of or pertaining to a joint. [EU]

Asbestos: Fibrous incombustible mineral composed of magnesium and calcium silicates with or without other elements. It is relatively inert chemically and used in thermal insulation and fireproofing. Inhalation of dust causes asbestosis and later lung and gastrointestinal neoplasms. [NIH]

Ascites: Accumulation or retention of free fluid within the peritoneal cavity. [NIH]

Aspirin: A drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention. [NIH]

Assay: Determination of the amount of a particular constituent of a mixture, or of the biological or pharmacological potency of a drug. [EU]

Asymptomatic: Having no signs or symptoms of disease. [NIH]

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. [NIH]

Atypical: Irregular; not conformable to the type; in microbiology, applied specifically to strains of unusual type. [EU]

Autoantibodies: Antibodies that react with self-antigens (autoantigens) of the organism that produced them. [NIH]

Autoantigens: Endogenous tissue constituents that have the ability to interact with autoantibodies and cause an immune response. [NIH]

Autodigestion: Autolysis; a condition found in disease of the stomach: the stomach wall is digested by the gastric juice. [NIH]

Autoimmune disease: A condition in which the body recognizes its own tissues as foreign and directs an immune response against them. [NIH]

Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccid, rodlike or bacillary, and spiral or spirochetal. [NIH]

Barbiturate: A drug with sedative and hypnotic effects. Barbiturates have been used as sedatives and anesthetics, and they have been used to treat the convulsions associated with epilepsy. [NIH]

Base: In chemistry, the nonacid part of a salt; a substance that combines with acids to form salts; a substance that dissociates to give hydroxide ions in aqueous solutions; a substance whose molecule or ion can combine with a proton (hydrogen ion); a substance capable of donating a pair of electrons (to an acid) for the formation of a coordinate covalent bond. [EU]

Base Sequence: The sequence of purines and pyrimidines in nucleic acids and polynucleotides. It is also called nucleotide or nucleoside sequence. [NIH]

Benign: Not cancerous; does not invade nearby tissue or spread to other parts of the body. [NIH]

Beta-pleated: Particular three-dimensional pattern of amyloidoses. [NIH]

Bewilderment: Impairment or loss of will power. [NIH]

Bile: An emulsifying agent produced in the liver and secreted into the duodenum. Its composition includes bile acids and salts, cholesterol, and electrolytes. It aids digestion of fats in the duodenum. [NIH]

Biliary: Having to do with the liver, bile ducts, and/or gallbladder. [NIH]

Biliary Tract: The gallbladder and its ducts. [NIH]

Bilirubin: A bile pigment that is a degradation product of heme. [NIH]

Biochemical: Relating to biochemistry; characterized by, produced by, or involving chemical reactions in living organisms. [EU]

Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body. [NIH]

Biopterin: A natural product that has been considered as a growth factor for some insects. [NIH]

Biosynthesis: The building up of a chemical compound in the physiologic processes of a living organism. [EU]

Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus; laboratory methods used include transfection and cloning technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction. [NIH]

Bladder: The organ that stores urine. [NIH]

Blastocyst: The mammalian embryo in the post-morula stage in which a fluid-filled cavity, enclosed primarily by trophoblast, contains an inner cell mass which becomes the embryonic disc. [NIH]

Blood Cell Count: A count of the number of leukocytes and erythrocytes per unit volume in a sample of venous blood. A complete blood count (CBC) also includes measurement of the hemoglobin, hematocrit, and erythrocyte indices. [NIH]

Blood Glucose: Glucose in blood. [NIH]

Blood pressure: The pressure of blood against the walls of a blood vessel or heart chamber. Unless there is reference to another location, such as the pulmonary artery or one of the heart chambers, it refers to the pressure in the systemic arteries, as measured, for example, in the forearm. [NIH]

Blood vessel: A tube in the body through which blood circulates. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins. [NIH]

Body Fluids: Liquid components of living organisms. [NIH]

Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. [NIH]

Bone marrow biopsy: The removal of a sample of tissue from the bone marrow with a needle for examination under a microscope. [NIH]

Bone Marrow Transplantation: The transference of bone marrow from one human or animal to another. [NIH]

Bone scan: A technique to create images of bones on a computer screen or on film. A small amount of radioactive material is injected into a blood vessel and travels through the bloodstream; it collects in the bones and is detected by a scanner. [NIH]

Bowel: The long tube-shaped organ in the abdomen that completes the process of digestion. There is both a small and a large bowel. Also called the intestine. [NIH]

Bradykinin: A nonapeptide messenger that is enzymatically produced from kallidin in the

blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from mast cells during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. [NIH]

Buccal: Pertaining to or directed toward the cheek. In dental anatomy, used to refer to the buccal surface of a tooth. [EU]

Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. [NIH]

Capillary: Any one of the minute vessels that connect the arterioles and venules, forming a network in nearly all parts of the body. Their walls act as semipermeable membranes for the interchange of various substances, including fluids, between the blood and tissue fluid; called also vas capillare. [EU]

Carbohydrate: An aldehyde or ketone derivative of a polyhydric alcohol, particularly of the pentahydric and hexahydric alcohols. They are so named because the hydrogen and oxygen are usually in the proportion to form water, (CH₂O)_n. The most important carbohydrates are the starches, sugars, celluloses, and gums. They are classified into mono-, di-, tri-, poly- and heterosaccharides. [EU]

Carcinogenic: Producing carcinoma. [EU]

Carcinoid: A type of tumor usually found in the gastrointestinal system (most often in the appendix), and sometimes in the lungs or other sites. Carcinoid tumors are usually benign. [NIH]

Cardiac: Having to do with the heart. [NIH]

Cardiovascular: Having to do with the heart and blood vessels. [NIH]

Cardiovascular disease: Any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease, which can lead to heart attacks), cerebrovascular disease (e.g., stroke), and hypertension (high blood pressure). [NIH]

Cardiovascular System: The heart and the blood vessels by which blood is pumped and circulated through the body. [NIH]

Carpal Tunnel Syndrome: A median nerve injury inside the carpal tunnel that results in symptoms of pain, numbness, tingling, clumsiness, and a lack of sweating, which can be caused by work with certain hand and wrist postures. [NIH]

Case report: A detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin). [NIH]

Catecholamine: A group of chemical substances manufactured by the adrenal medulla and secreted during physiological stress. [NIH]

Cause of Death: Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. [NIH]

Cell: The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells. [NIH]

Cell Cycle: The complex series of phenomena, occurring between the end of one cell division and the end of the next, by which cellular material is divided between daughter

cells. [NIH]

Cell Death: The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. [NIH]

Cell Division: The fission of a cell. [NIH]

Cell Respiration: The metabolic process of all living cells (animal and plant) in which oxygen is used to provide a source of energy for the cell. [NIH]

Central Nervous System: The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. [NIH]

Centromere: The clear constricted portion of the chromosome at which the chromatids are joined and by which the chromosome is attached to the spindle during cell division. [NIH]

Cerebrovascular: Pertaining to the blood vessels of the cerebrum, or brain. [EU]

Chemotactic Factors: Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult. [NIH]

Chemotaxis: The movement of cells or organisms toward or away from a substance in response to its concentration gradient. [NIH]

Chin: The anatomical frontal portion of the mandible, also known as the mentum, that contains the line of fusion of the two separate halves of the mandible (symphysis menti). This line of fusion divides inferiorly to enclose a triangular area called the mental protuberance. On each side, inferior to the second premolar tooth, is the mental foramen for the passage of blood vessels and a nerve. [NIH]

Cholesterol: The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. [NIH]

Chromatin: The material of chromosomes. It is a complex of DNA, histones, and nonhistone proteins (chromosomal proteins, non-histone) found within the nucleus of a cell. [NIH]

Chromosomal: Pertaining to chromosomes. [EU]

Chromosome: Part of a cell that contains genetic information. Except for sperm and eggs, all human cells contain 46 chromosomes. [NIH]

Chromosome Fragility: Susceptibility of chromosomes to breakage and translocation or other aberrations. Chromosome fragile sites are regions that show up in karyotypes as a gap (uncondensed stretch) on the chromatid arm. They are associated with chromosome break sites and other aberrations. A fragile site on the X chromosome is associated with fragile X syndrome. Fragile sites are designated by the letters "FRA" followed by the designation for the specific chromosome and a letter which refers to the different fragile sites on a chromosome (e.g. FRAXA). [NIH]

Chronic: A disease or condition that persists or progresses over a long period of time. [NIH]

Chronic renal: Slow and progressive loss of kidney function over several years, often resulting in end-stage renal disease. People with end-stage renal disease need dialysis or transplantation to replace the work of the kidneys. [NIH]

Cirrhosis: A type of chronic, progressive liver disease. [NIH]

CIS: Cancer Information Service. The CIS is the National Cancer Institute's link to the public, interpreting and explaining research findings in a clear and understandable manner, and providing personalized responses to specific questions about cancer. Access the CIS by calling 1-800-4-CANCER, or by using the Web site at <http://cis.nci.nih.gov>. [NIH]

Clinical Medicine: The study and practice of medicine by direct examination of the patient.

[NIH]

Clinical trial: A research study that tests how well new medical treatments or other interventions work in people. Each study is designed to test new methods of screening, prevention, diagnosis, or treatment of a disease. [NIH]

Cloning: The production of a number of genetically identical individuals; in genetic engineering, a process for the efficient replication of a great number of identical DNA molecules. [NIH]

Codon: A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (codon, terminator). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, transfer) complementary to all codons. These codons are referred to as unassigned codons (codons, nonsense). [NIH]

Cofactor: A substance, microorganism or environmental factor that activates or enhances the action of another entity such as a disease-causing agent. [NIH]

Colchicine: A major alkaloid from *Colchicum autumnale* L. and found also in other *Colchicum* species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (periodic disease). [NIH]

Colitis: Inflammation of the colon. [NIH]

Collagen: A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of skin, connective tissue, and the organic substance of bones and teeth. Different forms of collagen are produced in the body but all consist of three alpha-polypeptide chains arranged in a triple helix. Collagen is differentiated from other fibrous proteins, such as elastin, by the content of proline, hydroxyproline, and hydroxylysine; by the absence of tryptophan; and particularly by the high content of polar groups which are responsible for its swelling properties. [NIH]

Colloidal: Of the nature of a colloid. [EU]

Colon: The long, coiled, tubelike organ that removes water from digested food. The remaining material, solid waste called stool, moves through the colon to the rectum and leaves the body through the anus. [NIH]

Colonoscopy: Endoscopic examination, therapy or surgery of the luminal surface of the colon. [NIH]

Complement: A term originally used to refer to the heat-labile factor in serum that causes immune cytolysis, the lysis of antibody-coated cells, and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed 'components of complement' and are designated by the symbols C1 through C9. C1 is a calcium-dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower-case letter suffixes, e.g., C3a. Inactivated fragments may be designated with the suffix 'i', e.g. C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol e.g. C1 or C4b,2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3; C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides, and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3; activation of the

alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins, or chemotactic factors. [EU]

Complementary and alternative medicine: CAM. Forms of treatment that are used in addition to (complementary) or instead of (alternative) standard treatments. These practices are not considered standard medical approaches. CAM includes dietary supplements, megadose vitamins, herbal preparations, special teas, massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]

Complementary medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used to enhance or complement the standard treatments. Complementary medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]

Computational Biology: A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories applicable to molecular biology and areas of computer-based techniques for solving biological problems including manipulation of models and datasets. [NIH]

Concentric: Having a common center of curvature or symmetry. [NIH]

Conception: The onset of pregnancy, marked by implantation of the blastocyst; the formation of a viable zygote. [EU]

Confusion: A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation. [NIH]

Congestion: Excessive or abnormal accumulation of blood in a part. [EU]

Connective Tissue: Tissue that supports and binds other tissues. It consists of connective tissue cells embedded in a large amount of extracellular matrix. [NIH]

Connective Tissue: Tissue that supports and binds other tissues. It consists of connective tissue cells embedded in a large amount of extracellular matrix. [NIH]

Consciousness: Sense of awareness of self and of the environment. [NIH]

Constipation: Infrequent or difficult evacuation of feces. [NIH]

Constriction: The act of constricting. [NIH]

Consultation: A deliberation between two or more physicians concerning the diagnosis and the proper method of treatment in a case. [NIH]

Contraindications: Any factor or sign that it is unwise to pursue a certain kind of action or treatment, e. g. giving a general anesthetic to a person with pneumonia. [NIH]

Coordination: Muscular or motor regulation or the harmonious cooperation of muscles or groups of muscles, in a complex action or series of actions. [NIH]

Cor: The muscular organ that maintains the circulation of the blood. c. adiposum a heart that has undergone fatty degeneration or that has an accumulation of fat around it; called also fat or fatty, heart. c. arteriosum the left side of the heart, so called because it contains oxygenated (arterial) blood. c. biloculare a congenital anomaly characterized by failure of formation of the atrial and ventricular septums, the heart having only two chambers, a single atrium and a single ventricle, and a common atrioventricular valve. c. bovinum (L. 'ox heart') a greatly enlarged heart due to a hypertrophied left ventricle; called also c. taurinum and bucardia. c. dextrum (L. 'right heart') the right atrium and ventricle. c. hirsutum, c.

villosum. *c. mobile* (obs.) an abnormally movable heart. *c. pendulum* a heart so movable that it seems to be hanging by the great blood vessels. *c. pseudotriloculare biatriatum* a congenital cardiac anomaly in which the heart functions as a three-chambered heart because of tricuspid atresia, the right ventricle being extremely small or rudimentary and the right atrium greatly dilated. Blood passes from the right to the left atrium and thence disease due to pulmonary hypertension secondary to disease of the lung, or its blood vessels, with hypertrophy of the right ventricle. [EU]

Cornea: The transparent part of the eye that covers the iris and the pupil and allows light to enter the inside. [NIH]

Coronary: Encircling in the manner of a crown; a term applied to vessels; nerves, ligaments, etc. The term usually denotes the arteries that supply the heart muscle and, by extension, a pathologic involvement of them. [EU]

Coronary heart disease: A type of heart disease caused by narrowing of the coronary arteries that feed the heart, which needs a constant supply of oxygen and nutrients carried by the blood in the coronary arteries. When the coronary arteries become narrowed or clogged by fat and cholesterol deposits and cannot supply enough blood to the heart, CHD results. [NIH]

Coronary Thrombosis: Presence of a thrombus in a coronary artery, often causing a myocardial infarction. [NIH]

Corticosteroid: Any of the steroids elaborated by the adrenal cortex (excluding the sex hormones of adrenal origin) in response to the release of corticotrophin (adrenocorticotrophic hormone) by the pituitary gland, to any of the synthetic equivalents of these steroids, or to angiotensin II. They are divided, according to their predominant biological activity, into three major groups: glucocorticoids, chiefly influencing carbohydrate, fat, and protein metabolism; mineralocorticoids, affecting the regulation of electrolyte and water balance; and C19 androgens. Some corticosteroids exhibit both types of activity in varying degrees, and others exert only one type of effect. The corticosteroids are used clinically for hormonal replacement therapy, for suppression of ACTH secretion by the anterior pituitary, as antineoplastic, antiallergic, and anti-inflammatory agents, and to suppress the immune response. Called also adrenocortical hormone and corticoid. [EU]

Cortisol: A steroid hormone secreted by the adrenal cortex as part of the body's response to stress. [NIH]

Cranial: Pertaining to the cranium, or to the anterior (in animals) or superior (in humans) end of the body. [EU]

Cutaneous: Having to do with the skin. [NIH]

Cyclic: Pertaining to or occurring in a cycle or cycles; the term is applied to chemical compounds that contain a ring of atoms in the nucleus. [EU]

Cytochrome: Any electron transfer hemoprotein having a mode of action in which the transfer of a single electron is effected by a reversible valence change of the central iron atom of the heme prosthetic group between the +2 and +3 oxidation states; classified as cytochromes a in which the heme contains a formyl side chain, cytochromes b, which contain protoheme or a closely similar heme that is not covalently bound to the protein, cytochromes c in which protoheme or other heme is covalently bound to the protein, and cytochromes d in which the iron-tetrapyrrole has fewer conjugated double bonds than the hemes have. Well-known cytochromes have been numbered consecutively within groups and are designated by subscripts (beginning with no subscript), e.g. cytochromes c, c₁, C₂, . . . New cytochromes are named according to the wavelength in nanometres of the absorption maximum of the a-band of the iron (II) form in pyridine, e.g., c-555. [EU]

Cytokine: Small but highly potent protein that modulates the activity of many cell types, including T and B cells. [NIH]

Cytoplasm: The protoplasm of a cell exclusive of that of the nucleus; it consists of a continuous aqueous solution (cytosol) and the organelles and inclusions suspended in it (phaneroplasm), and is the site of most of the chemical activities of the cell. [EU]

Cytosine: A pyrimidine base that is a fundamental unit of nucleic acids. [NIH]

Cytoskeleton: The network of filaments, tubules, and interconnecting filamentous bridges which give shape, structure, and organization to the cytoplasm. [NIH]

De novo: In cancer, the first occurrence of cancer in the body. [NIH]

Death Certificates: Official records of individual deaths including the cause of death certified by a physician, and any other required identifying information. [NIH]

Defense Mechanisms: Unconscious process used by an individual or a group of individuals in order to cope with impulses, feelings or ideas which are not acceptable at their conscious level; various types include reaction formation, projection and self reversal. [NIH]

Degenerative: Undergoing degeneration : tending to degenerate; having the character of or involving degeneration; causing or tending to cause degeneration. [EU]

Deletion: A genetic rearrangement through loss of segments of DNA (chromosomes), bringing sequences, which are normally separated, into close proximity. [NIH]

Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. [NIH]

Denaturation: Rupture of the hydrogen bonds by heating a DNA solution and then cooling it rapidly causes the two complementary strands to separate. [NIH]

Dendrites: Extensions of the nerve cell body. They are short and branched and receive stimuli from other neurons. [NIH]

Deoxyribonucleic: A polymer of subunits called deoxyribonucleotides which is the primary genetic material of a cell, the material equivalent to genetic information. [NIH]

Deoxyribonucleic acid: A polymer of subunits called deoxyribonucleotides which is the primary genetic material of a cell, the material equivalent to genetic information. [NIH]

Deoxyribonucleotides: A purine or pyrimidine base bonded to a deoxyribose containing a bond to a phosphate group. [NIH]

Diabetes Mellitus: A heterogeneous group of disorders that share glucose intolerance in common. [NIH]

Digestion: The process of breakdown of food for metabolism and use by the body. [NIH]

Diploid: Having two sets of chromosomes. [NIH]

Direct: 1. Straight; in a straight line. 2. Performed immediately and without the intervention of subsidiary means. [EU]

Discrimination: The act of qualitative and/or quantitative differentiation between two or more stimuli. [NIH]

Disorientation: The loss of proper bearings, or a state of mental confusion as to time, place, or identity. [EU]

Dopamine: An endogenous catecholamine and prominent neurotransmitter in several systems of the brain. In the synthesis of catecholamines from tyrosine, it is the immediate

precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of dopaminergic receptor subtypes mediate its action. Dopamine is used pharmacologically for its direct (beta adrenergic agonist) and indirect (adrenergic releasing) sympathomimetic effects including its actions as an inotropic agent and as a renal vasodilator. [NIH]

Drug Tolerance: Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from maximum tolerated dose and no-observed-adverse-effect level. [NIH]

Duodenum: The first part of the small intestine. [NIH]

Dyes: Chemical substances that are used to stain and color other materials. The coloring may or may not be permanent. Dyes can also be used as therapeutic agents and test reagents in medicine and scientific research. [NIH]

Dystrophy: Any disorder arising from defective or faulty nutrition, especially the muscular dystrophies. [EU]

Edema: Excessive amount of watery fluid accumulated in the intercellular spaces, most commonly present in subcutaneous tissue. [NIH]

Effector: It is often an enzyme that converts an inactive precursor molecule into an active second messenger. [NIH]

Efficacy: The extent to which a specific intervention, procedure, regimen, or service produces a beneficial result under ideal conditions. Ideally, the determination of efficacy is based on the results of a randomized control trial. [NIH]

Elastic: Susceptible of resisting and recovering from stretching, compression or distortion applied by a force. [EU]

Electrolytes: Substances that break up into ions (electrically charged particles) when they are dissolved in body fluids or water. Some examples are sodium, potassium, chloride, and calcium. Electrolytes are primarily responsible for the movement of nutrients into cells, and the movement of wastes out of cells. [NIH]

Electrons: Stable elementary particles having the smallest known negative charge, present in all elements; also called negatrons. Positively charged electrons are called positrons. The numbers, energies and arrangement of electrons around atomic nuclei determine the chemical identities of elements. Beams of electrons are called cathode rays or beta rays, the latter being a high-energy biproduct of nuclear decay. [NIH]

Embryo: The prenatal stage of mammalian development characterized by rapid morphological changes and the differentiation of basic structures. [NIH]

Endogenous: Produced inside an organism or cell. The opposite is external (exogenous) production. [NIH]

Endorphins: One of the three major groups of endogenous opioid peptides. They are large peptides derived from the pro-opiomelanocortin precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; opioid peptides is used for the broader group. [NIH]

Endothelium: A layer of epithelium that lines the heart, blood vessels (endothelium, vascular), lymph vessels (endothelium, lymphatic), and the serous cavities of the body. [NIH]

Endothelium-derived: Small molecule that diffuses to the adjacent muscle layer and relaxes it. [NIH]

Endotoxin: Toxin from cell walls of bacteria. [NIH]

End-stage renal: Total chronic kidney failure. When the kidneys fail, the body retains fluid and harmful wastes build up. A person with ESRD needs treatment to replace the work of the failed kidneys. [NIH]

Energy balance: Energy is the capacity of a body or a physical system for doing work. Energy balance is the state in which the total energy intake equals total energy needs. [NIH]

Enkephalins: One of the three major families of endogenous opioid peptides. The enkephalins are pentapeptides that are widespread in the central and peripheral nervous systems and in the adrenal medulla. [NIH]

Environmental Health: The science of controlling or modifying those conditions, influences, or forces surrounding man which relate to promoting, establishing, and maintaining health. [NIH]

Enzymatic: Phase where enzyme cuts the precursor protein. [NIH]

Enzyme: A protein that speeds up chemical reactions in the body. [NIH]

Eosinophils: Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. [NIH]

Epidermis: Nonvascular layer of the skin. It is made up, from within outward, of five layers: 1) basal layer (stratum basale epidermidis); 2) spinous layer (stratum spinosum epidermidis); 3) granular layer (stratum granulosum epidermidis); 4) clear layer (stratum lucidum epidermidis); and 5) horny layer (stratum corneum epidermidis). [NIH]

Epinephrine: The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [NIH]

Epithelial: Refers to the cells that line the internal and external surfaces of the body. [NIH]

Epithelial Cells: Cells that line the inner and outer surfaces of the body. [NIH]

Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of causes. [NIH]

Erythrocyte Indices: Quantification of size and cell hemoglobin content or concentration of the erythrocyte, usually derived from erythrocyte count, blood hemoglobin concentration, and hematocrit. Includes the mean cell volume (MCV), mean cell hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC). Use also for cell diameter and thickness. [NIH]

Erythrocytes: Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing hemoglobin whose function is to transport oxygen. [NIH]

Esophagus: The muscular tube through which food passes from the throat to the stomach. [NIH]

Ethnic Groups: A group of people with a common cultural heritage that sets them apart from others in a variety of social relationships. [NIH]

Eukaryotic Cells: Cells of the higher organisms, containing a true nucleus bounded by a nuclear membrane. [NIH]

Excitation: An act of irritation or stimulation or of responding to a stimulus; the addition of energy, as the excitation of a molecule by absorption of photons. [EU]

Excrete: To get rid of waste from the body. [NIH]

Exon: The part of the DNA that encodes the information for the actual amino acid sequence

of the protein. In many eucaryotic genes, the coding sequences consist of a series of exons alternating with intron sequences. [NIH]

Extracellular: Outside a cell or cells. [EU]

Extracellular Matrix: A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. [NIH]

Extrapyramidal: Outside of the pyramidal tracts. [EU]

Eye Color: Color of the iris. [NIH]

Eye Infections: Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness. [NIH]

Family Planning: Programs or services designed to assist the family in controlling reproduction by either improving or diminishing fertility. [NIH]

Fat: Total lipids including phospholipids. [NIH]

Fathers: Male parents, human or animal. [NIH]

Fatty acids: A major component of fats that are used by the body for energy and tissue development. [NIH]

Febrile: Pertaining to or characterized by fever. [EU]

Femoral: Pertaining to the femur, or to the thigh. [EU]

Femur: The longest and largest bone of the skeleton, it is situated between the hip and the knee. [NIH]

Fetus: The developing offspring from 7 to 8 weeks after conception until birth. [NIH]

Fibril: Most bacterial viruses have a hollow tail with specialized fibrils at its tip. The tail fibers attach to the cell wall of the host. [NIH]

Fibrin: A protein derived from fibrinogen in the presence of thrombin, which forms part of the blood clot. [NIH]

Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. [NIH]

Fibroblasts: Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. [NIH]

Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. [NIH]

Fold: A plication or doubling of various parts of the body. [NIH]

Forearm: The part between the elbow and the wrist. [NIH]

Frameshift: A type of mutation which causes out-of-phase transcription of the base sequence; such mutations arise from the addition or deletion of nucleotide(s) in numbers other than 3 or multiples of 3. [NIH]

Frameshift Mutation: A type of mutation in which a number of nucleotides not divisible by three is deleted from or inserted into a coding sequence, thereby causing an alteration in the reading frame of the entire sequence downstream of the mutation. These mutations may be induced by certain types of mutagens or may occur spontaneously. [NIH]

Gallbladder: The pear-shaped organ that sits below the liver. Bile is concentrated and stored in the gallbladder. [NIH]

Ganglia: Clusters of multipolar neurons surrounded by a capsule of loosely organized connective tissue located outside the central nervous system. [NIH]

Gas: Air that comes from normal breakdown of food. The gases are passed out of the body through the rectum (flatulence) or the mouth (burp). [NIH]

Gastrin: A hormone released after eating. Gastrin causes the stomach to produce more acid. [NIH]

Gastrointestinal: Refers to the stomach and intestines. [NIH]

Gene: The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein. [NIH]

Gene Expression: The phenotypic manifestation of a gene or genes by the processes of gene action. [NIH]

Gene Products, rev: Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (CAR) in env, also known as the rev-responsive element (RRE), is responsive to the rev gene product. rev is short for regulator of virion. [NIH]

Gene Therapy: The introduction of new genes into cells for the purpose of treating disease by restoring or adding gene expression. Techniques include insertion of retroviral vectors, transfection, homologous recombination, and injection of new genes into the nuclei of single cell embryos. The entire gene therapy process may consist of multiple steps. The new genes may be introduced into proliferating cells in vivo (e.g., bone marrow) or in vitro (e.g., fibroblast cultures) and the modified cells transferred to the site where the gene expression is required. Gene therapy may be particularly useful for treating enzyme deficiency diseases, hemoglobinopathies, and leukemias and may also prove useful in restoring drug sensitivity, particularly for leukemia. [NIH]

Genes, env: DNA sequences that form the coding region for the viral envelope (env) proteins in retroviruses. The env genes contain a cis-acting RNA target sequence for the rev protein (= gene products, rev), termed the rev-responsive element (RRE). [NIH]

Genetic testing: Analyzing DNA to look for a genetic alteration that may indicate an increased risk for developing a specific disease or disorder. [NIH]

Genetics: The biological science that deals with the phenomena and mechanisms of heredity. [NIH]

Genomics: The systematic study of the complete DNA sequences (genome) of organisms. [NIH]

Genotype: The genetic constitution of the individual; the characterization of the genes. [NIH]

Germ Cells: The reproductive cells in multicellular organisms. [NIH]

Germline mutation: A gene change in the body's reproductive cells (egg or sperm) that becomes incorporated into the DNA of every cell in the body of offspring; germline mutations are passed on from parents to offspring. Also called hereditary mutation. [NIH]

Gland: An organ that produces and releases one or more substances for use in the body. Some glands produce fluids that affect tissues or organs. Others produce hormones or participate in blood production. [NIH]

Glomerular: Pertaining to or of the nature of a glomerulus, especially a renal glomerulus.

[EU]

Glomeruli: Plural of glomerulus. [NIH]

Glomerulonephritis: Glomerular disease characterized by an inflammatory reaction, with leukocyte infiltration and cellular proliferation of the glomeruli, or that appears to be the result of immune glomerular injury. [NIH]

Glucocorticoids: A group of corticosteroids that affect carbohydrate metabolism (gluconeogenesis, liver glycogen deposition, elevation of blood sugar), inhibit corticotropin secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. [NIH]

Gluconeogenesis: The process by which glucose is formed from a non-carbohydrate source. [NIH]

Glucose: D-Glucose. A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. [NIH]

Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid (glutamate) is the most common excitatory neurotransmitter in the central nervous system. [NIH]

Glycine: A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [NIH]

Glycogen: A sugar stored in the liver and muscles. It releases glucose into the blood when cells need it for energy. Glycogen is the chief source of stored fuel in the body. [NIH]

Glycoprotein: A protein that has sugar molecules attached to it. [NIH]

Glycosaminoglycans: Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine or N-acetylgalactosamine. [NIH]

Gonadal: Pertaining to a gonad. [EU]

Gout: Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi. [NIH]

Governing Board: The group in which legal authority is vested for the control of health-related institutions and organizations. [NIH]

Graft: Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body. [NIH]

Graft Survival: The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. [NIH]

Granule: A small pill made from sucrose. [EU]

Granulocytes: Leukocytes with abundant granules in the cytoplasm. They are divided into three groups: neutrophils, eosinophils, and basophils. [NIH]

Guanine: One of the four DNA bases. [NIH]

Guanylate Cyclase: An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2. [NIH]

Hair Color: Color of hair or fur. [NIH]

Heart attack: A seizure of weak or abnormal functioning of the heart. [NIH]

Hematocrit: Measurement of the volume of packed red cells in a blood specimen by centrifugation. The procedure is performed using a tube with graduated markings or with automated blood cell counters. It is used as an indicator of erythrocyte status in disease. For example, anemia shows a low hematocrit, polycythemia, high values. [NIH]

Hemochromatosis: A disease that occurs when the body absorbs too much iron. The body stores the excess iron in the liver, pancreas, and other organs. May cause cirrhosis of the liver. Also called iron overload disease. [NIH]

Hemodialysis: The use of a machine to clean wastes from the blood after the kidneys have failed. The blood travels through tubes to a dialyzer, which removes wastes and extra fluid. The cleaned blood then flows through another set of tubes back into the body. [NIH]

Hemoglobin: One of the fractions of glycosylated hemoglobin A1c. Glycosylated hemoglobin is formed when linkages of glucose and related monosaccharides bind to hemoglobin A and its concentration represents the average blood glucose level over the previous several weeks. HbA1c levels are used as a measure of long-term control of plasma glucose (normal, 4 to 6 percent). In controlled diabetes mellitus, the concentration of glycosylated hemoglobin A is within the normal range, but in uncontrolled cases the level may be 3 to 4 times the normal concentration. Generally, complications are substantially lower among patients with Hb levels of 7 percent or less than in patients with HbA1c levels of 9 percent or more. [NIH]

Hemoglobinopathies: A group of inherited disorders characterized by structural alterations within the hemoglobin molecule. [NIH]

Hemophilia: Refers to a group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots. [NIH]

Hemorrhage: Bleeding or escape of blood from a vessel. [NIH]

Hepatic: Refers to the liver. [NIH]

Hepatitis: Inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes. [NIH]

Hepatocytes: The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. [NIH]

Hereditary: Of, relating to, or denoting factors that can be transmitted genetically from one generation to another. [NIH]

Hereditary mutation: A gene change in the body's reproductive cells (egg or sperm) that becomes incorporated into the DNA of every cell in the body of offspring; hereditary mutations are passed on from parents to offspring. Also called germline mutation. [NIH]

Heredity: 1. The genetic transmission of a particular quality or trait from parent to offspring. 2. The genetic constitution of an individual. [EU]

Heterogeneity: The property of one or more samples or populations which implies that they are not identical in respect of some or all of their parameters, e. g. heterogeneity of variance. [NIH]

Heterozygote: An individual having different alleles at one or more loci in homologous chromosome segments. [NIH]

Histones: Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. [NIH]

Homologous: Corresponding in structure, position, origin, etc., as (a) the feathers of a bird and the scales of a fish, (b) antigen and its specific antibody, (c) allelic chromosomes. [EU]

Hormone: A substance in the body that regulates certain organs. Hormones such as gastrin help in breaking down food. Some hormones come from cells in the stomach and small intestine. [NIH]

Hybrid: Cross fertilization between two varieties or, more usually, two species of vines, see also crossing. [NIH]

Hybridization: The genetic process of crossbreeding to produce a hybrid. Hybrid nucleic acids can be formed by nucleic acid hybridization of DNA and RNA molecules. Protein hybridization allows for hybrid proteins to be formed from polypeptide chains. [NIH]

Hybridomas: Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure or "monoclonal" antibodies or T-cell products, identical to those produced by the immunologically competent parent, and continually grow and divide as the neoplastic parent. [NIH]

Hydrogen: The first chemical element in the periodic table. It has the atomic symbol H, atomic number 1, and atomic weight 1. It exists, under normal conditions, as a colorless, odorless, tasteless, diatomic gas. Hydrogen ions are protons. Besides the common H1 isotope, hydrogen exists as the stable isotope deuterium and the unstable, radioactive isotope tritium. [NIH]

Hydrolysis: The process of cleaving a chemical compound by the addition of a molecule of water. [NIH]

Hyperbilirubinemia: Pathologic process consisting of an abnormal increase in the amount of bilirubin in the circulating blood, which may result in jaundice. [NIH]

Hyperlipidemia: An excess of lipids in the blood. [NIH]

Hypersensitivity: Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. [NIH]

Hypertension: Persistently high arterial blood pressure. Currently accepted threshold levels are 140 mm Hg systolic and 90 mm Hg diastolic pressure. [NIH]

Hypesthesia: Absent or reduced sensitivity to cutaneous stimulation. [NIH]

Hypnotic: A drug that acts to induce sleep. [EU]

Hypotension: Abnormally low blood pressure. [NIH]

Hypothalamic: Of or involving the hypothalamus. [EU]

Hypothalamus: Ventral part of the diencephalon extending from the region of the optic chiasm to the caudal border of the mammillary bodies and forming the inferior and lateral walls of the third ventricle. [NIH]

Idiopathic: Describes a disease of unknown cause. [NIH]

Ileal: Related to the ileum, the lowest end of the small intestine. [NIH]

Ileitis: Inflammation of the ileum. [EU]

Ileum: The lower end of the small intestine. [NIH]

Immune response: The activity of the immune system against foreign substances (antigens). [NIH]

Immune system: The organs, cells, and molecules responsible for the recognition and disposal of foreign ("non-self") material which enters the body. [NIH]

Immunity: Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. [NIH]

Immunologic: The ability of the antibody-forming system to recall a previous experience with an antigen and to respond to a second exposure with the prompt production of large amounts of antibody. [NIH]

Impairment: In the context of health experience, an impairment is any loss or abnormality of psychological, physiological, or anatomical structure or function. [NIH]

Implantation: The insertion or grafting into the body of biological, living, inert, or radioactive material. [EU]

In situ: In the natural or normal place; confined to the site of origin without invasion of neighbouring tissues. [EU]

In vitro: In the laboratory (outside the body). The opposite of in vivo (in the body). [NIH]

In vivo: In the body. The opposite of in vitro (outside the body or in the laboratory). [NIH]

Induction: The act or process of inducing or causing to occur, especially the production of a specific morphogenetic effect in the developing embryo through the influence of evocators or organizers, or the production of anaesthesia or unconsciousness by use of appropriate agents. [EU]

Infancy: The period of complete dependency prior to the acquisition of competence in walking, talking, and self-feeding. [NIH]

Infarction: A pathological process consisting of a sudden insufficient blood supply to an area, which results in necrosis of that area. It is usually caused by a thrombus, an embolus, or a vascular torsion. [NIH]

Infection: 1. Invasion and multiplication of microorganisms in body tissues, which may be clinically unapparent or result in local cellular injury due to competitive metabolism, toxins, intracellular replication, or antigen-antibody response. The infection may remain localized, subclinical, and temporary if the body's defensive mechanisms are effective. A local infection may persist and spread by extension to become an acute, subacute, or chronic clinical infection or disease state. A local infection may also become systemic when the microorganisms gain access to the lymphatic or vascular system. 2. An infectious disease. [EU]

Infiltration: The diffusion or accumulation in a tissue or cells of substances not normal to it or in amounts of the normal. Also, the material so accumulated. [EU]

Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. [NIH]

Informed Consent: Voluntary authorization, given to the physician by the patient, with full comprehension of the risks involved, for diagnostic or investigative procedures and medical and surgical treatment. [NIH]

Initiation: Mutation induced by a chemical reactive substance causing cell changes; being a step in a carcinogenic process. [NIH]

Initiator: A chemically reactive substance which may cause cell changes if ingested, inhaled or absorbed into the body; the substance may thus initiate a carcinogenic process. [NIH]

Inotropic: Affecting the force or energy of muscular contractions. [EU]

Insulator: Material covering the metal conductor of the lead. It is usually polyurethane or silicone. [NIH]

Interferon: A biological response modifier (a substance that can improve the body's natural response to disease). Interferons interfere with the division of cancer cells and can slow tumor growth. There are several types of interferons, including interferon-alpha, -beta, and -

gamma. These substances are normally produced by the body. They are also made in the laboratory for use in treating cancer and other diseases. [NIH]

Interleukin-1: A soluble factor produced by monocytes, macrophages, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. IL-1 consists of two distinct forms, IL-1 alpha and IL-1 beta which perform the same functions but are distinct proteins. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. The factor is distinct from interleukin-2. [NIH]

Interleukin-10: Factor that is a coregulator of mast cell growth. It is produced by T-cells and B-cells and shows extensive homology with the Epstein-Barr virus BCRF1 gene. [NIH]

Interleukin-12: A heterodimeric cytokine that stimulates the production of interferon gamma from T-cells and natural killer cells, and also induces differentiation of Th1 helper cells. It is an initiator of cell-mediated immunity. [NIH]

Interleukin-2: Chemical mediator produced by activated T lymphocytes and which regulates the proliferation of T cells, as well as playing a role in the regulation of NK cell activity. [NIH]

Interleukin-6: Factor that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas. It is produced by many different cells including T-cells, monocytes, and fibroblasts. [NIH]

Interstitial: Pertaining to or situated between parts or in the interspaces of a tissue. [EU]

Intestine: A long, tube-shaped organ in the abdomen that completes the process of digestion. There is both a large intestine and a small intestine. Also called the bowel. [NIH]

Intoxication: Poisoning, the state of being poisoned. [EU]

Intracellular: Inside a cell. [NIH]

Intravascular: Within a vessel or vessels. [EU]

Ions: An atom or group of atoms that have a positive or negative electric charge due to a gain (negative charge) or loss (positive charge) of one or more electrons. Atoms with a positive charge are known as cations; those with a negative charge are anions. [NIH]

Iris: The most anterior portion of the uveal layer, separating the anterior chamber from the posterior. It consists of two layers - the stroma and the pigmented epithelium. Color of the iris depends on the amount of melanin in the stroma on reflection from the pigmented epithelium. [NIH]

Isotretinoin: A topical dermatologic agent that is used in the treatment of acne vulgaris and several other skin diseases. The drug has teratogenic and other adverse effects. [NIH]

Jaundice: A clinical manifestation of hyperbilirubinemia, consisting of deposition of bile pigments in the skin, resulting in a yellowish staining of the skin and mucous membranes. [NIH]

Karyotype: The characteristic chromosome complement of an individual, race, or species as defined by their number, size, shape, etc. [NIH]

Kidney Failure: The inability of a kidney to excrete metabolites at normal plasma levels under conditions of normal loading, or the inability to retain electrolytes under conditions of normal intake. In the acute form (kidney failure, acute), it is marked by uremia and usually by oliguria or anuria, with hyperkalemia and pulmonary edema. The chronic form (kidney failure, chronic) is irreversible and requires hemodialysis. [NIH]

Kidney Failure, Acute: A clinical syndrome characterized by a sudden decrease in glomerular filtration rate, often to values of less than 1 to 2 ml per minute. It is usually associated with oliguria (urine volumes of less than 400 ml per day) and is always associated

with biochemical consequences of the reduction in glomerular filtration rate such as a rise in blood urea nitrogen (BUN) and serum creatinine concentrations. [NIH]

Kidney Failure, Chronic: An irreversible and usually progressive reduction in renal function in which both kidneys have been damaged by a variety of diseases to the extent that they are unable to adequately remove the metabolic products from the blood and regulate the body's electrolyte composition and acid-base balance. Chronic kidney failure requires hemodialysis or surgery, usually kidney transplantation. [NIH]

Labile: 1. Gliding; moving from point to point over the surface; unstable; fluctuating. 2. Chemically unstable. [EU]

Laceration: 1. The act of tearing. 2. A torn, ragged, mangled wound. [EU]

Latent: Phoria which occurs at one distance or another and which usually has no troublesome effect. [NIH]

Latent period: A seemingly inactive period, as that between exposure of tissue to an injurious agent and the manifestation of response, or that between the instant of stimulation and the beginning of response. [EU]

Leptin: A 16-kD peptide hormone secreted from white adipocytes and implicated in the regulation of food intake and energy balance. Leptin provides the key afferent signal from fat cells in the feedback system that controls body fat stores. [NIH]

Lesion: An area of abnormal tissue change. [NIH]

Leucocyte: All the white cells of the blood and their precursors (myeloid cell series, lymphoid cell series) but commonly used to indicate granulocytes exclusive of lymphocytes. [NIH]

Leukemia: Cancer of blood-forming tissue. [NIH]

Ligase: An enzyme that repairs single stranded discontinuities in double-stranded DNA molecules in the cell. Purified DNA ligase is used in gene cloning to join DNA molecules together. [NIH]

Linkage: The tendency of two or more genes in the same chromosome to remain together from one generation to the next more frequently than expected according to the law of independent assortment. [NIH]

Lipid: Fat. [NIH]

Lipopolysaccharide: Substance consisting of polysaccharide and lipid. [NIH]

Liver: A large, glandular organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile. [NIH]

Localization: The process of determining or marking the location or site of a lesion or disease. May also refer to the process of keeping a lesion or disease in a specific location or site. [NIH]

Localized: Cancer which has not metastasized yet. [NIH]

Lupus: A form of cutaneous tuberculosis. It is seen predominantly in women and typically involves the nasal, buccal, and conjunctival mucosa. [NIH]

Lymphatic: The tissues and organs, including the bone marrow, spleen, thymus, and lymph nodes, that produce and store cells that fight infection and disease. [NIH]

Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells. [NIH]

Lymphoid: Referring to lymphocytes, a type of white blood cell. Also refers to tissue in which lymphocytes develop. [NIH]

Lysine: An essential amino acid. It is often added to animal feed. [NIH]

Macrophage: A type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells. [NIH]

Malignant: Cancerous; a growth with a tendency to invade and destroy nearby tissue and spread to other parts of the body. [NIH]

Malignant mesothelioma: A rare type of cancer in which malignant cells are found in the sac lining the chest or abdomen. Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma. [NIH]

Malnutrition: A condition caused by not eating enough food or not eating a balanced diet. [NIH]

Mammography: Radiographic examination of the breast. [NIH]

Median Nerve: A major nerve of the upper extremity. In humans, the fibers of the median nerve originate in the lower cervical and upper thoracic spinal cord (usually C6 to T1), travel via the brachial plexus, and supply sensory and motor innervation to parts of the forearm and hand. [NIH]

Mediate: Indirect; accomplished by the aid of an intervening medium. [EU]

Medical Records: Recording of pertinent information concerning patient's illness or illnesses. [NIH]

MEDLINE: An online database of MEDLARS, the computerized bibliographic Medical Literature Analysis and Retrieval System of the National Library of Medicine. [NIH]

Meiosis: A special method of cell division, occurring in maturation of the germ cells, by means of which each daughter nucleus receives half the number of chromosomes characteristic of the somatic cells of the species. [NIH]

Melanoma: A form of skin cancer that arises in melanocytes, the cells that produce pigment. Melanoma usually begins in a mole. [NIH]

Membrane: A very thin layer of tissue that covers a surface. [NIH]

Memory: Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory. [NIH]

Mental: Pertaining to the mind; psychic. 2. (L. mentum chin) pertaining to the chin. [EU]

Mental Retardation: Refers to sub-average general intellectual functioning which originated during the developmental period and is associated with impairment in adaptive behavior. [NIH]

Mesothelioma: A benign (noncancerous) or malignant (cancerous) tumor affecting the lining of the chest or abdomen. Exposure to asbestos particles in the air increases the risk of developing malignant mesothelioma. [NIH]

Metaraminol: An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension. [NIH]

Microbe: An organism which cannot be observed with the naked eye; e. g. unicellular animals, lower algae, lower fungi, bacteria. [NIH]

Microbiology: The study of microorganisms such as fungi, bacteria, algae, archaea, and viruses. [NIH]

Microorganism: An organism that can be seen only through a microscope. Microorganisms include bacteria, protozoa, algae, and fungi. Although viruses are not considered living organisms, they are sometimes classified as microorganisms. [NIH]

Microscopy: The application of microscope magnification to the study of materials that cannot be properly seen by the unaided eye. [NIH]

Microtubules: Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein tubulin. [NIH]

Migration: The systematic movement of genes between populations of the same species, geographic race, or variety. [NIH]

Miscarriage: Spontaneous expulsion of the products of pregnancy before the middle of the second trimester. [NIH]

Mitochondria: Parts of a cell where aerobic production (also known as cell respiration) takes place. [NIH]

Mitochondrial Swelling: Increase in volume of mitochondria due to an influx of fluid; it occurs in hypotonic solutions due to osmotic pressure and in isotonic solutions as a result of altered permeability of the membranes of respiring mitochondria. [NIH]

Mitosis: A method of indirect cell division by means of which the two daughter nuclei normally receive identical complements of the number of chromosomes of the somatic cells of the species. [NIH]

Modification: A change in an organism, or in a process in an organism, that is acquired from its own activity or environment. [NIH]

Molecular: Of, pertaining to, or composed of molecules : a very small mass of matter. [EU]

Molecule: A chemical made up of two or more atoms. The atoms in a molecule can be the same (an oxygen molecule has two oxygen atoms) or different (a water molecule has two hydrogen atoms and one oxygen atom). Biological molecules, such as proteins and DNA, can be made up of many thousands of atoms. [NIH]

Monitor: An apparatus which automatically records such physiological signs as respiration, pulse, and blood pressure in an anesthetized patient or one undergoing surgical or other procedures. [NIH]

Monocyte: A type of white blood cell. [NIH]

Mononuclear: A cell with one nucleus. [NIH]

Monosomy: The condition in which one chromosome of a pair is missing. In a normally diploid cell it is represented symbolically as $2N-1$. [NIH]

Morphological: Relating to the configuration or the structure of live organs. [NIH]

Mosaicism: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from a single zygote, as opposed to chimerism in which the different cell populations are derived from more than one zygote. [NIH]

Mucosa: A mucous membrane, or tunica mucosa. [EU]

Mucus: The viscous secretion of mucous membranes. It contains mucin, white blood cells, water, inorganic salts, and exfoliated cells. [NIH]

Multiple sclerosis: A disorder of the central nervous system marked by weakness, numbness, a loss of muscle coordination, and problems with vision, speech, and bladder control. Multiple sclerosis is thought to be an autoimmune disease in which the body's immune system destroys myelin. Myelin is a substance that contains both protein and fat (lipid) and serves as a nerve insulator and helps in the transmission of nerve signals. [NIH]

Mutagens: Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. [NIH]

Myalgia: Pain in a muscle or muscles. [EU]

Myelin: The fatty substance that covers and protects nerves. [NIH]

Myocardial infarction: Gross necrosis of the myocardium as a result of interruption of the blood supply to the area; it is almost always caused by atherosclerosis of the coronary arteries, upon which coronary thrombosis is usually superimposed. [NIH]

Myocardium: The muscle tissue of the heart composed of striated, involuntary muscle known as cardiac muscle. [NIH]

Myopathy: Any disease of a muscle. [EU]

Myotonic Dystrophy: A condition presenting muscle weakness and wasting which may be progressive. [NIH]

Natural killer cells: NK cells. A type of white blood cell that contains granules with enzymes that can kill tumor cells or microbial cells. Also called large granular lymphocytes (LGL). [NIH]

NCI: National Cancer Institute. NCI, part of the National Institutes of Health of the United States Department of Health and Human Services, is the federal government's principal agency for cancer research. NCI conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Access the NCI Web site at <http://cancer.gov>. [NIH]

Necrosis: A pathological process caused by the progressive degradative action of enzymes that is generally associated with severe cellular trauma. It is characterized by mitochondrial swelling, nuclear flocculation, uncontrolled cell lysis, and ultimately cell death. [NIH]

Neopterin: A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. [NIH]

Nephropathy: Disease of the kidneys. [EU]

Nephrosis: Descriptive histopathologic term for renal disease without an inflammatory component. [NIH]

Nephrotic: Pertaining to, resembling, or caused by nephrosis. [EU]

Nephrotic Syndrome: Clinical association of heavy proteinuria, hypoalbuminemia, and generalized edema. [NIH]

Nervous System: The entire nerve apparatus composed of the brain, spinal cord, nerves and ganglia. [NIH]

Neuritis: A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include pain; paresthesias; paresis; or hypesthesia. [NIH]

Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures. [NIH]

Neuronal: Pertaining to a neuron or neurons (= conducting cells of the nervous system). [EU]

Neurons: The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system. [NIH]

Neuropathy: A problem in any part of the nervous system except the brain and spinal cord.

Neuropathies can be caused by infection, toxic substances, or disease. [NIH]

Neurotransmitter: Any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, norepinephrine, epinephrine, dopamine, glycine, γ -aminobutyrate, glutamic acid, substance P, enkephalins, endorphins, and serotonin. [EU]

Neutrophil: A type of white blood cell. [NIH]

Nitric Oxide: A free radical gas produced endogenously by a variety of mammalian cells. It is synthesized from arginine by a complex reaction, catalyzed by nitric oxide synthase. Nitric oxide is endothelium-derived relaxing factor. It is released by the vascular endothelium and mediates the relaxation induced by some vasodilators such as acetylcholine and bradykinin. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic guanylate cyclase and thus elevates intracellular levels of cyclic GMP. [NIH]

Norepinephrine: Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic. [NIH]

Nuclear: A test of the structure, blood flow, and function of the kidneys. The doctor injects a mildly radioactive solution into an arm vein and uses x-rays to monitor its progress through the kidneys. [NIH]

Nuclear Envelope: The membrane system of the cell nucleus that surrounds the nucleoplasm. It consists of two concentric membranes separated by the perinuclear space. The structures of the envelope where it opens to the cytoplasm are called the nuclear pores (nuclear pore). [NIH]

Nuclear Pore: An opening through the nuclear envelope formed by the nuclear pore complex which transports nuclear proteins or RNA into or out of the cell nucleus and which, under some conditions, acts as an ion channel. [NIH]

Nuclei: A body of specialized protoplasm found in nearly all cells and containing the chromosomes. [NIH]

Nucleic acid: Either of two types of macromolecule (DNA or RNA) formed by polymerization of nucleotides. Nucleic acids are found in all living cells and contain the information (genetic code) for the transfer of genetic information from one generation to the next. [NIH]

Nucleic Acid Hybridization: The process whereby two single-stranded polynucleotides form a double-stranded molecule, with hydrogen bonding between the complementary bases in the two strands. [NIH]

Nucleus: A body of specialized protoplasm found in nearly all cells and containing the chromosomes. [NIH]

Nurse Practitioners: Nurses who are specially trained to assume an expanded role in providing medical care under the supervision of a physician. [NIH]

Oliguria: Clinical manifestation of the urinary system consisting of a decrease in the amount of urine secreted. [NIH]

Organelles: Specific particles of membrane-bound organized living substances present in

eukaryotic cells, such as the mitochondria; the golgi apparatus; endoplasmic reticulum; lysosomes; plastids; and vacuoles. [NIH]

Osmotic: Pertaining to or of the nature of osmosis (= the passage of pure solvent from a solution of lesser to one of greater solute concentration when the two solutions are separated by a membrane which selectively prevents the passage of solute molecules, but is permeable to the solvent). [EU]

Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. [NIH]

Ovaries: The pair of female reproductive glands in which the ova, or eggs, are formed. The ovaries are located in the pelvis, one on each side of the uterus. [NIH]

Oxidative Phosphorylation: Electron transfer through the cytochrome system liberating free energy which is transformed into high-energy phosphate bonds. [NIH]

Paediatric: Of or relating to the care and medical treatment of children; belonging to or concerned with paediatrics. [EU]

Pancreas: A mixed exocrine and endocrine gland situated transversely across the posterior abdominal wall in the epigastric and hypochondriac regions. The endocrine portion is comprised of the Islets of Langerhans, while the exocrine portion is a compound acinar gland that secretes digestive enzymes. [NIH]

Pancreatic: Having to do with the pancreas. [NIH]

Pancreatitis: Acute or chronic inflammation of the pancreas, which may be asymptomatic or symptomatic, and which is due to autodigestion of a pancreatic tissue by its own enzymes. It is caused most often by alcoholism or biliary tract disease; less commonly it may be associated with hyperlipaemia, hyperparathyroidism, abdominal trauma (accidental or operative injury), vasculitis, or uraemia. [EU]

Paresis: A general term referring to a mild to moderate degree of muscular weakness, occasionally used as a synonym for paralysis (severe or complete loss of motor function). In the older literature, paresis often referred specifically to paretic neurosyphilis. "General paresis" and "general paralysis" may still carry that connotation. Bilateral lower extremity paresis is referred to as paraparesis. [NIH]

Paresthesias: Abnormal touch sensations, such as burning or prickling, that occur without an outside stimulus. [NIH]

Paternity: Establishing the father relationship of a man and a child. [NIH]

Pathologic: 1. Indicative of or caused by a morbid condition. 2. Pertaining to pathology (= branch of medicine that treats the essential nature of the disease, especially the structural and functional changes in tissues and organs of the body caused by the disease). [EU]

Pathologic Processes: The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. [NIH]

PDQ: Physician Data Query. PDQ is an online database developed and maintained by the National Cancer Institute. Designed to make the most current, credible, and accurate cancer information available to health professionals and the public, PDQ contains peer-reviewed summaries on cancer treatment, screening, prevention, genetics, and supportive care; a registry of cancer clinical trials from around the world; and directories of physicians, professionals who provide genetics services, and organizations that provide cancer care. Most of this information is available on the CancerNet Web site, and more specific information about PDQ can be found at <http://cancer.net.ncl.nih.gov/pdq.html>. [NIH]

Pelvis: The lower part of the abdomen, located between the hip bones. [NIH]

Penicillin: An antibiotic drug used to treat infection. [NIH]

Peptide: Any compound consisting of two or more amino acids, the building blocks of proteins. Peptides are combined to make proteins. [NIH]

Perforation: 1. The act of boring or piercing through a part. 2. A hole made through a part or substance. [EU]

Pericarditis: Inflammation of the pericardium. [EU]

Pericardium: The fibroserous sac surrounding the heart and the roots of the great vessels. [NIH]

Peripheral blood: Blood circulating throughout the body. [NIH]

Peripheral Nervous System: The nervous system outside of the brain and spinal cord. The peripheral nervous system has autonomic and somatic divisions. The autonomic nervous system includes the enteric, parasympathetic, and sympathetic subdivisions. The somatic nervous system includes the cranial and spinal nerves and their ganglia and the peripheral sensory receptors. [NIH]

Peritoneal: Having to do with the peritoneum (the tissue that lines the abdominal wall and covers most of the organs in the abdomen). [NIH]

Peritoneal Cavity: The space enclosed by the peritoneum. It is divided into two portions, the greater sac and the lesser sac or omental bursa, which lies behind the stomach. The two sacs are connected by the foramen of Winslow, or epiploic foramen. [NIH]

Peritoneum: Endothelial lining of the abdominal cavity, the parietal peritoneum covering the inside of the abdominal wall and the visceral peritoneum covering the bowel, the mesentery, and certain of the organs. The portion that covers the bowel becomes the serosal layer of the bowel wall. [NIH]

Peritonitis: Inflammation of the peritoneum; a condition marked by exudations in the peritoneum of serum, fibrin, cells, and pus. It is attended by abdominal pain and tenderness, constipation, vomiting, and moderate fever. [EU]

Pharmacologic: Pertaining to pharmacology or to the properties and reactions of drugs. [EU]

Phenotype: The outward appearance of the individual. It is the product of interactions between genes and between the genotype and the environment. This includes the killer phenotype, characteristic of yeasts. [NIH]

Phosphorus: A non-metallic element that is found in the blood, muscles, nevers, bones, and teeth, and is a component of adenosine triphosphate (ATP; the primary energy source for the body's cells.) [NIH]

Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. [NIH]

Physical Examination: Systematic and thorough inspection of the patient for physical signs of disease or abnormality. [NIH]

Physiologic: Having to do with the functions of the body. When used in the phrase "physiologic age," it refers to an age assigned by general health, as opposed to calendar age. [NIH]

Pilot study: The initial study examining a new method or treatment. [NIH]

Plasma: The clear, yellowish, fluid part of the blood that carries the blood cells. The proteins that form blood clots are in plasma. [NIH]

Plasma cells: A type of white blood cell that produces antibodies. [NIH]

Plasma protein: One of the hundreds of different proteins present in blood plasma, including carrier proteins (such as albumin, transferrin, and haptoglobin), fibrinogen and other coagulation factors, complement components, immunoglobulins, enzyme inhibitors, precursors of substances such as angiotensin and bradykinin, and many other types of proteins. [EU]

Plastids: Self-replicating cytoplasmic organelles of plant and algal cells that contain pigments and may synthesize and accumulate various substances. Plastids are used in phylogenetic studies. [NIH]

Platelet Aggregation: The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. [NIH]

Platelets: A type of blood cell that helps prevent bleeding by causing blood clots to form. Also called thrombocytes. [NIH]

Pneumonia: Inflammation of the lungs. [NIH]

Point Mutation: A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair. [NIH]

Polyarteritis Nodosa: A form of necrotizing vasculitis involving small- and medium-sized arteries. The signs and symptoms result from infarction and scarring of the affected organ system. [NIH]

Polymerase: An enzyme which catalyses the synthesis of DNA using a single DNA strand as a template. The polymerase copies the template in the 5'-3' direction provided that sufficient quantities of free nucleotides, dATP and dTTP are present. [NIH]

Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. [NIH]

Polymorphism: The occurrence together of two or more distinct forms in the same population. [NIH]

Polypeptide: A peptide which on hydrolysis yields more than two amino acids; called tripeptides, tetrapeptides, etc. according to the number of amino acids contained. [EU]

Polysaccharide: A type of carbohydrate. It contains sugar molecules that are linked together chemically. [NIH]

Potentiate: A degree of synergism which causes the exposure of the organism to a harmful substance to worsen a disease already contracted. [NIH]

Practice Guidelines: Directions or principles presenting current or future rules of policy for the health care practitioner to assist him in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. [NIH]

Precursor: Something that precedes. In biological processes, a substance from which another, usually more active or mature substance is formed. In clinical medicine, a sign or symptom that heralds another. [EU]

Predisposition: A latent susceptibility to disease which may be activated under certain conditions, as by stress. [EU]

Prenatal: Existing or occurring before birth, with reference to the fetus. [EU]

Presynaptic: Situated proximal to a synapse, or occurring before the synapse is crossed. [EU]

Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from incidence, which refers to the number of new cases in the population at a given time. [NIH]

Progesterone: Pregn-4-ene-3,20-dione. The principal progestational hormone of the body, secreted by the corpus luteum, adrenal cortex, and placenta. Its chief function is to prepare the uterus for the reception and development of the fertilized ovum. It acts as an antiovaratory agent when administered on days 5-25 of the menstrual cycle. [NIH]

Progression: Increase in the size of a tumor or spread of cancer in the body. [NIH]

Progressive: Advancing; going forward; going from bad to worse; increasing in scope or severity. [EU]

Projection: A defense mechanism, operating unconsciously, whereby that which is emotionally unacceptable in the self is rejected and attributed (projected) to others. [NIH]

Promoter: A chemical substance that increases the activity of a carcinogenic process. [NIH]

Prone: Having the front portion of the body downwards. [NIH]

Prophase: The first phase of cell division, in which the chromosomes become visible, the nucleus starts to lose its identity, the spindle appears, and the centrioles migrate toward opposite poles. [NIH]

Prophylaxis: An attempt to prevent disease. [NIH]

Protease: Proteinase (= any enzyme that catalyses the splitting of interior peptide bonds in a protein). [EU]

Protein C: A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation. [NIH]

Protein S: The vitamin K-dependent cofactor of activated protein C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S can lead to recurrent venous and arterial thrombosis. [NIH]

Proteins: Polymers of amino acids linked by peptide bonds. The specific sequence of amino acids determines the shape and function of the protein. [NIH]

Proteinuria: The presence of protein in the urine, indicating that the kidneys are not working properly. [NIH]

Proteolytic: 1. Pertaining to, characterized by, or promoting proteolysis. 2. An enzyme that promotes proteolysis (= the splitting of proteins by hydrolysis of the peptide bonds with formation of smaller polypeptides). [EU]

Protocol: The detailed plan for a clinical trial that states the trial's rationale, purpose, drug or vaccine dosages, length of study, routes of administration, who may participate, and other aspects of trial design. [NIH]

Pseudoxanthoma: A rare disease of the skin characterized by the appearance of elevated yellowish papules or plaques, particularly on the neck, chest and abdomen and infrequently on the eyelids. [NIH]

Pseudoxanthoma Elasticum: A rare, progressive inherited disorder resulting from extensive basophilic degeneration of elastic tissue, usually presenting after puberty and involving the

skin, eye, and cardiovascular system. Characteristic manifestations are small, circumscribed yellowish patches at sites of considerable movement of the skin, angioid streaks in the retina, and a tendency towards hemorrhage and arterial insufficiency. [NIH]

Psychiatric: Pertaining to or within the purview of psychiatry. [EU]

Psychiatry: The medical science that deals with the origin, diagnosis, prevention, and treatment of mental disorders. [NIH]

Psychic: Pertaining to the psyche or to the mind; mental. [EU]

Puberty: The period during which the secondary sex characteristics begin to develop and the capability of sexual reproduction is attained. [EU]

Public Policy: A course or method of action selected, usually by a government, from among alternatives to guide and determine present and future decisions. [NIH]

Pulmonary: Relating to the lungs. [NIH]

Pulmonary Artery: The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. [NIH]

Pulmonary Edema: An accumulation of an excessive amount of watery fluid in the lungs, may be caused by acute exposure to dangerous concentrations of irritant gasses. [NIH]

Pulse: The rhythmical expansion and contraction of an artery produced by waves of pressure caused by the ejection of blood from the left ventricle of the heart as it contracts. [NIH]

Purines: A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include adenine and guanine, constituents of nucleic acids, as well as many alkaloids such as caffeine and theophylline. Uric acid is the metabolic end product of purine metabolism. [NIH]

Purpura: Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. [NIH]

Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (cytosine, thymine, and uracil) and form the basic structure of the barbiturates. [NIH]

Quality of Life: A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment. [NIH]

Race: A population within a species which exhibits general similarities within itself, but is both discontinuous and distinct from other populations of that species, though not sufficiently so as to achieve the status of a taxon. [NIH]

Radiation: Emission or propagation of electromagnetic energy (waves/rays), or the waves/rays themselves; a stream of electromagnetic particles (electrons, neutrons, protons, alpha particles) or a mixture of these. The most common source is the sun. [NIH]

Radiation therapy: The use of high-energy radiation from x-rays, gamma rays, neutrons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body in the area near cancer cells (internal radiation therapy, implant radiation, or brachytherapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that circulates throughout the body. Also called radiotherapy. [NIH]

Radioactive: Giving off radiation. [NIH]

Randomized: Describes an experiment or clinical trial in which animal or human subjects are assigned by chance to separate groups that compare different treatments. [NIH]

Receptor: A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell. [NIH]

Recombinant: A cell or an individual with a new combination of genes not found together in either parent; usually applied to linked genes. [EU]

Recombination: The formation of new combinations of genes as a result of segregation in crosses between genetically different parents; also the rearrangement of linked genes due to crossing-over. [NIH]

Rectum: The last 8 to 10 inches of the large intestine. [NIH]

Recurrence: The return of a sign, symptom, or disease after a remission. [NIH]

Refer: To send or direct for treatment, aid, information, de decision. [NIH]

Refractory: Not readily yielding to treatment. [EU]

Regimen: A treatment plan that specifies the dosage, the schedule, and the duration of treatment. [NIH]

Remission: A decrease in or disappearance of signs and symptoms of cancer. In partial remission, some, but not all, signs and symptoms of cancer have disappeared. In complete remission, all signs and symptoms of cancer have disappeared, although there still may be cancer in the body. [NIH]

Reproductive cells: Egg and sperm cells. Each mature reproductive cell carries a single set of 23 chromosomes. [NIH]

Reserpine: An alkaloid found in the roots of *Rauwolfia serpentina* and *R. vomitoria*. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [NIH]

Retina: The ten-layered nervous tissue membrane of the eye. It is continuous with the optic nerve and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the choroid and the inner surface with the vitreous body. The outer-most layer is pigmented, whereas the inner nine layers are transparent. [NIH]

Retinoblastoma: An eye cancer that most often occurs in children younger than 5 years. It occurs in hereditary and nonhereditary (sporadic) forms. [NIH]

Retrospective: Looking back at events that have already taken place. [NIH]

Retroviral vector: RNA from a virus that is used to insert genetic material into cells. [NIH]

Rheumatic Heart Disease: Disease of the heart resulting from rheumatic fever and characterized by inflammatory changes in the myocardium or scarring of the valves. [NIH]

Rheumatoid: Resembling rheumatism. [EU]

Rheumatoid arthritis: A form of arthritis, the cause of which is unknown, although infection, hypersensitivity, hormone imbalance and psychologic stress have been suggested as possible causes. [NIH]

Ribonucleic acid: RNA. One of the two nucleic acids found in all cells. The other is deoxyribonucleic acid (DNA). Ribonucleic acid transfers genetic information from DNA to proteins produced by the cell. [NIH]

Ribose: A pentose active in biological systems usually in its D-form. [NIH]

Ribosome: A granule of protein and RNA, synthesized in the nucleolus and found in the cytoplasm of cells. Ribosomes are the main sites of protein synthesis. Messenger RNA attaches to them and there receives molecules of transfer RNA bearing amino acids. [NIH]

Risk factor: A habit, trait, condition, or genetic alteration that increases a person's chance of developing a disease. [NIH]

Saponins: Sapogenin glycosides. A type of glycoside widely distributed in plants. Each consists of a sapogenin as the aglycon moiety, and a sugar. The sapogenin may be a steroid or a triterpene and the sugar may be glucose, galactose, a pentose, or a methylpentose. Sapogenins are poisonous towards the lower forms of life and are powerful hemolytics when injected into the blood stream able to dissolve red blood cells at even extreme dilutions. [NIH]

Scatter: The extent to which relative success and failure are divergently manifested in qualitatively different tests. [NIH]

Schizophrenia: A mental disorder characterized by a special type of disintegration of the personality. [NIH]

Sclera: The tough white outer coat of the eyeball, covering approximately the posterior five-sixths of its surface, and continuous anteriorly with the cornea and posteriorly with the external sheath of the optic nerve. [EU]

Sclerosis: A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve. [NIH]

Screening: Checking for disease when there are no symptoms. [NIH]

Secretion: 1. The process of elaborating a specific product as a result of the activity of a gland; this activity may range from separating a specific substance of the blood to the elaboration of a new chemical substance. 2. Any substance produced by secretion. [EU]

Segregation: The separation in meiotic cell division of homologous chromosome pairs and their contained allelomorphous gene pairs. [NIH]

Sepsis: The presence of bacteria in the bloodstream. [NIH]

Septic: Produced by or due to decomposition by microorganisms; putrefactive. [EU]

Sequencing: The determination of the order of nucleotides in a DNA or RNA chain. [NIH]

Serotonin: A biochemical messenger and regulator, synthesized from the essential amino acid L-tryptophan. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (receptors, serotonin) explain the broad physiological actions and distribution of this biochemical mediator. [NIH]

Serum: The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed. [NIH]

Shock: The general bodily disturbance following a severe injury; an emotional or moral upset occasioned by some disturbing or unexpected experience; disruption of the circulation, which can upset all body functions: sometimes referred to as circulatory shock. [NIH]

Side effect: A consequence other than the one(s) for which an agent or measure is used, as the adverse effects produced by a drug, especially on a tissue or organ system other than the one sought to be benefited by its administration. [EU]

Signs and Symptoms: Clinical manifestations that can be either objective when observed by a physician, or subjective when perceived by the patient. [NIH]

Skeleton: The framework that supports the soft tissues of vertebrate animals and protects many of their internal organs. The skeletons of vertebrates are made of bone and/or cartilage. [NIH]

Small intestine: The part of the digestive tract that is located between the stomach and the large intestine. [NIH]

Social Environment: The aggregate of social and cultural institutions, forms, patterns, and processes that influence the life of an individual or community. [NIH]

Social Work: The use of community resources, individual case work, or group work to promote the adaptive capacities of individuals in relation to their social and economic environments. It includes social service agencies. [NIH]

Soft tissue: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. [NIH]

Soma: The body as distinct from the mind; all the body tissue except the germ cells; all the axial body. [NIH]

Somatic: 1. Pertaining to or characteristic of the soma or body. 2. Pertaining to the body wall in contrast to the viscera. [EU]

Somatic cells: All the body cells except the reproductive (germ) cells. [NIH]

Somatic mutations: Alterations in DNA that occur after conception. Somatic mutations can occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed on to children. These alterations can (but do not always) cause cancer or other diseases. [NIH]

Specialist: In medicine, one who concentrates on 1 special branch of medical science. [NIH]

Species: A taxonomic category subordinate to a genus (or subgenus) and superior to a subspecies or variety, composed of individuals possessing common characters distinguishing them from other categories of individuals of the same taxonomic level. In taxonomic nomenclature, species are designated by the genus name followed by a Latin or Latinized adjective or noun. [EU]

Specificity: Degree of selectivity shown by an antibody with respect to the number and types of antigens with which the antibody combines, as well as with respect to the rates and the extents of these reactions. [NIH]

Sperm: The fecundating fluid of the male. [NIH]

Spinal cord: The main trunk or bundle of nerves running down the spine through holes in the spinal bone (the vertebrae) from the brain to the level of the lower back. [NIH]

Spleen: An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach. [NIH]

Sporadic: Neither endemic nor epidemic; occurring occasionally in a random or isolated manner. [EU]

Steroid: A group name for lipids that contain a hydrogenated cyclopentanoperhydrophenanthrene ring system. Some of the substances included in this group are progesterone, adrenocortical hormones, the gonadal hormones, cardiac aglycones, bile acids, sterols (such as cholesterol), toad poisons, saponins, and some of the carcinogenic hydrocarbons. [EU]

Steroid therapy: Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation. [NIH]

Stillbirth: The birth of a dead fetus or baby. [NIH]

Stimulant: 1. Producing stimulation; especially producing stimulation by causing tension on muscle fibre through the nervous tissue. 2. An agent or remedy that produces stimulation. [EU]

Stomach: An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the esophagus and the beginning of the duodenum. [NIH]

Stool: The waste matter discharged in a bowel movement; feces. [NIH]

Strand: DNA normally exists in the bacterial nucleus in a helix, in which two strands are coiled together. [NIH]

Stress: Forcibly exerted influence; pressure. Any condition or situation that causes strain or tension. Stress may be either physical or psychological, or both. [NIH]

Stroke: Sudden loss of function of part of the brain because of loss of blood flow. Stroke may be caused by a clot (thrombosis) or rupture (hemorrhage) of a blood vessel to the brain. [NIH]

Subacute: Somewhat acute; between acute and chronic. [EU]

Subclinical: Without clinical manifestations; said of the early stage(s) of an infection or other disease or abnormality before symptoms and signs become apparent or detectable by clinical examination or laboratory tests, or of a very mild form of an infection or other disease or abnormality. [EU]

Subspecies: A category intermediate in rank between species and variety, based on a smaller number of correlated characters than are used to differentiate species and generally conditioned by geographical and/or ecological occurrence. [NIH]

Substrate: A substance upon which an enzyme acts. [EU]

Superoxide: Derivative of molecular oxygen that can damage cells. [NIH]

Supportive care: Treatment given to prevent, control, or relieve complications and side effects and to improve the comfort and quality of life of people who have cancer. [NIH]

Sympathomimetic: 1. Mimicking the effects of impulses conveyed by adrenergic postganglionic fibres of the sympathetic nervous system. 2. An agent that produces effects similar to those of impulses conveyed by adrenergic postganglionic fibres of the sympathetic nervous system. Called also adrenergic. [EU]

Symptomatic: Having to do with symptoms, which are signs of a condition or disease. [NIH]

Synapse: The region where the processes of two neurons come into close contiguity, and the nervous impulse passes from one to the other; the fibers of the two are intermeshed, but, according to the general view, there is no direct contiguity. [NIH]

Synapsis: The pairing between homologous chromosomes of maternal and paternal origin during the prophase of meiosis, leading to the formation of gametes. [NIH]

Synaptic: Pertaining to or affecting a synapse (= site of functional apposition between neurons, at which an impulse is transmitted from one neuron to another by electrical or chemical means); pertaining to synapsis (= pairing off in point-for-point association of homologous chromosomes from the male and female pronuclei during the early prophase of meiosis). [EU]

Synovial: Of pertaining to, or secreting synovia. [EU]

Synovial Fluid: The clear, viscous fluid secreted by the synovial membrane. It contains mucin, albumin, fat, and mineral salts and serves to lubricate joints. [NIH]

Synovial Membrane: The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes synovial fluid. [NIH]

Systemic: Affecting the entire body. [NIH]

Teratogenic: Tending to produce anomalies of formation, or teratism (= anomaly of formation or development : condition of a monster). [EU]

Terminator: A DNA sequence sited at the end of a transcriptional unit that signals the end

of transcription. [NIH]

Thalidomide: A pharmaceutical agent originally introduced as a non-barbiturate hypnotic, but withdrawn from the market because of its known teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of tumor necrosis factor alpha from monocytes, and modulates other cytokine action. [NIH]

Thermal: Pertaining to or characterized by heat. [EU]

Thigh: A leg; in anatomy, any elongated process or part of a structure more or less comparable to a leg. [NIH]

Thrombin: An enzyme formed from prothrombin that converts fibrinogen to fibrin. (Dorland, 27th ed) EC 3.4.21.5. [NIH]

Thrombomodulin: A cell surface glycoprotein of endothelial cells that binds thrombin and serves as a cofactor in the activation of protein C and its regulation of blood coagulation. [NIH]

Thrombosis: The formation or presence of a blood clot inside a blood vessel. [NIH]

Thyroid: A gland located near the windpipe (trachea) that produces thyroid hormone, which helps regulate growth and metabolism. [NIH]

Thyroid Gland: A highly vascular endocrine gland consisting of two lobes, one on either side of the trachea, joined by a narrow isthmus; it produces the thyroid hormones which are concerned in regulating the metabolic rate of the body. [NIH]

Thyroid Hormones: Hormones secreted by the thyroid gland. [NIH]

Thyroxine: An amino acid of the thyroid gland which exerts a stimulating effect on thyroid metabolism. [NIH]

Tissue: A group or layer of cells that are alike in type and work together to perform a specific function. [NIH]

Tolerance: 1. The ability to endure unusually large doses of a drug or toxin. 2. Acquired drug tolerance; a decreasing response to repeated constant doses of a drug or the need for increasing doses to maintain a constant response. [EU]

Topical: On the surface of the body. [NIH]

Toxic: Having to do with poison or something harmful to the body. Toxic substances usually cause unwanted side effects. [NIH]

Toxicity: The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. [EU]

Toxicology: The science concerned with the detection, chemical composition, and pharmacologic action of toxic substances or poisons and the treatment and prevention of toxic manifestations. [NIH]

Toxin: A poison; frequently used to refer specifically to a protein produced by some higher plants, certain animals, and pathogenic bacteria, which is highly toxic for other living organisms. Such substances are differentiated from the simple chemical poisons and the vegetable alkaloids by their high molecular weight and antigenicity. [EU]

Trachea: The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. [NIH]

Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. [NIH]

Transfection: The uptake of naked or purified DNA into cells, usually eukaryotic. It is

analogous to bacterial transformation. [NIH]

Translation: The process whereby the genetic information present in the linear sequence of ribonucleotides in mRNA is converted into a corresponding sequence of amino acids in a protein. It occurs on the ribosome and is unidirectional. [NIH]

Transmitter: A chemical substance which effects the passage of nerve impulses from one cell to the other at the synapse. [NIH]

Transplantation: Transference of a tissue or organ, alive or dead, within an individual, between individuals of the same species, or between individuals of different species. [NIH]

Trauma: Any injury, wound, or shock, must frequently physical or structural shock, producing a disturbance. [NIH]

Trinucleotide Repeat Expansion: DNA region comprised of a variable number of repetitive, contiguous trinucleotide sequences. The presence of these regions is associated with diseases such as Fragile X Syndrome and myotonic dystrophy. Many chromosome fragile sites (chromosome fragility) contain expanded trinucleotide repeats. [NIH]

Trinucleotide Repeats: Microsatellite repeats consisting of three nucleotides dispersed in the euchromatic arms of chromosomes. [NIH]

Trisomy: The possession of a third chromosome of any one type in an otherwise diploid cell. [NIH]

Tuberculosis: Any of the infectious diseases of man and other animals caused by species of Mycobacterium. [NIH]

Tubulin: A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from sperm flagella, cilia, and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to colchicine, vincristine, and vinblastine. [NIH]

Tumor Necrosis Factor: Serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes which has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. It mimics the action of endotoxin but differs from it. It has a molecular weight of less than 70,000 kDa. [NIH]

Tyrosine: A non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin. [NIH]

Ubiquitin: A highly conserved 76 amino acid-protein found in all eukaryotic cells. [NIH]

Ulcerative colitis: Chronic inflammation of the colon that produces ulcers in its lining. This condition is marked by abdominal pain, cramps, and loose discharges of pus, blood, and mucus from the bowel. [NIH]

Ultraviolet radiation: Invisible rays that are part of the energy that comes from the sun. UV radiation can damage the skin and cause melanoma and other types of skin cancer. UV radiation that reaches the earth's surface is made up of two types of rays, called UVA and UVB rays. UVB rays are more likely than UVA rays to cause sunburn, but UVA rays pass deeper into the skin. Scientists have long thought that UVB radiation can cause melanoma and other types of skin cancer. They now think that UVA radiation also may add to skin damage that can lead to skin cancer and cause premature aging. For this reason, skin specialists recommend that people use sunscreens that reflect, absorb, or scatter both kinds of UV radiation. [NIH]

Uraemia: 1. An excess in the blood of urea, creatinine, and other nitrogenous end products of protein and amino acids metabolism; more correctly referred to as azotemia. 2. In current usage the entire constellation of signs and symptoms of chronic renal failure, including nausea, vomiting, anorexia, a metallic taste in the mouth, a uraemic odour of the breath,

pruritus, uraemic frost on the skin, neuromuscular disorders, pain and twitching in the muscles, hypertension, edema, mental confusion, and acid-base and electrolyte imbalances. [EU]

Uremia: The illness associated with the buildup of urea in the blood because the kidneys are not working effectively. Symptoms include nausea, vomiting, loss of appetite, weakness, and mental confusion. [NIH]

Urinary: Having to do with urine or the organs of the body that produce and get rid of urine. [NIH]

Urine: Fluid containing water and waste products. Urine is made by the kidneys, stored in the bladder, and leaves the body through the urethra. [NIH]

Urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. [NIH]

Uterus: The small, hollow, pear-shaped organ in a woman's pelvis. This is the organ in which a fetus develops. Also called the womb. [NIH]

Uvea: The middle coat of the eyeball, consisting of the choroid in the back of the eye and the ciliary body and iris in the front of the eye. [NIH]

Uveitis: An inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (the sclera and cornea, and the retina). [EU]

Vaccine: A substance or group of substances meant to cause the immune system to respond to a tumor or to microorganisms, such as bacteria or viruses. [NIH]

Vacuoles: Any spaces or cavities within a cell. They may function in digestion, storage, secretion, or excretion. [NIH]

Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway. [NIH]

Valves: Flap-like structures that control the direction of blood flow through the heart. [NIH]

Vascular: Pertaining to blood vessels or indicative of a copious blood supply. [EU]

Vasculitis: Inflammation of a blood vessel. [NIH]

Vasodilator: An agent that widens blood vessels. [NIH]

Vector: Plasmid or other self-replicating DNA molecule that transfers DNA between cells in nature or in recombinant DNA technology. [NIH]

Vein: Vessel-carrying blood from various parts of the body to the heart. [NIH]

Venous: Of or pertaining to the veins. [EU]

Venous blood: Blood that has given up its oxygen to the tissues and carries carbon dioxide back for gas exchange. [NIH]

Ventricle: One of the two pumping chambers of the heart. The right ventricle receives oxygen-poor blood from the right atrium and pumps it to the lungs through the pulmonary artery. The left ventricle receives oxygen-rich blood from the left atrium and pumps it to the body through the aorta. [NIH]

Venules: The minute vessels that collect blood from the capillary plexuses and join together to form veins. [NIH]

Veterinary Medicine: The medical science concerned with the prevention, diagnosis, and treatment of diseases in animals. [NIH]

Viral: Pertaining to, caused by, or of the nature of virus. [EU]

Virulence: The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. [NIH]

Virus: Submicroscopic organism that causes infectious disease. In cancer therapy, some viruses may be made into vaccines that help the body build an immune response to, and kill, tumor cells. [NIH]

Viscera: Any of the large interior organs in any one of the three great cavities of the body, especially in the abdomen. [NIH]

Vitro: Descriptive of an event or enzyme reaction under experimental investigation occurring outside a living organism. Parts of an organism or microorganism are used together with artificial substrates and/or conditions. [NIH]

White blood cell: A type of cell in the immune system that helps the body fight infection and disease. White blood cells include lymphocytes, granulocytes, macrophages, and others. [NIH]

Windpipe: A rigid tube, 10 cm long, extending from the cricoid cartilage to the upper border of the fifth thoracic vertebra. [NIH]

Womb: A hollow, thick-walled, muscular organ in which the impregnated ovum is developed into a child. [NIH]

X-ray: High-energy radiation used in low doses to diagnose diseases and in high doses to treat cancer. [NIH]

Yeasts: A general term for single-celled rounded fungi that reproduce by budding. Brewers' and bakers' yeasts are *Saccharomyces cerevisiae*; therapeutic dried yeast is dried yeast. [NIH]

Zygote: The fertilized ovum. [NIH]

Zymogen: Inactive form of an enzyme which can then be converted to the active form, usually by excision of a polypeptide, e. g. trypsinogen is the zymogen of trypsin. [NIH]

INDEX

3

3-dimensional, 71, 102, 116

A

Abdomen, 3, 4, 116, 121, 136, 137, 138, 143, 145, 149, 150, 154

Abdominal, 21, 54, 57, 113, 116, 142, 143, 152

Abdominal Pain, 54, 57, 116, 143, 152

Acetylcholine, 116, 141

Acetylgalactosamine, 116, 132

Acetylglucosamine, 116, 132

Acne, 116, 136

Acne Vulgaris, 116, 136

Actin, 8, 72, 116

Adaptability, 116, 123

Adenine, 65, 116, 146

Adenosine, 66, 116, 143

Adenosine Triphosphate, 66, 116, 143

Adenovirus, 98, 116

Adipocytes, 116, 137

Adrenal Glands, 116, 118

Adrenergic, 117, 119, 128, 129, 138, 150

Adverse Effect, 39, 117, 136, 147, 148

Aerobic, 117, 139

Afferent, 117, 137

Agonist, 117, 128, 138

Albumin, 56, 117, 144, 150

Algorithms, 117, 121

Alkaloid, 117, 124, 147

Alleles, 10, 53, 55, 67, 84, 117, 133

Allograft, 22, 117, 140

Alpha-1, 80, 84, 117

Alternative medicine, 117

Amino Acid Sequence, 117, 118, 129

Amino Acids, 7, 9, 67, 71, 77, 117, 124, 143, 144, 145, 147, 152

Amnion, 117

Amniotic Fluid, 93, 95, 117

Amplification, 16, 21, 118

Amyloid, 8, 9, 10, 11, 12, 16, 25, 37, 53, 60, 118

Amyloidosis, 4, 7, 8, 9, 10, 11, 12, 14, 16, 17, 20, 23, 25, 27, 32, 33, 34, 36, 37, 39, 41, 42, 43, 45, 47, 48, 49, 50, 51, 52, 53, 54, 57, 61, 118

Anaesthesia, 43, 54, 57, 118, 135

Anaphylatoxins, 118, 125

Anatomical, 118, 123, 135, 148

Anemia, 79, 80, 83, 84, 89, 118, 133

Aneuploidy, 78, 118

Angioid Streaks, 118, 146

Anions, 117, 118, 136

Annealing, 118, 144

Antibacterial, 9, 118

Antibodies, 22, 72, 118, 120, 134, 143

Antibody, 72, 118, 119, 124, 134, 135, 146, 149

Anticoagulant, 118, 145

Antigen, 35, 118, 119, 124, 134, 135

Antigen-Antibody Complex, 119, 124

Antihypertensive, 119, 147

Anti-inflammatory, 119, 120, 126, 132

Anti-Inflammatory Agents, 119, 120, 126

Antipsychotic, 119, 147

Anuria, 119, 136

Anus, 119, 124

Apoptosis, 37, 66, 75, 119

Aqueous, 119, 120, 127

Arginine, 118, 119, 133, 141

Arterial, 54, 119, 125, 132, 134, 145, 146

Arteries, 119, 121, 126, 140, 144

Arterioles, 119, 121, 122

Artery, 109, 119, 126, 146

Articular, 42, 119, 142

Asbestos, 120, 138

Ascites, 17, 19, 120

Aspirin, 39, 120

Assay, 11, 46, 120

Asymptomatic, 120, 142

Atrophy, 120, 140

Atypical, 88, 120

Autoantibodies, 22, 120

Autoantigens, 120

Autodigestion, 120, 142

Autoimmune disease, 120, 139

B

Bacteria, 64, 72, 76, 118, 119, 120, 129, 130, 138, 139, 148, 151, 153

Barbiturate, 120, 151

Base, 7, 9, 10, 65, 66, 69, 71, 75, 76, 77, 100, 116, 120, 127, 130, 137, 144, 153

Base Sequence, 76, 120, 130

Benign, 17, 120, 122, 138

Beta-pleated, 118, 120

Bewilderment, 120, 125

Bile, 120, 121, 131, 136, 137, 149

Biliary, 120, 142

Biliary Tract, 120, 142

- Bilirubin, 117, 121, 134
 Biochemical, 12, 44, 51, 80, 117, 121, 137, 142, 148
 Biopsy, 121
 Biopterin, 121, 140
 Biosynthesis, 121, 140
 Biotechnology, 5, 14, 62, 71, 98, 100, 105, 121
 Bladder, 121, 139, 153
 Blastocyst, 121, 125
 Blood Cell Count, 121, 133
 Blood Glucose, 121, 133
 Blood pressure, 83, 119, 121, 122, 132, 134, 139
 Blood vessel, 87, 121, 122, 123, 126, 128, 149, 150, 151, 153
 Body Fluids, 121, 128, 140
 Bone Marrow, 23, 59, 99, 121, 131, 137
 Bone marrow biopsy, 23, 121
 Bone Marrow Transplantation, 59, 121
 Bone scan, 27, 121
 Bowel, 53, 121, 136, 143, 150, 152
 Bradykinin, 121, 141, 144
 Buccal, 93, 95, 122, 137
C
 Calcium, 120, 122, 124, 128
 Capillary, 45, 122, 153
 Carbohydrate, 122, 126, 132, 144
 Carcinogenic, 122, 135, 145, 149
 Carcinoid, 53, 122
 Cardiac, 29, 122, 126, 129, 140, 149
 Cardiovascular, 19, 102, 122, 146, 148
 Cardiovascular disease, 102, 122
 Cardiovascular System, 122, 146
 Carpal Tunnel Syndrome, 18, 122
 Case report, 38, 60, 122
 Catecholamine, 122, 127
 Cause of Death, 122, 127
 Cell Cycle, 74, 75, 122
 Cell Death, 75, 119, 123, 140
 Cell Division, 67, 74, 75, 87, 88, 120, 122, 123, 138, 139, 145, 148
 Cell Respiration, 123, 139
 Central Nervous System, 116, 123, 131, 132, 139, 148
 Centromere, 67, 70, 123
 Cerebrovascular, 122, 123
 Chemotactic Factors, 123, 125
 Chemotaxis, 39, 123
 Chin, 123, 138
 Cholesterol, 66, 120, 123, 126, 149
 Chromatin, 119, 123, 129, 137
 Chromosomal, 19, 75, 77, 78, 88, 89, 90, 92, 118, 123, 133, 139
 Chromosome Fragility, 123, 152
 Chronic, 12, 19, 37, 39, 116, 123, 129, 135, 136, 137, 142, 150, 152
 Chronic renal, 39, 123, 152
 Cirrhosis, 123, 133
 CIS, 13, 123, 131
 Clinical Medicine, 60, 101, 123, 144
 Clinical trial, 11, 60, 98, 99, 102, 105, 124, 142, 145, 146
 Cloning, 121, 124, 137
 Codon, 72, 124
 Cofactor, 124, 145, 151
 Colchicine, 18, 19, 20, 24, 25, 28, 30, 33, 38, 39, 41, 46, 48, 51, 52, 54, 55, 59, 60, 124, 152
 Colitis, 124
 Collagen, 124, 130, 144
 Colloidal, 117, 124
 Colon, 81, 124, 152
 Colonoscopy, 83, 124
 Complement, 19, 118, 124, 125, 136, 144
 Complementary medicine, 59, 125
 Computational Biology, 105, 125
 Concentric, 125, 141
 Conception, 74, 125, 130, 149
 Confusion, 81, 125, 127, 153
 Congestion, 119, 125, 129
 Connective Tissue, 121, 124, 125, 130, 131, 132
 Consciousness, 125, 127
 Constipation, 119, 125, 143
 Constriction, 67, 70, 125
 Consultation, 89, 90, 93, 94, 125
 Contraindications, ii, 125
 Coordination, 125, 139
 Cor, 125, 132
 Cornea, 20, 126, 148, 153
 Coronary, 109, 122, 126, 140
 Coronary heart disease, 122, 126
 Coronary Thrombosis, 126, 140
 Corticosteroid, 126, 149
 Cortisol, 117, 126
 Cranial, 21, 126, 140, 143
 Cutaneous, 18, 126, 134, 137
 Cyclic, 126, 132, 141
 Cytochrome, 126, 142
 Cytokine, 26, 127, 136, 151
 Cytoplasm, 64, 65, 66, 72, 119, 127, 129, 132, 137, 141, 147
 Cytosine, 65, 127, 146

Cytoskeleton, 6, 7, 127, 139

D

De novo, 75, 127

Death Certificates, 83, 127

Defense Mechanisms, 8, 127

Degenerative, 127, 133, 142

Deletion, 77, 119, 127

Dementia, 78, 119, 127

Denaturation, 127, 144

Dendrites, 127, 140

Deoxyribonucleic, 65, 127, 147

Deoxyribonucleic acid, 65, 127, 147

Deoxyribonucleotides, 127

Diabetes Mellitus, 127, 133

Digestion, 120, 121, 127, 136, 137, 150, 153

Diploid, 118, 127, 139, 152

Direct, iii, 7, 13, 24, 93, 94, 95, 123, 127, 128, 147, 150

Discrimination, 95, 96, 101, 127

Disorientation, 125, 127

Dopamine, 24, 48, 119, 127, 141

Drug Tolerance, 128, 151

Duodenum, 120, 128, 150

Dyes, 118, 128

Dystrophy, 51, 128

E

Edema, 128, 140, 153

Effector, 116, 124, 128

Efficacy, 24, 25, 128

Elastic, 128, 145

Electrolytes, 120, 128, 136

Electrons, 120, 128, 136, 146

Embryo, 74, 75, 76, 84, 117, 121, 128, 135

Endogenous, 120, 127, 128, 129, 151

Endorphins, 128, 141

Endothelium, 128, 141

Endothelium-derived, 128, 141

Endotoxin, 36, 129, 152

End-stage renal, 26, 123, 129

Energy balance, 129, 137

Enkephalins, 129, 141

Environmental Health, 104, 105, 129

Enzymatic, 122, 124, 129, 144

Enzyme, 12, 39, 66, 72, 128, 129, 131, 132, 137, 144, 145, 150, 151, 154

Eosinophils, 6, 129, 132

Epidermis, 129, 146

Epinephrine, 117, 128, 129, 141, 152

Epithelial, 11, 26, 129, 133

Epithelial Cells, 11, 129, 133

Erythema, 26, 114, 129, 153

Erythrocyte Indices, 121, 129

Erythrocytes, 118, 121, 129

Esophagus, 129, 150

Ethnic Groups, 34, 57, 89, 92, 129

Eukaryotic Cells, 129, 142, 152

Excitation, 129, 141

Excrete, 119, 129, 136

Exon, 21, 129

Extracellular, 12, 118, 125, 130

Extracellular Matrix, 125, 130

Extrapyramidal, 119, 128, 130

Eye Color, 76, 130

Eye Infections, 116, 130

F

Family Planning, 105, 130

Fat, 116, 121, 125, 126, 130, 132, 137, 139, 149, 150

Fathers, 84, 130

Fatty acids, 117, 130

Febrile, 30, 49, 130

Femoral, 17, 54, 130

Femur, 130

Fetus, 92, 93, 95, 99, 130, 145, 149, 153

Fibril, 12, 130

Fibrin, 130, 143, 151

Fibrinogen, 114, 130, 144, 151

Fibroblasts, 40, 130, 136

Fibrosis, 24, 76, 79, 83, 84, 130, 148

Fold, 42, 130

Forearm, 121, 130, 138

Frameshift, 77, 130

Frameshift Mutation, 77, 130

G

Gallbladder, 116, 120, 131

Ganglia, 116, 119, 131, 140, 143

Gas, 131, 134, 141, 153

Gastrin, 131, 134

Gastrointestinal, 30, 120, 122, 129, 131, 148

Gene Expression, 72, 73, 131

Gene Products, rev, 131

Gene Therapy, 97, 98, 99, 100, 116, 131

Genes, env, 83, 131

Genetic testing, 6, 8, 19, 32, 44, 86, 90, 91, 92, 93, 94, 95, 96, 101, 131, 144

Genomics, 102, 131

Genotype, 8, 10, 11, 30, 32, 33, 43, 131, 143

Germ Cells, 75, 99, 131, 138, 149

Germline mutation, 75, 131, 133

Gland, 126, 131, 142, 148, 151

Glomerular, 33, 131, 132, 136

Glomeruli, 132

Glomerulonephritis, 45, 132

Glucocorticoids, 11, 126, 132

- Gluconeogenesis, 132
 Glucose, 121, 127, 132, 133, 148
 Glutamic Acid, 132, 141
 Glycine, 132, 141
 Glycogen, 132
 Glycoprotein, 24, 130, 132, 151, 152
 Glycosaminoglycans, 21, 56, 132
 Gonadal, 132, 149
 Gout, 124, 132
 Governing Board, 132, 144
 Graft, 22, 132
 Graft Survival, 22, 132
 Granule, 132, 147
 Granulocytes, 132, 137, 154
 Guanine, 65, 132, 146
 Guanylate Cyclase, 132, 141
- H**
- Hair Color, 76, 132
 Heart attack, 122, 133
 Hematocrit, 121, 129, 133
 Hemochromatosis, 92, 133
 Hemodialysis, 133, 136, 137
 Hemoglobin, 66, 118, 121, 129, 133
 Hemoglobinopathies, 131, 133
 Hemophilia, 84, 133
 Hemorrhage, 133, 146, 150
 Hepatic, 11, 117, 133
 Hepatitis, 54, 133
 Hepatocytes, 133
 Hereditary, 41, 55, 64, 65, 75, 84, 90, 131, 132, 133, 140, 147
 Hereditary mutation, 75, 131, 133
 Heredity, 67, 116, 131, 133
 Heterogeneity, 31, 133
 Heterozygote, 38, 133
 Histones, 67, 123, 133
 Homologous, 117, 131, 133, 134, 148, 150
 Hormone, 72, 126, 129, 131, 134, 137, 145, 147, 151
 Hybrid, 134
 Hybridization, 32, 52, 134
 Hybridomas, 134, 136
 Hydrogen, 120, 122, 127, 134, 139, 141
 Hydrolysis, 134, 144, 145
 Hyperbilirubinemia, 38, 134, 136
 Hyperlipidemia, 14, 134
 Hypersensitivity, 134, 147
 Hypertension, 122, 126, 134, 153
 Hypesthesia, 134, 140
 Hypnotic, 120, 134, 151
 Hypotension, 119, 134, 138
 Hypothalamic, 38, 134
 Hypothalamus, 134
- I**
- Idiopathic, 36, 53, 134
 Ileal, 15, 134
 Ileitis, 55, 134
 Ileum, 134
 Immune response, 119, 120, 126, 134, 154
 Immune system, 134, 138, 139, 140, 153, 154
 Immunity, 20, 26, 49, 134, 136
 Immunologic, 56, 123, 135
 Impairment, 120, 130, 135, 138
 Implantation, 125, 135
 In situ, 13, 135
 In vitro, 22, 131, 135, 144
 In vivo, 131, 135
 Induction, 36, 119, 135
 Infancy, 102, 135
 Infarction, 135, 144
 Infection, 6, 8, 20, 33, 54, 123, 130, 135, 137, 141, 143, 147, 150, 153, 154
 Infiltration, 132, 135
 Informed Consent, 93, 96, 101, 135
 Initiation, 12, 135, 151
 Initiator, 135, 136
 Inotropic, 128, 135
 Insulator, 135, 139
 Interferon, 37, 135, 136
 Interleukin-1, 48, 136
 Interleukin-10, 48, 136
 Interleukin-12, 48, 136
 Interleukin-2, 136
 Interleukin-6, 37, 40, 136
 Interstitial, 23, 24, 136
 Intestine, 121, 136, 147, 149
 Intoxication, 60, 136
 Intracellular, 12, 135, 136, 141
 Intravascular, 45, 136
 Ions, 120, 128, 134, 136
 Iris, 126, 130, 136, 153
 Isotretinoin, 30, 136
- J**
- Jaundice, 134, 136
- K**
- Karyotype, 69, 136
 Kidney Failure, 4, 7, 9, 78, 109, 129, 136, 137
 Kidney Failure, Acute, 136
 Kidney Failure, Chronic, 136, 137
- L**
- Labile, 124, 137
 Laceration, 54, 137

- Latent, 11, 137, 145
 Latent period, 11, 137
 Leptin, 53, 137
 Lesion, 18, 137
 Leucocyte, 117, 137
 Leukemia, 131, 137
 Ligase, 12, 137
 Linkage, 12, 31, 40, 137
 Lipid, 137, 139
 Lipopolysaccharide, 22, 40, 137
 Liver, 8, 20, 40, 73, 116, 117, 118, 120, 123, 131, 132, 133, 137
 Localization, 12, 33, 137
 Localized, 118, 135, 137, 153
 Lupus, 18, 36, 109, 137
 Lymphatic, 128, 135, 137, 149
 Lymphocytes, 119, 132, 134, 136, 137, 138, 140, 149, 154
 Lymphoid, 118, 137, 138
 Lysine, 133, 138
M
 Macrophage, 13, 75, 136, 138
 Malignant, 28, 138, 140
 Malignant mesothelioma, 28, 138
 Malnutrition, 117, 120, 138
 Mammography, 83, 138
 Median Nerve, 122, 138
 Mediate, 128, 138
 Medical Records, 83, 96, 138
 MEDLINE, 105, 138
 Meiosis, 74, 138, 150
 Melanoma, 138, 152
 Membrane, 65, 117, 125, 129, 130, 138, 139, 141, 142, 147, 150
 Memory, 127, 138
 Mental, iv, 11, 88, 90, 92, 104, 106, 123, 125, 127, 138, 146, 148, 153
 Mental Retardation, 88, 90, 92, 138
 Mesothelioma, 17, 138
 Metaraminol, 43, 57, 138
 Microbe, 138, 151
 Microbiology, 120, 138
 Microorganism, 124, 139, 154
 Microscopy, 12, 139
 Microtubules, 8, 139
 Migration, 7, 9, 35, 139
 Miscarriage, 95, 139
 Mitochondria, 65, 66, 78, 84, 85, 139, 142
 Mitochondrial Swelling, 139, 140
 Mitosis, 74, 119, 139
 Modification, 139, 146
 Molecule, 45, 65, 66, 67, 72, 119, 120, 124, 128, 129, 133, 134, 139, 141, 144, 147, 153
 Monitor, 139, 141
 Monocyte, 13, 47, 139
 Mononuclear, 59, 139, 152
 Monosomy, 78, 118, 139
 Morphological, 128, 139
 Mosaicism, 75, 139
 Mucosa, 137, 139
 Mucus, 139, 152
 Multiple sclerosis, 20, 60, 139
 Mutagens, 130, 140
 Myalgia, 30, 49, 140
 Myelin, 139, 140
 Myocardial infarction, 28, 126, 140
 Myocardium, 140, 147
 Myopathy, 34, 140
 Myotonic Dystrophy, 87, 140, 152
N
 Natural killer cells, 136, 140
 NCI, 1, 103, 123, 140, 142
 Necrosis, 17, 61, 119, 135, 140
 Neopterin, 34, 56, 59, 140
 Nephropathy, 25, 36, 140
 Nephrosis, 140
 Nephrotic, 27, 51, 52, 140
 Nephrotic Syndrome, 27, 51, 52, 140
 Nervous System, 87, 117, 123, 140, 143, 150
 Neuritis, 46, 140
 Neurodegenerative Diseases, 12, 140
 Neuronal, 11, 140
 Neurons, 12, 127, 131, 140, 150
 Neuropathy, 84, 140
 Neurotransmitter, 12, 116, 122, 127, 132, 141
 Neutrophil, 26, 45, 47, 141
 Nitric Oxide, 60, 61, 141
 Norepinephrine, 117, 128, 138, 141, 147
 Nuclear, 65, 128, 129, 131, 140, 141
 Nuclear Envelope, 65, 141
 Nuclear Pore, 141
 Nuclei, 128, 131, 133, 139, 141
 Nucleic acid, 120, 127, 134, 140, 141, 146, 147
 Nucleic Acid Hybridization, 134, 141
 Nucleus, 12, 65, 66, 67, 72, 78, 97, 100, 119, 123, 126, 127, 129, 137, 138, 139, 141, 145, 150
 Nurse Practitioners, 93, 141
O
 Oliguria, 136, 141

- Organelles, 64, 65, 127, 141, 144
 Osmotic, 117, 139, 142
 Osteoarthritis, 23, 142
 Ovaries, 92, 142
 Oxidative Phosphorylation, 66, 142
- P**
- Paediatric, 22, 142
 Pancreas, 116, 133, 142
 Pancreatic, 142
 Pancreatitis, 14, 142
 Paresis, 140, 142
 Paresthesias, 140, 142
 Paternity, 92, 142
 Pathologic, 119, 121, 126, 134, 142
 Pathologic Processes, 119, 142
 PDQ, 103, 142
 Pelvis, 116, 142, 143, 153
 Penicillin, 143, 153
 Peptide, 12, 137, 143, 144, 145
 Perforation, 15, 143
 Pericarditis, 36, 50, 143
 Pericardium, 143
 Peripheral blood, 59, 143
 Peripheral Nervous System, 129, 140, 141, 143
 Peritoneal, 28, 47, 120, 143
 Peritoneal Cavity, 120, 143
 Peritoneum, 143
 Peritonitis, 19, 25, 143
 Pharmacologic, 55, 143, 151
 Phenotype, 10, 30, 32, 33, 42, 43, 143
 Phosphorus, 122, 143
 Phosphorylation, 66, 143
 Physical Examination, 90, 143
 Physiologic, 117, 121, 143, 147
 Pilot study, 56, 143
 Plasma, 30, 48, 60, 65, 114, 117, 118, 130, 133, 136, 143, 144
 Plasma cells, 118, 143
 Plasma protein, 117, 144
 Plastids, 142, 144
 Platelet Aggregation, 118, 141, 144
 Platelets, 141, 144, 148
 Pneumonia, 125, 144
 Point Mutation, 21, 144
 Polyarteritis Nodosa, 54, 144
 Polymerase, 21, 144
 Polymerase Chain Reaction, 21, 144
 Polymorphism, 13, 21, 37, 38, 39, 61, 94, 144
 Polypeptide, 12, 117, 124, 130, 134, 144, 154
 Polysaccharide, 119, 144
 Potentiates, 136, 144
 Practice Guidelines, 106, 144
 Precursor, 128, 129, 140, 141, 144, 152, 153
 Predisposition, 31, 145
 Prenatal, 92, 95, 128, 145
 Presynaptic, 141, 145
 Prevalence, 22, 48, 49, 80, 145
 Progesterone, 145, 149
 Progression, 13, 20, 145
 Progressive, 54, 78, 123, 127, 128, 137, 140, 142, 145
 Projection, 127, 141, 145
 Promoter, 61, 145
 Prone, 78, 87, 145
 Prophase, 145, 150
 Prophylaxis, 40, 41, 145
 Protease, 13, 145
 Proteinuria, 47, 140, 145
 Proteolytic, 117, 124, 130, 145
 Protocol, 98, 145
 Pseudoxanthoma, 21, 25, 145
 Pseudoxanthoma Elasticum, 21, 25, 145
 Psychiatric, 12, 146
 Psychiatry, 21, 40, 146
 Psychic, 138, 146
 Puberty, 145, 146
 Public Policy, 105, 146
 Pulmonary, 23, 49, 121, 126, 136, 146, 153
 Pulmonary Artery, 121, 146, 153
 Pulmonary Edema, 136, 146
 Pulse, 54, 139, 146
 Purines, 120, 146
 Purpura, 34, 49, 146
 Pyrimidines, 120, 146
- Q**
- Quality of Life, 41, 146, 150
- R**
- Race, 136, 139, 146
 Radiation, 116, 146, 152, 154
 Radiation therapy, 116, 146
 Radioactive, 121, 134, 135, 141, 146
 Randomized, 60, 128, 146
 Receptor, 40, 81, 119, 128, 147, 148
 Recombinant, 12, 98, 147, 153
 Recombination, 131, 147
 Rectum, 119, 124, 131, 147
 Recurrence, 39, 147
 Refer, 1, 70, 74, 76, 81, 100, 122, 124, 128, 137, 147, 151
 Refractory, 16, 21, 147
 Regimen, 128, 147

- Remission, 51, 147
- Reproductive cells, 78, 88, 89, 131, 133, 147
- Reserpine, 60, 147
- Retina, 118, 146, 147, 153
- Retinoblastoma, 80, 147
- Retrospective, 42, 147
- Retroviral vector, 131, 147
- Rheumatic Heart Disease, 29, 147
- Rheumatoid, 11, 12, 21, 23, 147
- Rheumatoid arthritis, 11, 12, 21, 23, 147
- Ribonucleic acid, 72, 147
- Ribose, 116, 147
- Ribosome, 72, 147, 152
- Risk factor, 10, 31, 148
- S**
- Saponins, 148, 149
- Scatter, 148, 152
- Schizophrenia, 85, 148
- Sclera, 148, 153
- Sclerosis, 12, 81, 139, 148
- Screening, 31, 83, 92, 93, 95, 109, 124, 142, 148
- Secretion, 116, 126, 132, 139, 148, 153
- Segregation, 30, 38, 147, 148
- Sepsis, 13, 148
- Septic, 13, 148
- Sequencing, 52, 100, 144, 148
- Serotonin, 119, 141, 147, 148
- Serum, 8, 9, 10, 11, 12, 37, 42, 53, 60, 117, 118, 124, 137, 143, 148, 152
- Shock, 13, 148, 152
- Side effect, 99, 102, 117, 119, 148, 150, 151
- Signs and Symptoms, 4, 86, 87, 92, 144, 147, 148, 152
- Skeleton, 116, 130, 148
- Small intestine, 128, 134, 136, 149
- Social Environment, 146, 149
- Social Work, 89, 149
- Soft tissue, 121, 148, 149
- Soma, 149
- Somatic, 75, 78, 89, 138, 139, 143, 149
- Somatic cells, 75, 78, 89, 138, 139, 149
- Somatic mutations, 78, 149
- Specialist, 93, 110, 149
- Species, 102, 124, 129, 134, 136, 138, 139, 146, 149, 150, 152, 154
- Specificity, 12, 149
- Sperm, 74, 75, 78, 87, 88, 89, 92, 99, 123, 131, 133, 147, 149, 152
- Spinal cord, 54, 123, 138, 140, 143, 149
- Spleen, 118, 137, 149
- Sporadic, 140, 147, 149
- Steroid, 15, 126, 148, 149
- Steroid therapy, 15, 149
- Stillbirth, 90, 149
- Stimulant, 149, 153
- Stomach, 58, 116, 120, 129, 131, 134, 143, 149, 150
- Stool, 124, 150
- Strand, 65, 144, 150
- Stress, 47, 122, 126, 145, 147, 150, 153
- Stroke, 83, 104, 122, 150
- Subacute, 135, 150
- Subclinical, 19, 48, 52, 135, 150
- Subspecies, 149, 150
- Substrate, 12, 150
- Superoxide, 47, 150
- Supportive care, 142, 150
- Sympathomimetic, 128, 129, 141, 150
- Symptomatic, 115, 142, 150
- Synapse, 117, 145, 150, 152
- Synapsis, 150
- Synaptic, 12, 141, 150
- Synovial, 21, 23, 40, 150
- Synovial Fluid, 23, 150
- Synovial Membrane, 150
- Systemic, 10, 27, 118, 121, 129, 135, 146, 150
- T**
- Teratogenic, 136, 150
- Terminator, 124, 150
- Thalidomide, 54, 151
- Thermal, 120, 144, 151
- Thigh, 130, 151
- Thrombin, 130, 144, 145, 151
- Thrombomodulin, 145, 151
- Thrombosis, 145, 150, 151
- Thyroid, 92, 151, 152
- Thyroid Gland, 92, 151
- Thyroid Hormones, 151, 152
- Thyroxine, 117, 151
- Tolerance, 36, 116, 151
- Topical, 136, 151
- Toxic, iv, 64, 134, 141, 151
- Toxicity, 98, 151
- Toxicology, 105, 151
- Toxin, 129, 151
- Trachea, 151
- Transcription Factors, 73, 151
- Transfection, 121, 131, 151
- Translation, 72, 73, 131, 152
- Transmitter, 116, 128, 141, 152
- Transplantation, 22, 24, 33, 39, 41, 42, 44, 51, 52, 123, 137, 152

Trauma, 140, 142, 152
Trinucleotide Repeat Expansion, 87, 152
Trinucleotide Repeats, 152
Trisomy, 78, 118, 152
Tuberculosis, 38, 137, 152
Tubulin, 139, 152
Tumor Necrosis Factor, 47, 151, 152
Tyrosine, 127, 152

U

Ubiquitin, 12, 152
Ulcerative colitis, 36, 152
Ultraviolet radiation, 75, 152
Uraemia, 142, 152
Uremia, 136, 153
Urinary, 21, 34, 56, 141, 153
Urine, 57, 119, 121, 136, 141, 145, 153
Urticaria, 50, 153
Uterus, 92, 142, 145, 153
Uvea, 153
Uveitis, 18, 153

V

Vaccine, 145, 153
Vacuoles, 142, 153
Valine, 7, 153
Valves, 147, 153
Vascular, 17, 128, 135, 141, 151, 153

Vasculitis, 45, 57, 142, 144, 153
Vasodilator, 122, 128, 153
Vector, 97, 98, 153
Vein, 141, 153
Venous, 121, 145, 153
Venous blood, 121, 153
Ventricle, 125, 134, 146, 153
Venules, 121, 122, 153
Veterinary Medicine, 105, 153
Viral, 97, 131, 140, 153
Virulence, 151, 154
Virus, 35, 97, 136, 147, 153, 154
Viscera, 149, 154
Vitro, 92, 154

W

White blood cell, 4, 6, 7, 75, 114, 118, 137,
138, 139, 140, 141, 143, 154
Windpipe, 151, 154
Womb, 153, 154

X

X-ray, 115, 141, 146, 154

Y

Yeasts, 143, 154

Z

Zygote, 125, 139, 154
Zymogen, 145, 154